WO2020085511A1 - タンパク質の分泌生産法 - Google Patents
タンパク質の分泌生産法 Download PDFInfo
- Publication number
- WO2020085511A1 WO2020085511A1 PCT/JP2019/042069 JP2019042069W WO2020085511A1 WO 2020085511 A1 WO2020085511 A1 WO 2020085511A1 JP 2019042069 W JP2019042069 W JP 2019042069W WO 2020085511 A1 WO2020085511 A1 WO 2020085511A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- gene
- amino acid
- acid sequence
- seq
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/77—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/104—Aminoacyltransferases (2.3.2)
- C12N9/1044—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/86—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides, e.g. penicillinase (3.5.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21014—Microbial serine proteases (3.4.21.14)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/15—Corynebacterium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
- C12Y107/02—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with a cytochrome as acceptor (1.7.2)
- C12Y107/02003—Trimethylamine-N-oxide reductase (cytochrome c)(1.7.2.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/02—Aminoacyltransferases (2.3.2)
- C12Y203/02013—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/13—Protein-histidine kinases (2.7.13)
- C12Y207/13003—Histidine kinase (2.7.13.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21089—Signal peptidase I (3.4.21.89)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01044—Protein-glutamine glutaminase (3.5.1.44)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/02—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amides (3.5.2)
- C12Y305/02006—Beta-lactamase (3.5.2.6)
Definitions
- the present invention relates to a method for secretory production of a heterologous protein.
- a method for secreting and producing a heterologous protein for example, a method using a microorganism such as coryneform bacterium as an expression host is known.
- a signal peptide also referred to as “signal sequence” can be used. That is, a heterologous protein can be efficiently secreted and produced by expressing a heterologous protein by fusing a signal peptide corresponding to the protein secretory pathway of the host to the N-terminus.
- the general protein secretion pathway is a pathway called the Sec system that exists widely from prokaryotes to eukaryotes.
- the Sec system In secretory production of a heterologous protein by a coryneform bacterium using the Sec system, for example, by inserting an amino acid sequence containing Gln-Glu-Thr or Ala-Glu-Thr between the signal peptide and the heterologous protein, the heterologous protein is inserted. Secretory production can be improved.
- Non-patent document 1 a protein secretion pathway completely different from the Sec system has been found in the thylakoid membrane of chloroplasts of plant cells.
- This novel secretory pathway is named as Tat system (Twin-Arginine Translocation system) because the arginine-arginine sequence is commonly present in the signal peptides of proteins secreted by it (Non-patent document 1).
- Tat system Twin-Arginine Translocation system
- the signal peptide is generally cleaved from the protein by signal peptidase at the C-terminus when the protein is secreted outside the cell.
- signal peptidase in the secretory production of a protein, there may be a problem that the signal peptide is not cleaved and the protein accumulates in cells. In that case, it is known that protein secretion efficiency can be enhanced by highly expressing a signal peptidase such as LepB protein (Patent Documents 3 to 8 and Non-Patent Documents 3 to 7).
- the protein is secreted outside the cell while retaining the partial sequence at the C-terminal side of the signal peptide because the signal peptide is cleaved inside the signal peptide rather than at the C-terminal.
- the present inventors In the secretory production of a heterologous protein using a TorA signal peptide by a coryneform bacterium, the present inventors have not cleaved the TorA signal peptide at the correct position and left off 15 residues at the C-terminal side (mis-cleavage). Have been found to occur. It is an object of the present invention to develop a novel technique for reducing the uncut residue of TorA signal peptide and to provide an efficient method for secretory production of a heterologous protein using a TorA signal peptide by a coryneform bacterium.
- the present inventors as a result of intensive studies to solve the above problems, by modifying the coryneform bacterium so that the activity of the LepB protein is increased, the heterologous protein utilizing the TorA signal peptide by the bacterium.
- the present invention has been completed by finding that the truncation of the TorA signal peptide can be reduced during secretory production.
- a method for producing a heterologous protein comprising: Culturing a coryneform bacterium having a genetic construct for secretory expression of a heterologous protein, and recovering the secreted and produced heterologous protein,
- the coryneform bacterium has been modified so that the activity of the LepB protein is increased as compared to the unmodified strain
- the gene construct comprises, in the 5 ′ to 3 ′ direction, a promoter sequence that functions in a coryneform bacterium, a nucleic acid sequence that encodes a TorA signal peptide, and a nucleic acid sequence that encodes a heterologous protein,
- the method wherein the heterologous protein is expressed as a fusion protein with the TorA signal peptide.
- LepB protein is the protein described in (a), (b), or (c) below:
- A a protein containing the amino acid sequence shown in SEQ ID NO: 2;
- B The amino acid sequence shown in SEQ ID NO: 2 contains an amino acid sequence containing substitution, deletion, insertion, and / or addition of 1 to 10 amino acid residues, and has signal peptidase activity for the TorA signal peptide protein;
- C A protein comprising an amino acid sequence having 90% or more identity with the amino acid sequence shown in SEQ ID NO: 2 and having a signal peptidase activity against a TorA signal peptide.
- TorA signal peptide is the peptide described in (a), (b), or (c) below: (A) a peptide containing the amino acid sequence shown in SEQ ID NO: 46; (B) an amino acid sequence represented by SEQ ID NO: 46, which contains an amino acid sequence containing substitution, deletion, insertion, and / or addition of 1 to 3 amino acid residues, and has a function as a Tat-dependent signal peptide.
- the TorA signal peptide consists of the amino acid sequence shown in SEQ ID NO: 46.
- the secreted and produced heterologous protein is a heterologous protein in which the TorA signal peptide is completely removed.
- the coryneform bacterium is further modified to carry a phoS gene encoding a mutant PhoS protein.
- the method, wherein the mutation is a mutation in the wild-type PhoS protein in which the amino acid residue corresponding to the tryptophan residue at position 302 of SEQ ID NO: 29 is replaced with an amino acid residue other than an aromatic amino acid and histidine.
- the amino acid residue other than the aromatic amino acid and histidine is a lysine residue, alanine residue, valine residue, serine residue, cysteine residue, methionine residue, aspartic acid residue, or asparagine residue, Method.
- coryneform bacterium is further modified so that expression of one or more genes selected from genes encoding Tat-based secretory apparatus is increased as compared to an unmodified strain.
- the gene encoding the Tat-type secretory apparatus comprises a tatA gene, a tatB gene, a tatC gene and a tatE gene.
- the coryneform bacterium is a bacterium of the genus Corynebacterium.
- coryneform bacterium is Corynebacterium glutamicum.
- coryneform bacterium is a modified strain derived from Corynebacterium glutamicum AJ12036 (FERM BP-734) or a modified strain derived from Corynebacterium glutamicum ATCC 13869.
- the coryneform bacterium is a coryneform bacterium in which the number of molecules of cell surface protein per cell is reduced as compared with the unmodified strain.
- the figure which shows the structure of a vector The photograph which shows the result of SDS-PAGE when PTG (transglutaminase with a pro structure part) fused with TorA signal peptide was expressed in C. glutamicum YDK010 :: phoS (W302C) strain and its lepB gene expression-enhancing strain. The amino acid sequence in the figure is shown in SEQ ID NO: 54.
- the amino acid sequence in the figure is shown in SEQ ID NO: 55. Photographs showing the results of SDS-PAGE when Bla ( ⁇ -lactamase) fused with a TorA signal peptide was expressed in the C. glutamicum YDK010 :: phoS (W302C) strain and its lepB gene expression-enhancing strain. The amino acid sequence in the figure is shown in SEQ ID NO: 56. The photograph which shows the result of SDS-PAGE when Trx (thioredoxin) which fused the TorA signal peptide was expressed in C.glutamicumYDK010 :: phoS (W302C) strain and its lepB gene expression enhancement strain. The amino acid sequence in the figure is shown in SEQ ID NO: 57.
- the amino acid sequences in the figure are shown in SEQ ID NOs: 58 and 59.
- the amino acid sequence in the figure is shown in SEQ ID NO: 54.
- the method of the present invention is a method for producing a heterologous protein, which comprises culturing a coryneform bacterium having a gene construct for secretory expression of the heterologous protein, and recovering the secreted and produced heterologous protein.
- Type bacterium has been modified to increase the activity of the LepB protein, and the TorA signal peptide is used for secretory production of a heterologous protein.
- the “heterologous protein” secreted and produced by the method of the present invention refers to a completely truncated heterologous protein, unless otherwise specified.
- the “completely cleaved heterologous protein” refers to a heterologous protein in which the TorA signal peptide has been completely removed, that is, has no TorA signal peptide.
- Coryneform bacterium used in the method of the present invention is a coryneform bacterium having a gene construct for secretory expression of a heterologous protein, and having an activity of LepB protein. It is a coryneform bacterium modified to increase.
- the coryneform bacterium used in the method of the present invention is also referred to as "the bacterium of the present invention” or "the coryneform bacterium of the present invention”.
- the gene construct for secretory expression of a heterologous protein possessed by the bacterium of the present invention is also referred to as “gene construct used in the present invention”.
- the bacterium of the present invention or the strain used for constructing the bacterium is also referred to as "host”.
- Coryneform bacterium capable of secreting and producing a heterologous protein has a capability of secreting and producing a heterologous protein (specifically, a completely cleaved heterologous protein).
- the coryneform bacterium of the present invention has the ability to secrete and produce a heterologous protein, at least depending on having a gene construct for secretory expression of the heterologous protein (gene construct used in the present invention).
- the coryneform bacterium of the present invention is specifically heterologous by having a gene construct for secretory expression of a heterologous protein, or by having a gene construct for secretory expression of a heterologous protein in combination with other properties. It may have the ability to secrete a protein.
- secretion of a protein means that the protein is transferred outside the bacterial cell (extracellular).
- the outside of the bacterial cell (extracellular) include the medium and the surface layer of the bacterial cell. That is, the secreted protein molecule may be present in the medium, may be present in the cell surface layer, or may be present in both the medium and the cell surface layer, for example. That is, the term "secretion" of a protein is not limited to the case where all the molecules of the protein are finally completely free in the medium. For example, all the molecules of the protein are present on the cell surface. And the case where some molecules of the protein are present in the medium and the rest of the molecules are present on the cell surface.
- the “ability to secrete and produce a heterologous protein” means that when the bacterium of the present invention is cultured in a medium, the heterologous protein is secreted into the medium and / or the cell surface layer, Alternatively, it refers to the ability to accumulate to the extent that it can be recovered from the cell surface.
- the accumulated amount is, for example, 10 ⁇ g / L or more, more preferably 1 mg / L or more, particularly preferably 100 mg / L or more, further preferably 1 mg / L or more, as the accumulated amount in the medium.
- the accumulated amount for example, as the accumulated amount on the bacterial cell surface, when the heterologous protein on the bacterial cell surface is recovered and suspended in the same amount of liquid as the medium, the concentration of the heterologous protein in the suspension is preferably The amount may be 10 ⁇ g / L or more, more preferably 1 mg / L or more, and particularly preferably 100 mg / L or more.
- the “protein” secreted and produced in the present invention is a concept that also includes a mode called a peptide such as an oligopeptide or a polypeptide.
- heterologous protein refers to a protein that is exogenous to a coryneform bacterium that expresses and secretes the protein.
- the heterologous protein may be, for example, a protein derived from a microorganism, a protein derived from a plant, a protein derived from an animal, a protein derived from a virus, or an artificial protein. It may be a protein whose amino acid sequence has been designed.
- the heterologous protein may in particular be a protein of human origin.
- the heterologous protein may be a monomeric protein or a multimeric protein.
- a multimeric protein refers to a protein that can exist as a multimer composed of two or more subunits.
- each subunit may be linked by a covalent bond such as a disulfide bond, may be linked by a non-covalent bond such as a hydrogen bond or a hydrophobic interaction, or may be linked by a combination thereof. May be.
- the multimer contains one or more intermolecular disulfide bonds.
- a multimer may be a homomultimer consisting of a single type of subunit or a heteromultimer consisting of two or more types of subunits.
- the multimeric protein is a heteromultimer, at least one subunit among the subunits forming the multimer may be a heterologous protein. That is, all subunits may be of different origin, or only some of the subunits may be of different origin.
- the heterologous protein may be a naturally secreted protein or a naturally non-secreted protein, but is preferably a naturally secreted protein. Further, the heterologous protein may be a secretory protein that naturally depends on the Tat system, or may be a secretory protein that naturally depends on the Sec system. Specific examples of “heterologous protein” will be described later.
- the heterologous protein produced may be only one type, or may be two or more types.
- the heterologous protein is a heteromultimer, only one kind of subunit may be produced, or two or more kinds of subunits may be produced.
- secreting and producing a heterologous protein means that secretory production of all of the subunits constituting the target heterologous protein, as well as secretory production of only a part of the subunits. Is also included.
- Coryneform bacteria are aerobic gram-positive bacilli.
- Examples of coryneform bacteria include bacteria of the genus Corynebacterium, bacteria of the genus Brevibacterium, and bacteria of the genus Microbacterium.
- the advantage of using a coryneform bacterium is that compared to filamentous fungi, yeast, Bacillus genus bacteria, etc., which have been conventionally used for secretory production of heterologous proteins, the proteins originally secreted outside the cells are extremely small, and It can be expected to simplify or simplify the purification process when secreted and secreted, and it grows well in a simple medium containing sugar, ammonia, inorganic salts, etc., and is excellent in medium cost, culture method, and culture productivity. And so on.
- coryneform bacterium include the following species. Corynebacterium acetoacidophilum Corynebacterium acetoglutamicum Corynebacterium alkanolyticum Corynebacterium callunae Corynebacterium crenatum Corynebacterium glutamicum Corynebacterium lilium Corynebacterium melassecola Corynebacterium thermoaminogenes (Corynebacterium efficiens) Corynebacterium herculis Brevibacterium divaricatum (Corynebacterium glutamicum) Brevibacterium flavum (Corynebacterium glutamicum) Brevibacterium immariophilum Brevibacterium lactofermentum (Corynebacterium glutamicum) Brevibacterium roseum Brevibacterium saccharolyticum Brevibacterium thiogenitalis Corynebacterium ammoniagenes (Corynebacterium stationis) Brevibacterium album Brevibacterium
- coryneform bacterium include the following strains. Corynebacterium acetoacidophilum ATCC 13870 Corynebacterium acetoglutamicum ATCC 15806 Corynebacterium alkanolyticum ATCC 21511 Corynebacterium callunae ATCC 15991 Corynebacterium crenatum AS1.542 Corynebacterium glutamicum ATCC 13020, ATCC 13032, ATCC 13060, ATCC 13869, FERM BP-734 Corynebacterium lilium ATCC 15990 Corynebacterium melassecola ATCC 17965 Corynebacterium efficiens (Corynebacterium thermoaminogenes) AJ12340 (FERM BP-1539) Corynebacterium herculis ATCC 13868 Brevibacterium divaricatum (Corynebacterium glutamicum) ATCC 14020 Brevibacterium flavum (Corynebacterium glutamicum)
- Corynebacterium genus bacteria were previously classified into the genus Brevibacterium, but bacteria currently integrated into the genus Corynebacterium (Int. J. Syst. Bacteriol., 41, 255 (1991)) included.
- Corynebacterium stationis also includes bacteria that were previously classified as Corynebacterium ammoniagenes, but were reclassified as Corynebacterium stationis by 16S rRNA nucleotide sequence analysis (Int. .Syst. Evol.Microbiol., 60, 874-879 (2010)).
- strains can be subdivided from, for example, the American Type Culture Collection (Address 12301 Parklawn Drive, Rockville, Maryland 20852 P.O.BoxBox 1549, Manassas, VA 20108, UnitedStates of America). That is, a registration number corresponding to each strain is given, and the distribution number can be used for distribution (see http://www.atcc.org/). The registration number corresponding to each strain is listed in the American Type Culture Collection catalog. In addition, these strains can be obtained, for example, from the depository in which each strain has been deposited.
- C.glutamicum AJ12036 (FERM BP-734), which was isolated as a streptomycin (Sm) -resistant mutant from the wild strain C.glutamicum ATCC 13869, is a gene that controls the function of protein secretion compared to its parent strain (wild strain). It is predicted that there is a mutation in the protein, and the secretory production ability of the protein is extremely high, about 2 to 3 times as much as the accumulated amount under the optimal culture conditions, and it is suitable as a host bacterium (WO2002 / 081694).
- the AJ12036 was developed on March 26, 1984 by the Institute of Microbial Technology, Institute of Industrial Science and Technology (now the Incorporated Administrative Agency, Product Evaluation Technology Platform Organization, Patent Biological Deposit Center, ZIP code: 292-0818, address: Kisarazu City, Chiba Prefecture, Japan. It was originally deposited as an international deposit in Kazusa Kama feet 2-5-8 room 120) and has been given the deposit number FERMBP-734.
- Corynebacterium thermoaminogenes AJ12340 (FERMBP-1539) is the Institute of Microbial Technology, Institute of Industrial Science and Technology (now the Independent Administrative Agency Product Evaluation Technology Infrastructure Organization, Patent Biological Deposit Center, ZIP code: 292- 0818, address: 2-5-8, Kazusa, Kamasa, Kisarazu, Chiba, Japan, room 120), which was originally deposited as an international deposit, and is given the deposit number FERMBP-1539.
- Brevibacterium flavum AJ12418 (FERM BP-2205) is the Institute of Microbial Science and Technology, Institute of Industrial Science and Technology (now the Independent Administrative Agency, Product Evaluation Technology Platform Organization, Patent Biological Deposit Center, Zip code: 292-) on December 24, 1988. 0818, address: 2-5-8, Kazusa, Kamasa, Kazusa, Chiba Prefecture, Japan, Room No. 120), which was originally deposited as an international deposit, and has been given the deposit number FERMBP-2205.
- the above-mentioned coryneform bacterium may be used as a parent strain to select a strain having an increased protein secretory production capacity by using a mutation method or a gene recombination method and used as a host.
- a mutation method or a gene recombination method for example, it is possible to select a strain having enhanced secretory productivity of a protein after being subjected to ultraviolet irradiation or treatment with a chemical mutagen such as N-methyl-N′-nitrosoguanidine.
- a strain modified so as not to produce a cell surface protein from such a strain because the heterologous protein secreted in the medium or on the cell surface layer can be easily purified.
- modification can be carried out by introducing a mutation into the coding region of the cell surface protein on the chromosome or its expression control region by a mutation method or a gene recombination method.
- coryneform bacteria modified so as not to produce cell surface protein include C.glutamicum YJK010 strain (WO2002 / 081694), which is a defective strain of cell surface protein PS2 of C.glutamicum AJ12036 (FERMBP-734).
- a coryneform bacterium having the ability to secrete and produce a heterologous protein can be obtained by introducing the gene construct used in the present invention into the coryneform bacterium as described above and holding it. That is, the bacterium of the present invention may be, for example, a modified strain derived from the coryneform bacterium as described above. Specifically, the bacterium of the present invention may be, for example, a modified strain derived from C. glutamicum AJ12036 (FERMBP-734) or a modified strain derived from C. glutamicum ATCC 13869. The modified strain derived from C. glutamicum AJ12036 (FERMBP-734) also corresponds to the modified strain derived from C. glutamicum ATCC 13869. The gene construct used in the present invention and the method for introducing it will be described later.
- the bacterium of the present invention is modified so that the activity of LepB protein is increased.
- the bacterium of the present invention is specifically modified so that the activity of the LepB protein is increased as compared with the unmodified strain. More specifically, the bacterium of the present invention may be modified so that expression of the lepB gene is increased.
- the “remaining residual amount of TorA signal peptide” refers to the weight ratio of the secretory production amount of the mis-cleaved form of the heterologous protein to the total secretory production amount of the heterologous protein.
- the “total secretory production of heterologous protein” refers to the total of the secretory production of completely cleaved heterologous protein and the secretory production of uncut residual protein.
- the "truncated heterologous protein” refers to a heterologous protein in which the TorA signal peptide is partially removed, that is, the C-terminal partial sequence of the TorA signal peptide is retained.
- the C-terminal side partial sequence of the TorA signal peptide include an amino acid sequence of 15 residues at the C-terminal side of the TorA signal peptide.
- Specific examples of the C-terminal side partial sequence of the TorA signal peptide include the amino acid sequences at positions 25 to 39 of SEQ ID NO: 46.
- the residual fraction of the TorA signal peptide in the method of the present invention may be, for example, 3% or less, 1% or less, 0.5% or less, 0.3% or less, 0.1% or less, or 0%.
- the residual ratio of the TorA signal peptide in the method of the present invention is, for example, the residual residue of the TorA signal peptide when an unmodified strain (here, a strain that has not been modified to increase the activity of LepB protein) is used.
- the rate may be 50% or less, 30% or less, 10% or less, 5% or less, 3% or less, 1% or less, or 0%.
- a heterologous protein of the bacterium specifically, a completely cleaved heterologous protein
- the ability can be improved, that is, the secretory production of a heterologous protein (specifically, a completely cleaved heterologous protein) utilizing the TorA signal peptide by the bacterium can be increased.
- the bacterium of the present invention can be obtained by modifying a coryneform bacterium capable of secreting and producing a heterologous protein so that the activity of the LepB protein is increased.
- the bacterium of the present invention can also be obtained by modifying a coryneform bacterium so that the activity of the LepB protein is increased, and then imparting the ability to secrete and produce a heterologous protein.
- the modification for constructing the bacterium of the present invention can be performed in any order.
- the strain used for the construction of the bacterium of the present invention secretes the heterologous protein if it is assumed to have a gene construct for secretory expression of the heterologous protein. It may or may not be produced. That is, the bacterium of the present invention may be, for example, one that has been modified to increase the activity of the LepB protein and has acquired the ability to secrete and produce a heterologous protein. Specifically, for example, the bacterium of the present invention is capable of secreting and producing a heterologous protein even if it has a gene construct for secretory expression of the heterologous protein before it is modified to increase the activity of the LepB protein. Alternatively, it may be obtained from a strain that could not be produced, and is capable of secreting and producing a heterologous protein by being modified so that the activity of the LepB protein is increased.
- LepB protein is a signal peptidase.
- Signal peptidase refers to a protein (enzyme) having an activity of catalyzing the processing of a signal peptide. The same activity is also referred to as “signal peptidase activity”.
- Signal peptidase activity “Processing of a signal peptide” refers to a reaction of removing the entire signal peptide from a protein having the signal peptide.
- the LepB protein has at least a signal peptidase activity for the TorA signal peptide, that is, an activity that catalyzes the processing of the TorA signal peptide.
- the lepB gene and LepB protein include those of various organisms such as coryneform bacteria and bacteria of the Enterobacteriaceae family.
- the nucleotide sequences of lepB genes of various organisms and the amino acid sequences of LepB proteins encoded by them can be obtained from public databases such as NCBI (National Center for Biotechnology Information).
- the nucleotide sequence of the lepB gene of C. glutamicum ATCC 13869 and the amino acid sequence of the LepB protein encoded by the gene are shown in SEQ ID NOS: 1 and 2, respectively. That is, the lepB gene may be, for example, a gene having the base sequence shown in SEQ ID NO: 1.
- the LepB protein may be, for example, a protein having the amino acid sequence shown in SEQ ID NO: 2.
- the expression “having an (amino acid or base) sequence” means “including the (amino acid or base) sequence”, and also includes “consisting of the (amino acid or base) sequence” unless otherwise specified. To do.
- the lepB gene may be a variant of the lepB gene exemplified above (for example, the gene having the nucleotide sequence shown in SEQ ID NO: 1) as long as the original function is maintained.
- the LepB protein may be a variant of the above-exemplified LepB protein (for example, a protein having the amino acid sequence shown in SEQ ID NO: 2) as long as the original function is maintained.
- a variant in which such original function is maintained may be referred to as a "conservative variant".
- the term “lepB gene” is not limited to the lepB gene exemplified above, but includes conservative variants thereof.
- LepB protein is not limited to the above-exemplified LepB proteins, but includes conservative variants thereof. Examples of conservative variants include the homologues of the lepB gene and the LepB protein exemplified above, and artificial variants.
- the original function is maintained means that the gene or protein variant has a function (eg, activity or property) corresponding to the function (eg, activity or property) of the original gene or protein. That is, “the original function is maintained” means that in the lepB gene, a gene variant encodes a protein in which the original function is maintained. Further, “the original function is maintained” means that in the LepB protein, the protein variant has a signal peptidase activity for the TorA signal peptide.
- the signal peptidase activity can be measured, for example, by incubating an enzyme with a substrate (that is, a protein having a signal peptide) and measuring the enzyme-dependent processing of the signal peptide.
- a substrate that is, a protein having a signal peptide
- the processing of the signal peptide can be measured using, for example, the molecular weight of the substrate after incubation or the N-terminal amino acid sequence as an index.
- a homolog of lepB gene or homolog of LepB protein can be easily obtained from a public database by, for example, BLAST search or FASTA search using the nucleotide sequence of lepB gene exemplified above or the amino acid sequence of LepB protein exemplified above as a query sequence. You can Further, the homologue of the lepB gene can be obtained, for example, by PCR using a chromosome of a coryneform bacterium as a template and an oligonucleotide prepared based on the known nucleotide sequence of the lepB gene as a primer.
- the lepB gene has one or several amino acids at one or several positions in the amino acid sequence of the LepB protein exemplified above (for example, the amino acid sequence shown in SEQ ID NO: 2). It may be a gene encoding a protein having a substituted, deleted, inserted, and / or added amino acid sequence.
- the above-mentioned "1 or several” varies depending on the position of the amino acid residue in the three-dimensional structure of the protein and the kind of the amino acid residue. Specifically, for example, 1 to 50, 1 to 40, 1 It means ⁇ 30, preferably 1 to 20, more preferably 1 to 10, further preferably 1 to 5, and particularly preferably 1 to 3.
- substitution, deletion, insertion, and / or addition of one or several amino acids are conservative mutations in which the function of the protein is normally maintained.
- a typical conservative mutation is a conservative substitution.
- a conservative substitution is a polar amino acid between Phe, Trp, and Tyr when the substitution site is an aromatic amino acid, and a Leu, Ile, and Val when the substitution site is a hydrophobic amino acid.
- Gln and Asn in the case of a basic amino acid
- Lys, Arg, His in the case of an acidic amino acid
- Asp and Glu in the case of an amino acid having a hydroxyl group.
- substitution considered as a conservative substitution, specifically, substitution from Ala to Ser or Thr, substitution from Arg to Gln, His or Lys, substitution from Asn to Glu, Gln, Lys, His or Asp, Asp to Asn, Glu or Gln substitution, Cys to Ser or Ala substitution, Gln to Asn, Glu, Lys, His, Asp or Arg substitution, Glu to Gly, Asn, Gln, Lys or Asp substitution Substitution, Gly to Pro substitution, His to Asn, Lys, Gln, Arg or Tyr substitution, Ile to Leu, Met, Val or Phe substitution, Leu to Ile, Met, Val or Phe substitution, Lys to Asn, Glu, Gln, His or Arg substitution, Met to Ile, Leu, Val or Phe substitution, Phe to Trp, Tyr, Met, Ile or Leu substitution, Ser to Thr or Ala Substitution, Thr to Ser or Ala, Trp to Phe or Tyr, Tyr to His,
- the lepB gene is, as long as the original function is maintained, 80% or more, preferably 90% or more, with respect to the entire amino acid sequence of the above-described LepB protein (for example, the amino acid sequence shown in SEQ ID NO: 2), It may be a gene encoding a protein having an amino acid sequence having an identity of more preferably 95% or more, further preferably 97% or more, particularly preferably 99% or more.
- the lepB gene is a complementary sequence of the above-exemplified nucleotide sequence of the lepB gene (for example, the nucleotide sequence shown in SEQ ID NO: 1) or a probe and a stringent that can be prepared from the complementary sequence, as long as the original function is maintained. It may be a DNA that hybridizes under various conditions.
- the “stringent conditions” are conditions under which so-called specific hybrid is formed and non-specific hybrid is not formed.
- DNAs having high identity for example, 80% or more, preferably 90% or more, more preferably 95% or more, more preferably 97% or more, particularly preferably 99% or more DNA having identity Conditions under which DNAs that hybridize with each other and are less identical than those with each other do not hybridize, or conditions for washing in ordinary Southern hybridization are 60 ° C, 1 ⁇ SSC, 0.1% SDS, preferably 60 ° C, 0.1 ⁇ Conditions for washing once, preferably 2-3 times at a salt concentration and temperature corresponding to SSC, 0.1% SDS, more preferably 68 ° C., 0.1 ⁇ SSC, 0.1% SDS can be mentioned.
- the above-mentioned probe may be, for example, a part of a complementary sequence of a gene.
- a probe can be prepared by PCR using an oligonucleotide prepared based on the base sequence of a known gene as a primer and a DNA fragment containing these base sequences as a template.
- a DNA fragment having a length of about 300 bp can be used.
- the washing conditions for hybridization include 50 ° C., 2 ⁇ SSC, 0.1% SDS.
- the lepB gene may have a nucleotide sequence in which an arbitrary codon is replaced with an equivalent codon in the nucleotide sequence of the lepB gene or the conservative variant thereof exemplified above.
- the lepB gene may be modified to have optimal codons depending on the codon usage of the host used.
- genes and proteins can be applied correspondingly to PhoRS proteins, cell surface proteins, Tat-based secretory apparatus, arbitrary proteins such as heterologous proteins secreted and produced in the present invention, and genes encoding them. .
- the bacterium of the present invention may have desired properties as long as it can secrete and produce a heterologous protein.
- the bacterium of the present invention may have a reduced cell surface protein activity (WO2013 / 065869, WO2013 / 065772, WO2013 / 118544, WO2013 / 062029).
- the bacterium of the present invention may be modified so that the activity of the penicillin-binding protein is reduced (WO2013 / 065869).
- the bacterium of the present invention may be modified so that the expression of a gene encoding a metallopeptidase is increased (WO2013 / 065772).
- the bacterium of the present invention may be modified to have a mutant ribosomal protein S1 gene (mutant rpsA gene) (WO2013 / 118544). Further, the bacterium of the present invention may be modified so as to have a mutant phoS gene (WO2016 / 171224). In addition, the bacterium of the present invention may be modified so that the activity of RegX3 protein is reduced (WO2018 / 074578). Moreover, the bacterium of the present invention may be modified so that the activity of the HrrSA system is reduced (WO2018 / 074579). Further, the bacterium of the present invention may be modified so that the activity of the Tat secretion apparatus is increased. These properties or modifications can be used alone or in appropriate combination.
- mutant phoS gene The bacterium of the present invention may be modified to retain the mutant phoS gene. “Holding a mutant phoS gene” is also referred to as “having a mutant phoS gene” or “having a mutation in the phoS gene”. In addition, “having a mutant phoS gene” is also referred to as “having a mutant PhoS protein” or “having a mutation in the PhoS protein”.
- the phoS gene is a gene encoding a PhoS protein that is a sensor kinase of the PhoRS system.
- the PhoRS system is one of the two-component regulatory systems that elicits a response to phosphate deficiency in the environment.
- the PhoRS system consists of a sensor kinase PhoS encoded by the phoS gene and a response regulator PhoR encoded by the phoR gene.
- a PhoS protein having a “specific mutation” is also called a “mutant PhoS protein”, and a gene encoding it is also called a “mutant phoS gene”.
- the “mutant phoS gene” is a phoS gene having a “specific mutation”.
- a PhoS protein having no “specific mutation” is also referred to as a “wild-type PhoS protein”, and a gene encoding the PhoS protein is also referred to as a “wild-type phoS gene”.
- the “wild type phoS gene” is a phoS gene having no “specific mutation”.
- wild type used herein is a description for convenience of distinction from the "mutant type”, and is not limited to a naturally obtained one as long as it does not have a "specific mutation”. The “specific mutation” will be described later.
- the wild-type phoS gene includes, for example, the phoS gene of coryneform bacteria.
- Specific examples of the phoS gene of coryneform bacterium include C. glutamicum YDK010 strain, C. glutamicum ATCC13032 strain, C. glutamicum ATCC14067 strain, C. callunae, C. crenatum, and C. efficiens phoS gene.
- SEQ ID NO: 28 The nucleotide sequence of the phoS gene of the C. glutamicum YDK010 strain is shown in SEQ ID NO: 28.
- the amino acid sequences of wild-type PhoS proteins encoded by these phoS genes are shown in SEQ ID NOs: 29 to 34, respectively.
- the wild-type phoS gene may be a variant of the above-mentioned wild-type phoS gene as long as it has no "specific mutation” and the original function is maintained.
- the wild-type PhoS protein may be a variant of the above-exemplified wild-type PhoS protein as long as it has no “specific mutation” and the original function is maintained. That is, the term “wild-type phoS gene” is not limited to the above-exemplified wild-type phoS gene, but includes conservative variants thereof that do not have a “specific mutation”. Similarly, the term “wild-type PhoS protein” is not limited to the above-exemplified wild-type PhoS protein, but includes conservative variants thereof that do not have a “specific mutation”.
- the wild-type PhoS protein and wild-type phoS gene variants the above-mentioned descriptions regarding the conservative variants of LepB protein and lepB gene can be applied.
- the wild-type phoS gene does not have a “specific mutation”, and as long as the original function is maintained, one or several amino acids at one or several positions in the above amino acid sequence are It may be a gene encoding a protein having a substituted, deleted, inserted, and / or added amino acid sequence.
- the wild-type phoS gene does not have a "specific mutation", and as long as the original function is maintained, with respect to the entire amino acid sequence, 80% or more, preferably 90% or more, It may be a gene encoding a protein having an amino acid sequence having an identity of more preferably 95% or more, further preferably 97% or more, particularly preferably 99% or more.
- the original function is maintained means that in the wild-type PhoS protein, a variant of the protein has a function as the PhoS protein (for example, a protein consisting of the amino acid sequences shown in SEQ ID NOs: 29 to 34). Function).
- “maintaining the original function” may mean that in the wild-type PhoS protein, the protein variant has a function as a sensor kinase of the PhoRS system. That is, the “function as a PhoS protein” may specifically be a function as a sensor kinase of the PhoRS system.
- the “function of the PhoRS system as a sensor kinase” may be specifically a function of coupling with the response regulator PhoR protein to elicit a response to phosphate deficiency in the environment. More specifically, the "function of the PhoRS system as a sensor kinase” is a function of activating the PhoR protein by sensing phosphate deficiency in the environment, being autophosphorylated, and transphosphorylation. Good.
- Whether a variant of the PhoS protein functions as a sensor kinase of the PhoRS system can be determined by, for example, introducing a gene encoding the variant into a phoS gene-deficient strain of coryneform bacterium and complementing the responsiveness to phosphate deficiency. It can be confirmed by confirming whether or not it is done. Complementation of responsiveness to phosphate deficiency can be detected, for example, as an improvement in growth under phosphate deficiency conditions or as induction of expression of a gene whose expression is known to be induced under phosphate deficiency conditions ( J. Bacteriol., 188, 724-732 (2006)).
- phoS gene-deficient strain of coryneform bacterium for example, phoS gene-deficient strain of C. glutamicum YDK010 strain and phoS gene-deficient strain of C. glutamicum ATCC13032 strain can be used.
- histidine residues that are autophosphorylated are conserved. That is, the conservative mutation preferably occurs at amino acid residues other than histidine residues that are autophosphorylated.
- "Histidine residue that is autophosphorylated” refers to the histidine residue at position 276 of the wild-type PhoS protein.
- the wild-type PhoS protein preferably has, for example, a conserved sequence of the wild-type PhoS proteins exemplified above. That is, the conservative mutation preferably occurs at an amino acid residue that is not conserved in the above-exemplified wild-type PhoS protein.
- the mutant PhoS protein has a “specific mutation” in the amino acid sequence of the wild-type PhoS protein as described above.
- the mutant PhoS protein may be the same as the wild-type PhoS protein and the conservative variant thereof exemplified above except that it has a “specific mutation”.
- the mutant PhoS protein may be a protein having the amino acid sequences shown in SEQ ID NOs: 29 to 34, except that it has the “specific mutation”.
- the mutant PhoS protein has one or several amino acid substitutions, deletions, insertions in the amino acid sequences shown in SEQ ID NOs: 29 to 34, except that it has a “specific mutation”. And / or a protein having an amino acid sequence containing additions.
- the mutant PhoS protein has 80% or more, preferably 90% or more, more preferably 90% or more of the amino acid sequence shown in SEQ ID NOs: 29 to 34, except that it has a “specific mutation”. May be a protein having an amino acid sequence having an identity of 95% or more, more preferably 97% or more, and particularly preferably 99% or more.
- the mutant PhoS protein is a variant of the wild-type PhoS protein exemplified above, which has a “specific mutation” and further includes a conservative mutation at a position other than the “specific mutation”.
- the mutant PhoS protein has a “specific mutation” in the amino acid sequences shown in SEQ ID NOs: 29 to 34, and one or several additional positions other than the “specific mutation”.
- the protein may have an amino acid sequence containing amino acid substitutions, deletions, insertions, and / or additions of.
- the mutant phoS gene is not particularly limited as long as it encodes the mutant PhoS protein as described above.
- the “specific mutation” is not particularly limited as long as the amino acid sequence of the wild-type PhoS protein is changed as described above and it is effective for secretory production of a heterologous protein.
- the "specific mutation” is preferably a mutation that improves the secretory production of a heterologous protein.
- the phrase "improving the secretory production of a heterologous protein” means that a coryneform bacterium modified to have a mutant phoS gene (modified strain) can secrete and produce a larger amount of a heterologous protein than an unmodified strain.
- the "non-modified strain” refers to a control strain having no mutation in the phoS gene, that is, a control strain having no mutant phoS gene, and may be, for example, a wild strain or a parent strain.
- the term "secretes and produces a larger amount of a heterologous protein than the non-modified strain” is not particularly limited as long as the secretory production amount of the heterologous protein is increased as compared with the non-modified strain.
- the accumulated amount in the surface layer is preferably 1.1 times or more, more preferably 1.2 times or more, still more preferably 1.3 times or more, further preferably 2 times or more, particularly preferably 5 times that of the unmodified strain.
- the above-mentioned amount of the heterologous protein may be secreted and produced.
- “secreting and producing a larger amount of a heterologous protein than the non-modified strain” means that the heterologous protein cannot be detected when the culture supernatant of the non-modified strain is subjected to SDS-PAGE and stained with CBB. However, it may be that the heterologous protein can be detected when the culture supernatant of the unconcentrated modified strain is subjected to SDS-PAGE and stained with CBB.
- the phrase "improving the secretory production amount of a heterologous protein” does not need to improve the secretory production amount of any heterologous protein, and it is sufficient if the secretory production amount of a heterologous protein set as a target of secretory production is improved.
- the phrase “improving the secretory production amount of the heterologous protein” may specifically mean, for example, improving the secretory production amount of the heterologous protein described in Examples.
- Whether a certain mutation is a mutation that improves the secretory production of a heterologous protein is determined by, for example, preparing a strain modified to have a gene encoding a PhoS protein having the mutation based on a strain belonging to a coryneform bacterium. , Quantify the amount of heterologous protein secreted and produced when the modified strain is cultured in a medium, and compare it with the amount of heterologous protein secreted and produced when the strain before modification (non-modified strain) is cultured in the medium This can be confirmed.
- substitution of amino acid residue is preferable. That is, the “specific mutation” is preferably a substitution of any amino acid residue of the wild-type PhoS protein with another amino acid residue.
- the amino acid residue in which substitution is caused by the “specific mutation” may be one residue, or may be a combination of two residues or more.
- the amino acid residue in which substitution is caused by the "specific mutation” may be preferably an amino acid residue other than a histidine residue that is autophosphorylated.
- the amino acid residue in which the substitution is caused by the “specific mutation” may more preferably be an amino acid residue in the HisKA domain other than the histidine residue that is autophosphorylated.
- “Histidine residue that is autophosphorylated” refers to the histidine residue at position 276 of the wild-type PhoS protein.
- the “HisKA domain” refers to a region consisting of amino acid residues 266 to 330 of the wild-type PhoS protein.
- the amino acid residue in which the substitution is caused by the “specific mutation” may be particularly preferably the tryptophan residue at position 302 (W302) of the wild-type PhoS protein.
- the amino acid residues after substitution include K (Lys), R (Arg), H (His), A (Ala), V (Val), L (Leu), I (Ile) and G ( Gly), S (Ser), T (Thr), P (Pro), F (Phe), W (Trp), Y (Tyr), C (Cys), M (Met), D (Asp), E ( Among Glu), N (Asn), and Q (Gln), those other than the original amino acid residue can be mentioned.
- the amino acid residue after substitution for example, one that can improve the secretory production of a heterologous protein can be selected.
- amino acid residue after replacement examples include amino acid residues other than aromatic amino acids and histidine.
- amino acid residue other than aromatic amino acid and histidine specifically includes K (Lys), R (Arg), A (Ala), V (Val), L (Leu), I (Ile), and G. (Gly), S (Ser), T (Thr), P (Pro), C (Cys), M (Met), D (Asp), E (Glu), N (Asn), Q (Gln).
- amino acid residue other than aromatic amino acid and histidine K (Lys), A (Ala), V (Val), S (Ser), C (Cys), M (Met), Examples include D (Asp) and N (Asn).
- the “specific mutation” in the phoS gene means a mutation in the nucleotide sequence that causes the above-mentioned “specific mutation” in the encoded PhoS protein.
- amino acid residue at X position of wild-type PhoS protein means an amino acid residue corresponding to the amino acid residue at X position of SEQ ID NO: 29.
- W302 means an amino acid residue corresponding to the tryptophan residue at position 302 of SEQ ID NO: 29.
- the positions of the above-mentioned amino acid residues indicate relative positions, and their absolute positions may be changed due to deletion, insertion, addition of amino acids or the like.
- the original amino acid residue at the X position is Is the X-1th or X + 1th amino acid residue counted from the N-terminus, respectively, and is regarded as the "X-position amino acid residue of the wild-type PhoS protein".
- W302 means the positions 302, 302, 302, 321, 275, and 286, respectively. Refers to tryptophan residues.
- the histidine residue at position 276 of the wild-type PhoS protein (a histidine residue that is autophosphorylated)” means positions 276 and 276, respectively. Position, 276, 295, 249, and 260 positions of histidine residues.
- the region consisting of the amino acid residues at positions 266 to 330 of the wild-type PhoS protein (HisKA domain) means 266 to 330, respectively. Position 266-330 position, 266-330 position, 285-349 position, 239-303 position, and 250-314 position.
- W302 here is usually a tryptophan residue, but it does not have to be a tryptophan residue. That is, when the wild-type PhoS protein has an amino acid sequence other than the amino acid sequences shown in SEQ ID NOs: 29 to 34, “W302” may not be a tryptophan residue. Therefore, for example, “mutation in which W302 is replaced with a cysteine residue” is not limited to mutation in which the tryptophan residue is replaced with a cysteine residue when “W302” is a tryptophan residue, and is not limited to “W302”.
- amino acid sequence of an arbitrary PhoS protein which amino acid residue is the “amino acid residue corresponding to the amino acid residue at the X position in SEQ ID NO: 29” is determined by the amino acid sequence of the arbitrary PhoS protein and SEQ ID NO: 29. It can be determined by performing alignment with the amino acid sequence. The alignment can be performed by using, for example, known gene analysis software. Specific software includes DNASIS manufactured by Hitachi Solutions and GENETYX manufactured by Genetics (Elizabeth C. Tyler et al., Computers and Biomedical Research, 24 (1), 72-96, 1991; Barton GJ et al., Journal of molecular biology, 198 (2), 327-37.1987).
- the mutant phoS gene can be obtained, for example, by modifying the wild-type phoS gene so that the encoded PhoS protein has the above-mentioned “specific mutation”.
- the wild-type phoS gene to be modified can be obtained, for example, by cloning from an organism having the wild-type phoS gene or by chemical synthesis.
- the mutant phoS gene can also be obtained without intervention of the wild-type phoS gene.
- the mutant phoS gene may be directly obtained by chemical synthesis.
- the obtained mutant phoS gene may be further modified before use.
- the gene can be modified by known methods.
- a site-directed mutagenesis method can be used to introduce a target mutation into a target site of DNA.
- a site-directed mutation method a method using PCR (Higuchi, R., 61, in PCR technology, Erlich, H. A. Eds., Stockton press (1989); Carter, P., Meth. In Enzymol., 154, 382 (1987)) and methods using phage (Kramer, W. and Frits, H. J., Meth. In Enzymol., 154, 350 (1987); Kunkel, T. A. et al., Meth . In Enzymol., 154, 367 (1987)).
- Modifying a coryneform bacterium to have a mutant phoS gene can be achieved by introducing the mutant phoS gene into a coryneform bacterium. Further, the modification of the coryneform bacterium to have the mutant phoS gene can also be achieved by introducing the above-mentioned "specific mutation" into the phoS gene on the chromosome of the coryneform bacterium. Mutagenesis to a gene on a chromosome can be achieved by natural mutation, mutagen treatment, or a genetic engineering technique.
- the method for introducing the mutant phoS gene into coryneform bacteria is not particularly limited.
- the mutant phoS gene may be retained so that it can be expressed under the control of a promoter that functions in coryneform bacteria.
- the promoter may be a host-derived promoter or a heterologous-derived promoter.
- the promoter may be a promoter specific to the phoS gene or a promoter of another gene.
- the mutant phoS gene may be present on a vector that autonomously propagates extrachromosomally such as a plasmid, or may be integrated on the chromosome.
- the bacterium of the present invention may have only one copy of the mutant phoS gene, or may have two or more copies.
- the bacterium of the present invention may have only one kind of mutant phoS gene, or may have two or more kinds of mutant phoS gene.
- the introduction of the mutant phoS gene can be carried out, for example, in the same manner as the introduction of the gene in the method of increasing the expression of the gene described below and the introduction of the gene construct used in the present invention.
- the bacterium of the present invention may or may not have the wild-type phoS gene, but it is preferable not to have it.
- Coryneform bacteria that do not have the wild-type phoS gene can be obtained by disrupting the wild-type phoS gene on the chromosome.
- the wild-type phoS gene can be disrupted by a known method. Specifically, for example, the wild-type phoS gene can be destroyed by deleting part or all of the promoter region and / or coding region of the wild-type phoS gene.
- the PhoS protein functions by coupling with the response regulator PhoR protein, that is, it induces a response to phosphate deficiency in the environment. Therefore, the bacterium of the present invention has the phoR gene so that the mutant PhoS protein can function.
- the phoR gene is a gene encoding the PhoR protein that is a response regulator of the PhoRS system. “Having a phoR gene” is also referred to as “having a PhoR protein”. Usually, it suffices that the PhoR protein originally possessed by the bacterium of the present invention functions by coupling with the mutant PhoS protein.
- an appropriate phoR gene may be introduced in addition to or in place of the phoR gene originally possessed by the bacterium of the present invention.
- the introduced phoR gene is not particularly limited as long as it encodes a PhoR protein that functions in association with the mutant PhoS protein.
- the phoR gene includes, for example, the phoR gene of coryneform bacteria.
- Specific examples of the phoR gene of coryneform bacteria include the C. glutamicum YDK010 strain, C. glutamicum ATCC13032 strain, C. glutamicum ATCC14067 strain, C. callunae, C. crenatum, and C. efficiens phoR gene.
- the nucleotide sequence of the phoR gene and the amino acid sequence of the PhoR protein of C. glutamicum ATCC13032 strain are shown in SEQ ID NOs: 35 and 36, respectively.
- the phoR gene may be a variant of the phoR gene exemplified above as long as the original function is maintained.
- the PhoR protein may be a variant of the PhoR protein exemplified above as long as the original function is maintained. That is, the term “phoR gene” is intended to include conservative variants thereof in addition to the phoR gene exemplified above.
- the term “PhoR protein” is intended to include the PhoR protein exemplified above and conservative variants thereof. With regard to the variants of PhoR protein and phoR gene, the above-mentioned descriptions regarding the conservative variants of LepB protein and lepB gene can be applied.
- an amino acid in which one or several amino acids at one or several positions in the above amino acid sequence are substituted, deleted, inserted, and / or added as long as the original function is maintained. It may be a gene encoding a protein having a sequence. Further, for example, the phoR gene, as long as the original function is maintained, with respect to the entire amino acid sequence, 80% or more, preferably 90% or more, more preferably 95% or more, more preferably 97% or more, Particularly preferably, it may be a gene encoding a protein having an amino acid sequence having 99% or higher identity.
- the original function is maintained means that in the PhoR protein, a protein variant has a function as the PhoR protein (for example, a function of the protein having the amino acid sequence shown in SEQ ID NO: 36). Can be.
- the original function is maintained may mean that in the PhoR protein, a protein variant has a function as a response regulator of the PhoRS system. That is, the “function as a PhoR protein” may specifically be a function as a response regulator of the PhoRS system.
- the “function of the PhoRS system as a response regulator” may specifically be a function of coupling with a sensor kinase PhoS protein to elicit a response to phosphate deficiency in the environment.
- the “function of the PhoRS system as a response regulator” is activated by the transfer of a phosphate group from the PhoS protein that is autophosphorylated by sensing phosphate deficiency in the environment. It may have a function of controlling the expression of a gene that responds to phosphate deficiency.
- Whether a variant of the PhoR protein functions as a response regulator of the PhoRS system is determined by, for example, introducing a gene encoding the variant into a phoR gene-deficient strain of a coryneform bacterium and complementing the responsiveness to phosphate deficiency. It can be confirmed by confirming whether or not it is done. Complementation of responsiveness to phosphate deficiency can be detected, for example, as an improvement in growth under phosphate deficiency conditions or as induction of expression of a gene whose expression is known to be induced under phosphate deficiency conditions ( J. Bacteriol., 188, 724-732 (2006)).
- the phoR gene-deficient strain of coryneform bacterium for example, the phoR gene-deficient strain of C. glutamicum YDK010 strain and the phoR gene-deficient strain of C. glutamicum ATCC13032 strain can be used.
- the bacterium of the present invention may have a reduced activity of cell surface protein. Specifically, the bacterium of the present invention may have a reduced activity of cell surface protein as compared with an unmodified strain. "Reducing the activity of the cell surface protein” may particularly mean that the number of molecules of the cell surface protein per cell is decreased. The cell surface protein and the gene encoding it will be described below.
- Cell surface proteins are proteins that make up the cell surface (S layer) of bacteria and archaea.
- Examples of cell surface proteins of coryneform bacteria include C. glutamicum PS1 and PS2 (CspB) (Table 1-502548), and C. stationis SlpA (CspA) (JP-A-10-108675). Among these, it is preferable to reduce the activity of PS2 protein.
- the nucleotide sequence of the cspB gene of C. glutamicum ATCC13869 and the amino acid sequence of the PS2 protein (CspB protein) encoded by the gene are shown in SEQ ID NOs: 37 and 38, respectively.
- CspB homologs have been reported for 28 strains of C. glutamicum (J Biotechnol., 112, 177-193 (2004)).
- GenBank accession numbers of the NCBI database of C. glutamicum and cspB gene homologs of these 28 strains are exemplified below (the GenBank accession numbers in parentheses).
- C. glutamicum ATCC13058 (AY524990) C. glutamicum ATCC13744 (AY524991)
- glutamicum ATCC14017 AY524993
- glutamicum ATCC14020 AY525009
- glutamicum ATCC14067 AY524994
- glutamicum ATCC14068 (AY525010) C. glutamicum ATCC14747 (AY525011) C. glutamicum ATCC14751 (AY524995) C. glutamicum ATCC14752 (AY524996) C. glutamicum ATCC14915 (AY524997) C. glutamicum ATCC15243 (AY524998) C. glutamicum ATCC15354 (AY524999) C. glutamicum ATCC17965 (AY525000) C. glutamicum ATCC17966 (AY525001) C. glutamicum ATCC19223 (AY525002) C. glutamicum ATCC19240 (AY525012) C. glutamicum ATCC21341 (AY525003) C. glutamicum ATCC21645 (AY525004) C.
- glutamicum ATCC31808 (AY525013) C. glutamicum ATCC31830 (AY525007) C. glutamicum ATCC31832 (AY525008) C. glutamicum LP-6 (AY525014) C. glutamicum DSM20137 (AY525015) C. glutamicum DSM20598 (AY525016) C. glutamicum DSM46307 (AY525017) C. glutamicum 22220 (AY525005) C. glutamicum 22243 (AY525006)
- the gene encoding the cell surface protein is not limited to the above as long as the original function is maintained. It may be a variant of the gene encoding the exemplified cell surface protein. Similarly, the cell surface protein may be a variant of the cell surface protein exemplified above as long as the original function is maintained. That is, for example, the term “cspB gene” includes the above-exemplified cspB gene and conservative variants thereof.
- CspB protein is intended to include the CspB protein exemplified above and conservative variants thereof.
- the above description regarding the conservative variant of the LepB protein and lepB gene can be applied.
- the gene encoding the cell surface protein as long as the original function is maintained, 1 or several amino acids at one or several positions in the above amino acid sequence are substituted, deleted, inserted, and / or Alternatively, it may be a gene encoding a protein having an added amino acid sequence.
- the gene encoding the cell surface protein as long as the original function is maintained, with respect to the entire amino acid sequence, 80% or more, preferably 90% or more, more preferably 95% or more, more preferably May be a gene encoding a protein having an amino acid sequence with 97% or more, and particularly preferably 99% or more identity.
- “the original function is maintained” means that in the cell surface protein, for example, when the activity is decreased in a coryneform bacterium, the secretory production amount of the heterologous protein is increased as compared with the unmodified strain. It may have the property of causing.
- the property of increasing secretory production of a heterologous protein when the activity is reduced in coryneform bacteria compared to the non-modified strain means that the amount is higher than that of the non-modified strain when the activity is reduced in coryneform bacteria.
- the ability to secrete and produce the heterologous protein of the coryneform bacterium refers to a control strain in which the activity of cell surface protein is not reduced, and may be, for example, a wild strain or a parent strain.
- the term "secretes and produces a larger amount of a heterologous protein than the non-modified strain” is not particularly limited as long as the secretory production amount of the heterologous protein is increased as compared with the non-modified strain.
- the amount of heterologous protein accumulated in the surface layer is preferably 1.1 times or more, more preferably 1.2 times or more, further preferably 1.3 times or more, and particularly preferably 2 times or more that of the non-modified strain. It may be secretory production.
- “secreting and producing a larger amount of a heterologous protein than the non-modified strain” means that the heterologous protein cannot be detected when the culture supernatant of the non-modified strain is subjected to SDS-PAGE and stained with CBB. However, it may be that the heterologous protein can be detected when the culture supernatant of the unconcentrated modified strain is subjected to SDS-PAGE and stained with CBB.
- a protein has the property of increasing the secretory production amount of a heterologous protein when its activity is reduced in a coryneform bacterium as compared with that of an unmodified strain depends on the activity of the protein based on the strain belonging to the coryneform bacterium.
- a strain modified so as to reduce the amount of heterologous protein secreted and produced when the modified strain is cultured in the medium is quantified, and the strain before modification (non-modified strain) is secreted when cultured in the medium. This can be confirmed by comparison with the amount of heterologous protein produced.
- the activity of the cell surface protein is reduced means that when the coryneform bacterium is modified so that the activity of the cell surface protein is reduced, and in the coryneform bacterium, The case where the activity is decreased is included.
- the "case where the activity of the cell surface protein is originally reduced in the coryneform bacterium” includes the case where the coryneform bacterium originally does not have the cell surface protein. That is, as the coryneform bacterium in which the activity of the cell surface protein is reduced, for example, a coryneform bacterium originally having no cell surface protein can be mentioned.
- Examples of "when the coryneform bacterium originally does not have a cell surface protein” include a case where the coryneform bacterium originally does not have a gene encoding a cell surface protein.
- the coryneform bacterium originally does not have a cell surface protein means that the coryneform bacterium has one or more selected from cell surface proteins found in other strains of the species to which the coryneform bacterium belongs. It may be that the protein is not originally contained.
- C.glutamicum does not originally have a cell surface protein
- the C.glutamicum strain is one or more proteins selected from cell surface proteins found in other C.glutamicum strains, that is, For example, it may not have PS1 and / or PS2 (CspB) originally.
- An example of a coryneform bacterium originally having no cell surface protein is C. glutamicum ATCC 13032 which originally has no cspB gene.
- the bacterium of the present invention has a Tat system (Tat system secretory apparatus) which is a protein secretion system.
- the bacterium of the present invention may inherently have a Tat secretion apparatus.
- the bacterium of the present invention may be modified so that the activity of the Tat secretion apparatus is increased.
- the bacterium of the present invention may be modified so that the activity of the Tat secretion apparatus is increased as compared with the unmodified strain.
- the activity of the Tat-based secretory apparatus can be increased, for example, by increasing the expression of one or more genes selected from the genes encoding the Tat-based secretory apparatus.
- the bacterium of the present invention may be modified, more specifically, so that the expression of one or more genes selected from the genes encoding the Tat secretion apparatus is increased.
- a method for increasing the expression of the gene encoding the Tat secretory apparatus is described in Japanese Patent No. 4730302.
- a heterologous protein specifically, a completely truncated heterologous protein
- the ability can be improved, that is, the secretory production of a heterologous protein (specifically, a completely cleaved heterologous protein) utilizing the TorA signal peptide by the bacterium can be increased.
- the genes encoding the Tat secretory apparatus include the tatA gene, tatB gene, tatC gene, and tatE gene.
- the gene encoding the Tat secretory apparatus include the C. glutamicum tatA gene, tatB gene, and tatC gene.
- the tatA gene, tatB gene, and tatC gene of C. glutamicum ATCC 13032 are respectively the sequences of positions 1571065 to 1571382 in the genome sequence registered as GenBank accession NC_003450 (VERSION NC_003450.3 GI: 58036263) in the NCBI database. It corresponds to the complementary sequence, the sequence at positions 1167110 to 1167580, and the sequence complementary to the sequences at positions 1569929 to 1570873.
- the TatA protein, TatB protein, and TatC protein of C are respectively the sequences of positions 1571065 to 1571382 in the genome sequence registered as GenBank accession NC_003450 (VERSION NC_003450.3 GI: 58036263) in the NCBI database. It corresponds to the complementary sequence, the sequence at positions 1167110 to 1167580
- locus_tag "NCgl1077”
- the nucleotide sequences of the tatA gene, tatB gene, and tatC gene of C. glutamicum ATCC 13032 and the amino acid sequences of the TatA protein, TatB protein, and TatC protein are shown in SEQ ID NOs: 39 to 44.
- E. coli coli tatA gene tatB gene, tatC gene, and tatE gene.
- E.coli K-12 MG1655 tatA gene, tatB gene, tatC gene, and tatE gene are 4019968- It corresponds to the sequence at the 4020237 position, the sequence at the 4020241 to 4020756 position, the sequence at the 4020759 to 4021535 position, and the sequence at the 658170 to 658373 position.
- the gene encoding the Tat secretory apparatus may be a variant of the gene encoding the Tat secretory apparatus exemplified above as long as the original function is maintained.
- the Tat-based secretory apparatus may be a variant of the Tat-based secretory apparatus exemplified above as long as the original function is maintained. That is, for example, the terms "tatA gene”, “tatB gene”, “tatC gene”, and “tatE gene”, respectively, in addition to the tatA gene, tatB gene, tatC gene, and tatE gene exemplified above, Conservative variants shall be included.
- TatA protein “TatB protein”, “TatC protein”, and “TatE protein” respectively refer to the TatA protein, TatB protein, TatC protein, and TatE protein exemplified above, as well as the preservation thereof. Variants are intended to be included.
- the above-mentioned description regarding the conservative variant of the LepB protein and lepB gene can be applied.
- the gene encoding the Tat secretory apparatus has one or several amino acids at one or several positions in the above amino acid sequence substituted, deleted, inserted, and It may be a gene encoding a protein having an added amino acid sequence.
- the gene encoding the Tat secretion apparatus as long as the original function is maintained, with respect to the entire amino acid sequence, 80% or more, preferably 90% or more, more preferably 95% or more, further It may be a gene encoding a protein having an amino acid sequence having an identity of preferably 97% or more, particularly preferably 99% or more.
- the original function is maintained means that in the Tat-based secretory apparatus, the function of secreting a protein having a Tat-dependent signal peptide such as TorA signal peptide added to the N-terminus to the outside of the cell. May have.
- the increase in the activity of the Tat system secretory apparatus can be confirmed, for example, by confirming that the secretory production amount of the protein in which the Tat system dependent signal peptide such as TorA signal peptide is added to the N-terminus is increased.
- the secretory production amount of the protein in which the Tat-dependent signal peptide is added to the N-terminus may be increased by, for example, 1.5 times or more, 2 times or more, or 3 times or more that of the non-modified strain.
- “Increase in protein activity” means that the activity of the protein is increased as compared to the unmodified strain. “Increased activity of a protein” specifically means that the activity of the same protein per cell is increased relative to an unmodified strain.
- the term “non-modified strain” means a control strain that has not been modified to reduce the activity of the target protein. Non-modified strains include wild strains and parent strains. Specific examples of the non-modified strain include reference strains (type strains) of each bacterial species. Specific examples of the non-modified strain also include the strains exemplified in the explanation of coryneform bacteria.
- the activity of the protein may be increased relative to the reference strain (ie the reference strain of the species to which the bacterium of the invention belongs).
- the activity of the protein may be increased as compared to the C. glutamicum ATCC 13869 strain.
- the activity of the protein may be increased as compared to the C. glutamicum ATCC 13032 strain.
- the activity of the protein may be increased as compared to C. glutamicum AJ12036 (FERM BP-734).
- the activity of the protein may be increased as compared to the C. glutamicum YDK010 strain.
- “the activity of the protein is increased” is also referred to as "the activity of the protein is enhanced”.
- the "activity of a protein is increased” means that the number of molecules of the same protein per cell is increased and / or the number of molecules of the same protein per molecule is higher than that of an unmodified strain. It may mean increased functionality. That is, the term “activity” in the case of “increasing the activity of a protein” means not only the catalytic activity of a protein but the transcription amount (mRNA amount) or translation amount (protein amount) of a gene encoding the protein. May be.
- the “number of molecules of a protein per cell” may mean an average value of the number of molecules of the same protein per cell.
- increasing the activity of the protein means not only increasing the activity of the protein in the strain originally having the activity of the target protein, but also increasing the activity of the protein in the strain in which the activity of the target protein originally does not exist. It also includes imparting activity. Further, as long as the activity of the protein is increased as a result, the activity of the target protein originally possessed by the host may be reduced or eliminated, and then the activity of the suitable target protein may be imparted.
- the degree of increase in protein activity is not particularly limited as long as the protein activity is increased as compared with the non-modified strain.
- the activity of the protein may be increased by, for example, 1.5 times or more, 2 times or more, or 3 times or more that of the unmodified strain.
- the protein when the non-modified strain does not have the activity of the target protein, the protein may be produced by introducing a gene encoding the protein, for example, the activity of the protein is measured. It may be produced to the extent possible.
- Modification such that the activity of the protein is increased can be achieved by, for example, increasing the expression of a gene encoding the protein.
- the phrase "the expression of a gene is increased” means that the expression of the gene is increased as compared with an unmodified strain such as a wild strain or a parent strain.
- “Increasing the expression of a gene” specifically means that the expression level of the same gene per cell is increased as compared with the unmodified strain.
- the "expression amount of a gene per cell” may mean the average value of the expression amount of the same gene per cell.
- Increasing the expression of a gene means, more specifically, an increase in the transcription amount (mRNA amount) of the gene and / or an increase in the translation amount (protein amount) of the gene.
- the expression of a gene increases is also called “the expression of a gene is enhanced.”
- the expression of the gene may be increased by, for example, 1.5 times or more, 2 times or more, or 3 times or more that of the unmodified strain.
- increasing the expression of the gene means not only increasing the expression amount of the gene in the strain in which the target gene is originally expressed, but in the strain in which the target gene is not originally expressed, Expression of the same gene is also included. That is, “the expression of a gene is increased” may mean, for example, introducing the same gene into a strain that does not carry the target gene and expressing the same gene.
- Increase in gene expression can be achieved, for example, by increasing the copy number of the gene.
- Increase of gene copy number can be achieved by introducing the gene into the host chromosome.
- the gene can be introduced into the chromosome, for example, by utilizing homologous recombination (Miller, JJ.H. Experiments in-Molecular Genetics, 1972, Cold Spring Harbor Laboratory).
- homologous recombination for example, the Red-driven integration method (Datsenko, K. A, and Wanner, B. L. Proc. Natl. Acad. Sci. U S A.
- the gene can be introduced into the chromosome of the host by transforming the host with recombinant DNA containing the target gene and causing homologous recombination with the target site on the chromosome of the host.
- the structure of the recombinant DNA used for homologous recombination is not particularly limited as long as homologous recombination occurs in a desired manner.
- a linear DNA containing a target gene which has a homologous nucleotide sequence upstream and downstream of the target site on the chromosome at both ends of the gene, is used to transform the host to obtain the upstream of the target site.
- the target site can be replaced with the gene by causing homologous recombination in each of the gene and the downstream.
- the recombinant DNA used for homologous recombination may be equipped with a marker gene for selecting transformants. Only one copy of the gene may be introduced, or two copies or more may be introduced. For example, multiple copies of a gene can be introduced into a chromosome by performing homologous recombination targeting a nucleotide sequence having multiple copies on the chromosome.
- Sequences in which multiple copies are present on the chromosome include repetitive DNA sequences and inverted repeats present at both ends of transposons.
- homologous recombination may be carried out by targeting an appropriate sequence on the chromosome such as a gene unnecessary for production of the target substance.
- the gene can also be introduced randomly into the chromosome using a transposon or Mini-Mu (Japanese Patent Laid-Open No. 2-109985, US5,882,888, EP805867B1). It should be noted that such a method of modifying a chromosome using homologous recombination is not limited to the introduction of a target gene, and can be used for any modification of a chromosome such as modification of an expression regulatory sequence.
- an increase in the copy number of a gene can be achieved by introducing a vector containing the gene into a host.
- a vector containing the gene for example, it is possible to increase the copy number of the gene by linking a DNA fragment containing the target gene to a vector that functions in the host to construct an expression vector of the gene and transforming the host with the expression vector.
- the DNA fragment containing the target gene can be obtained by, for example, PCR using genomic DNA of a microorganism having the target gene as a template.
- a vector capable of autonomous replication in the cells of the host can be used.
- the vector is preferably a multicopy vector.
- the vector preferably has a marker such as an antibiotic resistance gene.
- the vector may include a promoter or terminator for expressing the inserted gene.
- the vector may be, for example, a bacterial plasmid-derived vector, a yeast plasmid-derived vector, a bacteriophage-derived vector, a cosmid, or a phagemid.
- a vector capable of autonomous replication in a coryneform bacterium specifically, for example, pHM1519 (Agric. Biol. Chem., 48, 2901-2903 (1984)); pAM330 (Agric. Biol.
- plasmid having an improved drug resistance gene pCRY30 (JP-A-3-210184); pCRY21, pCRY2KE, pCRY2KX, pCRY31, pCRY3KE, and pCRY3KX (JP-A-2-72876, US Pat. No. 5,185,262).
- PCRY2 and pCRY3 JP-A-1-91686; pAJ655, pAJ611, and pAJ1844 (JP-A-58-192900); pCG1 (JP-A-57-134500); pCG2 (JP-A-58-35197); pCG4 and pCG11 (JP-A-57-183799); pVK7 (JP-A-10-215883); pVK9 (US2006-0141588); pVC7 (JP-A-9-070291); pVS7 (WO2013 / 069634).
- the gene When introducing a gene, it is sufficient that the gene is retained in the host so that it can be expressed. Specifically, the gene may be retained so that it is expressed under the control of a promoter that functions in the host.
- the promoter is not particularly limited as long as it functions in the host.
- the “promoter that functions in the host” refers to a promoter having promoter activity in the host.
- the promoter may be a host-derived promoter or a heterologous-derived promoter.
- the promoter may be a promoter specific to the gene to be introduced or a promoter of another gene. As the promoter, for example, a stronger promoter as described below may be used.
- a transcription terminator can be placed downstream of the gene.
- the terminator is not particularly limited as long as it functions in the host.
- the terminator may be a host-derived terminator or a heterologous-derived terminator.
- the terminator may be a unique terminator of the gene to be introduced or a terminator of another gene.
- the vectors, promoters, and terminators that can be used in various microorganisms are described in detail in, for example, “Basic Microbiology Course 8, Genetic Engineering, Kyoritsu Shuppan, 1987”, and it is possible to use them.
- each gene when introducing two or more genes, it is sufficient that each gene is retained in the host so that it can be expressed.
- all of the genes may be carried on a single expression vector, or all of them may be carried on the chromosome.
- each gene may be separately retained on a plurality of expression vectors, or may be separately retained on a single or a plurality of expression vectors and on a chromosome.
- the operon may be constructed by introducing two or more genes.
- the gene to be introduced is not particularly limited as long as it encodes a protein that functions in the host.
- the gene to be introduced may be a host-derived gene or a heterologous-derived gene.
- the gene to be introduced can be obtained by PCR using, for example, a primer designed on the basis of the nucleotide sequence of the gene and using as a template a genomic DNA of an organism having the gene or a plasmid carrying the gene.
- the gene to be introduced may be wholly synthesized based on the nucleotide sequence of the gene (Gene, 60 (1), 115-127 (1987)).
- the obtained gene can be used as it is or after being modified appropriately. That is, the variant can be obtained by modifying the gene.
- the gene can be modified by a known method.
- a site-directed mutagenesis method can be used to introduce a target mutation into a target site of DNA.
- the coding region of a gene can be modified such that the encoded protein contains amino acid residue substitutions, deletions, insertions, and / or additions at specific sites.
- a site-directed mutation method a method using PCR (Higuchi, R., 61, in PCR technology, Erlich, H. A. Eds., Stockton press (1989); Carter, P., Meth. In Enzymol., 154, 382 (1987)) and methods using phage (Kramer, W. and Frits, H. J., Meth. In Enzymol., 154, 350 (1987); Kunkel, T. A. et al., Meth . In Enzymol., 154, 367 (1987)).
- the gene variant may be totally synthesized.
- each subunit constituting the complex may be derived from one type of organism or two or more different types of organisms as long as the complex has the function of the target protein. That is, for example, genes derived from the same organism, which code for a plurality of subunits, may be introduced into the host, or genes derived from different organisms may be introduced into the host.
- an increase in gene expression can be achieved by improving the transcription efficiency of the gene.
- the increase in gene expression can be achieved by improving the translation efficiency of the gene.
- the transcription efficiency and translation efficiency of a gene can be improved by, for example, modifying the expression control sequence.
- “Expression control sequence” is a generic term for sites that influence the expression of genes. Expression control sequences include, for example, a promoter, a Shine-Dalgarno (SD) sequence (also called a ribosome binding site (RBS)), and a spacer region between the RBS and the start codon.
- SD Shine-Dalgarno
- RBS ribosome binding site
- the expression control sequence can be determined using a promoter search vector or gene analysis software such as GENETYX. Modification of these expression control sequences can be carried out by, for example, a method using a temperature sensitive vector or a Red driven integration method (WO2005 / 010175).
- the improvement of gene transcription efficiency can be achieved, for example, by replacing the promoter of the gene on the chromosome with a stronger promoter.
- strong promoter is meant a promoter in which transcription of a gene is improved over the naturally occurring wild-type promoter.
- stronger promoters include artificially modified P54-6 promoter (Appl. Microbiol. Biotechnol., 53, 674-679 (2000)), acetic acid in coryneform bacteria.
- the activity of the promoter can be enhanced by bringing the -35 and -10 regions in the promoter region closer to the consensus sequence (WO00 / 18935).
- highly active promoters include various tac-like promoters (Katashkina JI et al. Russian Federation Federation Patent application 2006134574). Methods for evaluating promoter strength and examples of strong promoters are described in Goldstein et al.'S paper (Prokaryotic promoters in biotechnology. Biotechnol. Annu. Rev., 1, 105-128 (1995)).
- the translation efficiency of a gene can be improved, for example, by replacing the Shine-Dalgarno (SD) sequence (also called ribosome binding site (RBS)) of the gene on the chromosome with a stronger SD sequence.
- SD Shine-Dalgarno
- RBS ribosome binding site
- strong SD sequence is meant an SD sequence in which translation of mRNA is improved over the naturally occurring native SD sequence.
- An example of a stronger SD sequence is the RBS of gene 10 derived from phage T7 (Olins P. O. et al, Gene, 1988, 73, 227-235).
- substitution or insertion or deletion of several nucleotides in the spacer region between the RBS and the start codon, especially in the sequence immediately upstream of the start codon (5'-UTR), may improve mRNA stability and translation efficiency. It is known to have a great influence, and the translation efficiency of a gene can also be improved by modifying these.
- Improve the translation efficiency of a gene can also be achieved by modifying the codon, for example.
- the translation efficiency of a gene can be improved by replacing the rare codon present in the gene with a synonymous codon used more frequently. That is, the introduced gene may be modified to have an optimal codon according to the codon usage of the host to be used.
- the codon substitution can be performed by, for example, a site-directed mutagenesis method. Alternatively, a gene fragment in which the codon is replaced may be totally synthesized.
- the frequency of codon usage in various organisms can be found in the "codon usage database" (http://www.kazusa.or.jp/codon; Nakamura, Y. et al, Nucl. Acids Res., 28, 292 (2000)) Is disclosed in.
- the increase in gene expression can also be achieved by amplifying a regulator that increases gene expression, or by deleting or weakening a regulator that decreases gene expression.
- Modification such that the activity of the protein is increased can also be achieved by, for example, enhancing the specific activity of the protein.
- the protein with enhanced specific activity can be obtained by searching various organisms, for example.
- a highly active form may be obtained by introducing a mutation into a conventional protein.
- the introduced mutation may be, for example, a substitution, deletion, insertion, and / or addition of one or several amino acids at one or several positions of the protein.
- the mutation can be introduced, for example, by the site-specific mutation method as described above.
- the mutation may be introduced by, for example, mutation treatment.
- Mutation treatments include X-ray irradiation, ultraviolet irradiation, and N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), ethyl methane sulfonate (EMS), and methyl methane sulfonate (MMS). ) Etc. treatment with a mutagen.
- DNA may be directly treated with hydroxylamine in vitro to induce random mutation.
- the enhancement of the specific activity may be used alone, or may be used in any combination with the above-mentioned method for enhancing the expression of a gene.
- the transformation method is not particularly limited, and conventionally known methods can be used.
- a method of increasing the permeability of DNA by treating recipient cells with calcium chloride as reported for Escherichia coli K-12 (Mandel, M. and Higa, A., J. Mol.Biol. 1970, 53, 159-162) and methods for preparing competent cells from cells in the growth stage and introducing DNA (Duncan, C. H., Wilson, G., as reported for Bacillus subtilis). A. and Young, F. E .., 1977. Gene 1: 153-167) can be used.
- cells of DNA recipient cells such as those known for Bacillus subtilis, actinomycetes, and yeast, are made into protoplasts or spheroplasts that readily incorporate the recombinant DNA, and the recombinant DNA is transformed into the DNA recipient.
- How to introduce (Chang, S. and Sho, N., 1979.Mol. Gen. Genet. 168: 111-115; Bibb, M. J., Ward, J. M. and Hopwood, O. A. 1978.Nature 274: 398-400; Hinnen, A., Hicks, J. B. and Fink, G. R. 1978. Proc. Natl.Acad. Sci. USA75: 1929-1933) can also be applied.
- the electric pulse method Japanese Patent Laid-Open No. 2-207791 as reported for coryneform bacteria can be used.
- the increase in protein activity can be confirmed by measuring the activity of the protein.
- the fact that the activity of the protein has increased can also be confirmed by confirming that the expression of the gene encoding the protein has increased.
- the increase in the expression of the gene can be confirmed by confirming that the transcription amount of the gene has increased or by confirming that the amount of the protein expressed from the gene has increased.
- Confirmation that the transcription amount of a gene has increased can be performed by comparing the amount of mRNA transcribed from the gene with a non-modified strain such as a wild strain or a parent strain.
- a non-modified strain such as a wild strain or a parent strain.
- methods for evaluating the amount of mRNA include Northern hybridization, RT-PCR, microarray, RNA-seq, etc. (Sambrook, J., et al., Molecular Cloning: A Laboratory Manual / Third Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor (USA), 2001).
- the amount of mRNA (for example, the number of molecules per cell) may be increased by, for example, 1.5 times or more, 2 times or more, or 3 times or more that of an unmodified strain.
- the increase in the amount of protein can be confirmed by western blotting using an antibody (Sambrook, J., et al., Molecular Cloning: A Laboratory Manual / Third Edition, Cold Spring Harbor LaboratoryPress, Cold Spring Harbor (USA), 2001).
- the amount of protein (eg, number of molecules per cell) may be increased, eg, 1.5 fold or more, 2 fold or more, or 3 fold or more that of the unmodified strain.
- the above-mentioned method for increasing the activity of a protein can be used for enhancing the activity of any protein or enhancing the expression of any gene.
- Method for reducing protein activity A method for reducing protein activity will be described below. The method for reducing the activity of the protein described below can also be used for destroying the wild-type PhoS protein.
- non-modified strain means a control strain that has not been modified to reduce the activity of the target protein.
- Non-modified strains include wild strains and parent strains. Specific examples of the non-modified strain include reference strains (type strains) of each bacterial species. Specific examples of the non-modified strain also include the strains exemplified in the explanation of coryneform bacteria.
- the activity of the protein may be reduced as compared to the reference strain (ie the reference strain of the species to which the bacterium of the present invention belongs).
- the activity of the protein may be reduced compared to C. glutamicum ATCC 13032.
- the activity of the protein may be reduced compared to C. glutamicum ATCC 13869.
- the activity of the protein may be decreased as compared to C. glutamicum AJ12036 (FERM BP-734).
- the activity of the protein may be decreased as compared with the C. glutamicum YDK010 strain.
- “the activity of the protein is decreased” includes the case where the activity of the protein is completely lost.
- the activity of the protein is reduced means that the number of molecules of the protein per cell is reduced and / or the number of molecules of the protein per cell is lower than that of an unmodified strain. It may mean that the function is deteriorated. That is, the term “activity” in the case of “decreasing the activity of a protein” means not only the catalytic activity of a protein but also the transcription amount (mRNA amount) or translation amount (protein amount) of a gene encoding the protein. May be.
- the “number of molecules of a protein per cell” may mean an average value of the number of molecules of the same protein per cell.
- the number of molecules of the protein per cell is reduced includes the case where the protein is not present at all.
- the function per molecule of the protein is reduced also includes the case where the function per molecule of the protein is completely lost.
- the degree of decrease in the protein activity is not particularly limited as long as the protein activity is decreased as compared with the unmodified strain.
- the activity of the protein may be reduced to, for example, 50% or less, 20% or less, 10% or less, 5% or less, or 0% of that of an unmodified strain.
- Modification such that the activity of the protein is reduced can be achieved by, for example, reducing the expression of a gene encoding the protein.
- reduced gene expression is meant that the expression of the gene is reduced as compared to the unmodified strain.
- Reduced expression of a gene specifically means that the expression level of the same gene per cell is reduced as compared with an unmodified strain.
- the "expression amount of a gene per cell” may mean the average value of the expression amount of the same gene per cell.
- reduced expression of a gene means, more specifically, a decreased transcription amount (mRNA amount) of a gene, and / or a decreased translation amount (protein amount) of a gene.
- Gene expression of a gene includes the case where the gene is not expressed at all. Note that “reduction of gene expression” is also referred to as “weakening of gene expression”. Gene expression may be reduced to, for example, 50% or less, 20% or less, 10% or less, 5% or less, or 0% of the unmodified strain.
- the decrease in gene expression may be due to, for example, a decrease in transcription efficiency, a decrease in translation efficiency, or a combination thereof.
- the reduction of gene expression can be achieved, for example, by modifying the expression control sequence of the gene.
- "Expression control sequence” is a generic term for a site that affects gene expression, such as a promoter, a Shine-Dalgarno (SD) sequence (also called a ribosome binding site (RBS)), a spacer region between an RBS and a start codon. Is.
- SD Shine-Dalgarno
- RBS ribosome binding site
- the expression control sequence can be determined using, for example, a promoter search vector or gene analysis software such as GENETYX.
- the expression control sequence is preferably modified by 1 base or more, more preferably 2 bases or more, particularly preferably 3 bases or more.
- the reduction of gene transcription efficiency can be achieved, for example, by replacing the promoter of the gene on the chromosome with a weaker promoter.
- weaker promoter is meant a promoter in which transcription of a gene is weaker than the naturally occurring wild-type promoter.
- weaker promoters include inducible promoters. That is, an inducible promoter may function as a weaker promoter under non-inducing conditions (eg, in the absence of inducer). Further, part or all of the expression control sequence may be deleted (deleted).
- reduction of gene expression can also be achieved by, for example, manipulating factors involved in expression control.
- Factors involved in expression control include low molecules (inducers, inhibitors, etc.), proteins (transcription factors, etc.), nucleic acids (siRNA, etc.), etc. involved in transcription and translation control.
- the reduction of gene expression can also be achieved by, for example, introducing a mutation into the coding region of the gene that reduces the gene expression.
- the expression of a gene can be reduced by replacing a codon in the coding region of the gene with a synonymous codon used less frequently in the host.
- gene expression itself may be reduced by gene disruption as described below.
- Modification such that the activity of the protein is reduced can be achieved by, for example, destroying a gene encoding the protein.
- Gene disrupted means that the gene is modified so that it does not produce a normally functioning protein.
- Does not produce a protein that functions normally means that the gene is not produced at all, or that the gene produces a protein with reduced or disappeared function (eg, activity or property) per molecule. Is included.
- Destruction of a gene can be achieved by, for example, deleting (deleting) a gene on the chromosome.
- “Deletion of a gene” refers to a deletion of a part or all of the coding region of a gene.
- the entire gene may be deleted, including the sequences before and after the coding region of the gene on the chromosome.
- the sequences before and after the coding region of the gene may include, for example, a gene expression regulatory sequence.
- the region to be deleted may be an N-terminal region (a region encoding the N-terminal side of the protein), an internal region, a C-terminal region (a region encoding the C-terminal side of the protein), etc. It may be any area.
- the region to be deleted is, for example, 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more of the entire coding region of the gene. Alternatively, it may be a region having a length of 95% or more. Further, it is preferable that the reading frames of the sequences before and after the region to be deleted do not match. Reading frame mismatches can result in frameshifts downstream of the deleted region.
- gene disruption can be performed, for example, by introducing an amino acid substitution (missense mutation) into the coding region of the gene on the chromosome, introducing a stop codon (nonsense mutation), or adding or deleting one or two bases ( It can also be achieved by introducing (frameshift mutation) (Journal of Biological Chemistry 272: 8611-8617 (1997), Proceedings of the National Academy of Science, USA 95 5511-5515 (1998), Journal of Biological , 20833-20839 (1991)).
- gene disruption can be achieved, for example, by inserting another base sequence into the coding region of the gene on the chromosome.
- the insertion site may be in any region of the gene, but a longer nucleotide sequence to be inserted can surely inactivate the gene.
- the other base sequence is not particularly limited as long as it reduces or eliminates the activity of the encoded protein, and examples thereof include a marker gene such as an antibiotic resistance gene and a gene useful for producing a target substance.
- Gene disruption may be carried out in particular so that the amino acid sequence of the encoded protein is deleted (deleted).
- the modification that reduces the activity of the protein may be carried out, for example, by deleting the amino acid sequence of the protein (a part or the whole region of the amino acid sequence). This can be achieved by modifying the gene so as to encode a protein in which a partial or entire region) is deleted.
- the term “deletion of amino acid sequence of protein” refers to deletion of part or all of the amino acid sequence of protein.
- the term “deletion of amino acid sequence of protein” means that the original amino acid sequence does not exist in the protein, and also includes the case where the original amino acid sequence is changed to another amino acid sequence.
- a region in which another amino acid sequence is changed by frame shift may be regarded as a deleted region.
- deletion of the amino acid sequence of a protein typically shortens the total length of the protein, it is possible that the total length of the protein may be unchanged or extended.
- the region encoded by the deleted region can be deleted in the amino acid sequence of the encoded protein.
- the region encoded by the region downstream from the introduction site can be deleted in the amino acid sequence of the encoded protein.
- a frame shift in the coding region of a gene can delete the region encoded by the frame shift site.
- Modifying a gene on a chromosome as described above includes, for example, preparing a disrupted gene modified so as not to produce a normally functioning protein, and transforming a host with recombinant DNA containing the disrupted gene. Then, homologous recombination is caused between the disrupted gene and the wild-type gene on the chromosome to replace the wild-type gene on the chromosome with the disrupted gene. At that time, if the recombinant DNA contains a marker gene according to the traits such as auxotrophy of the host, the operation is easy.
- the disruptive gene a gene in which a part or all of the coding region of the gene is deleted, a gene in which a missense mutation is introduced, a gene in which a nonsense mutation is introduced, a gene in which a frameshift mutation is introduced, a transposon or a marker gene, etc.
- the gene in which the insertion sequence of The protein encoded by the disruption-type gene has a three-dimensional structure different from that of the wild-type protein even if it is produced, and its function is reduced or lost.
- the structure of the recombinant DNA used for homologous recombination is not particularly limited as long as homologous recombination occurs in a desired manner.
- a host is transformed with a linear DNA containing a disruption-type gene, and the linear DNA having the upstream and downstream sequences of the wild-type gene on the chromosome at both ends is transformed into the upstream and downstream of the wild-type gene.
- the wild-type gene can be replaced with the disrupted gene by causing homologous recombination.
- Gene disruption by gene replacement using such homologous recombination has already been established, and a method called “Red-driven integration” (Datsenko, K. A, and Wanner, B. L. Proc Natl. Acad. Sci. U S A. 97: 6640-6645 (2000)), Red driven integration method and ⁇ phage-derived excision system (Cho, E.
- the modification that reduces the activity of the protein may be carried out, for example, by a mutation treatment.
- Mutation treatments include X-ray irradiation, ultraviolet irradiation, and N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), ethyl methane sulfonate (EMS), and methyl methane sulfonate (MMS). ) Etc. treatment with a mutagen.
- the decrease in protein activity can be confirmed by measuring the activity of the protein.
- the decrease in protein activity can also be confirmed by confirming the decrease in expression of the gene encoding the protein.
- the decrease in the expression of the gene can be confirmed by confirming that the transcription amount of the gene has decreased or by confirming that the amount of the protein expressed from the gene has decreased.
- Confirmation that the transcription amount of a gene has decreased can be performed by comparing the amount of mRNA transcribed from the gene with an unmodified strain.
- Examples of the method for evaluating the amount of mRNA include Northern hybridization, RT-PCR, microarray, RNA-Seq, etc. (Sambrook, J., et al., Molecular Cloning: A Laboratory Manual / Third Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor (USA), 2001).
- the amount of mRNA may be reduced to, for example, 50% or less, 20% or less, 10% or less, 5% or less, or 0% of the unmodified strain.
- Confirmation that the amount of protein has decreased can be performed by performing SDS-PAGE and confirming the intensity of the separated protein band.
- the decrease in the amount of protein can be confirmed by Western blotting using an antibody (Sambrook, J., et al., Molecular Cloning: A Laboratory Laboratory Manual / Third Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor (USA), 2001).
- the amount of protein (eg, number of molecules per cell) may be reduced to, for example, 50% or less, 20% or less, 10% or less, 5% or less, or 0% of the unmodified strain.
- the fact that a gene has been destroyed can be confirmed by determining the base sequence of part or all of the gene, the restriction enzyme map, the full length, etc., depending on the method used for the destruction.
- the above-mentioned method of reducing the activity of a protein can be used to reduce the activity of any protein or the expression of any gene.
- a secretory protein is generally translated as a preprotein (also referred to as prepeptide) or a preproprotein (also referred to as prepropeptide), and then , Is known to become a mature protein by processing.
- a secretory protein is generally translated as a preprotein or preproprotein, and then a signal peptide that is a premoiety is cleaved by a protease (generally called a signal peptidase) to be converted into a mature protein or a proprotein.
- the proprotein is further cleaved at the pro portion by a protease to become a mature protein. Therefore, in the method of the present invention, a signal peptide is used for secretory production of a heterologous protein.
- the secretory protein preprotein and preproprotein may be collectively referred to as "secretory protein precursor".
- the gene construct used in the present invention comprises, in the 5 ′ to 3 ′ direction, a promoter sequence that functions in a coryneform bacterium, a nucleic acid sequence that encodes a TorA signal peptide, and a nucleic acid sequence that encodes a heterologous protein.
- the nucleic acid sequence encoding the TorA signal peptide may be linked downstream of the promoter sequence so that the TorA signal peptide is expressed under the control of the promoter.
- the nucleic acid sequence encoding the heterologous protein may be linked downstream of the nucleic acid sequence encoding the TorA signal peptide so that the heterologous protein is expressed as a fusion protein with the signal peptide.
- the fusion protein is also referred to as “fusion protein of the present invention”.
- a heterologous protein in which the TorA signal peptide is completely removed is secreted and produced. That is, the finally obtained heterologous protein does not have the TorA signal peptide. Therefore, "heterologous protein is expressed as a fusion protein with the TorA signal peptide” means that the heterologous protein constitutes a fusion protein with the TorA signal peptide at the time of expression, and the finally obtained heterologous protein is It does not mean that it constitutes a fusion protein with the TorA signal peptide.
- the nucleic acid sequence may be read as “gene”.
- a nucleic acid sequence encoding a heterologous protein is also referred to as a “gene encoding a heterologous protein” or a “heterologous protein gene”.
- the nucleic acid sequence includes DNA.
- the gene construct used in the present invention has a control sequence (operator, SD sequence, terminator, etc.) effective for expressing the fusion protein of the present invention in a coryneform bacterium at an appropriate position so that they can function. May have.
- the promoter used in the present invention is not particularly limited as long as it is a promoter that functions in coryneform bacteria.
- the promoter may be a promoter derived from coryneform bacteria (for example, derived from a host) or a promoter derived from a different species.
- the promoter may be the native promoter of the heterologous protein gene or the promoter of another gene.
- the “promoter that functions in coryneform bacteria” refers to a promoter that has a promoter activity in coryneform bacteria.
- heterologous promoter examples include E. coli-derived promoters such as tac promoter, lac promoter, trp promoter, and araBAD promoter. Among them, strong promoters such as tac promoter and inducible promoters such as araBAD promoter are preferable.
- promoters derived from coryneform bacteria include gene promoters of PS1, PS2 (also called CspB) and SlpA (also called CspA), which are cell surface proteins, and promoters of various amino acid biosynthesis genes.
- Specific examples of the promoter of various amino acid biosynthesis genes include, for example, glutamate dehydrogenase gene of glutamate biosynthesis system, glutamine synthetase gene of glutamine synthesis system, aspartokinase gene of lysine biosynthesis system, threonine biosynthesis.
- Homoserine dehydrogenase gene isoleucine and valine biosynthesis acetohydroxy acid synthase gene, leucine biosynthesis 2-isopropylmalate synthase gene, proline and arginine biosynthesis glutamate kinase gene, histidine biosynthesis Phosphoribosyl-ATP Pyrophosphorylase gene, such as tryptophan, tyrosine and phenylalanine.
- Aromatic amino acid biosynthesis system Deoxyarabinoheptulonate phosphate (DAHP) synthase gene, such as inosinate and guanylate Examples include promoters of phosphoribosyl pyrophosphate (PRPP) amide transferase gene, inosinate dehydrogenase gene, and guanylate synthase gene in a nucleic acid biosynthesis system.
- DAHP Deoxyarabinoheptulonate phosphate
- promoters that function in coryneform bacteria include the stronger promoters that can be used in coryneform bacteria as described above.
- various reporter genes may be used to obtain and use a highly active form of a conventional promoter.
- the promoter activity can be increased by bringing the -35 and -10 regions in the promoter region closer to the consensus sequence (WO00 / 18935).
- Methods for evaluating promoter strength and examples of strong promoters are described in Goldstein et al.'S paper (Prokaryotic promoters in biotechnology. Biotechnol. Annu. Rev., 1, 105-128 (1995)).
- TorA signal peptide is a Tat system-dependent signal peptide.
- Tat system-dependent signal peptide refers to a signal peptide recognized by the Tat system.
- the “Tat system-dependent signal peptide” may specifically be a peptide in which the protein is secreted by the Tat system secretory apparatus when linked to the N-terminus of the protein of interest.
- the Tat system-dependent signal peptide has a twin arginine motif. Examples of the twin arginine motif include R-R-X-#-# (#: hydrophobic residue) (SEQ ID NO: 45).
- the TorA signal peptide includes a signal peptide of the TorA protein (trimethylamine-N-oxidoreductase) of bacteria of the Enterobacteriaceae family such as E. coli.
- the amino acid sequence of the E. coli TorA signal peptide is "MNNNDLFQASRRRFLAQLGGLTVAGMLGPSLLTPRRATA (SEQ ID NO: 46)".
- the TorA signal peptide may be a variant of the TorA signal peptide exemplified above as long as it has a twin arginine motif and the original function is maintained.
- the TorA signal peptide and the variant of the gene encoding the same the above description regarding the conservative variants of the LepB protein and lepB gene can be applied.
- the TorA signal peptide has an amino acid sequence in which one or several amino acids at one or several positions are substituted, deleted, inserted, and / or added in the amino acid sequence of the TorA signal peptide exemplified above. It may be a peptide.
- TorA signal peptide is specifically, preferably 1 to 7, more preferably 1 to 5, further preferably 1 to 3, particularly preferably 1 Means ⁇ 2
- TorA signal peptide with respect to the entire amino acid sequence of the TorA signal peptide exemplified above, 80% or more, preferably 90% or more, more preferably 95% or more, more preferably 97% or more, particularly preferably It may be a peptide having an amino acid sequence having 99% or higher identity.
- the term “TorA signal peptide” is intended to include the peptide set forth in SEQ ID NO: 46 and conservative variants thereof.
- Whether a certain peptide has a function as a Tat system-dependent signal peptide is, for example, to confirm that the secretory production amount of a protein in which the peptide is added to the N-terminus is increased by enhancing the Tat system secretory apparatus, It can be confirmed by confirming that the secretory production amount of the protein in which the peptide is added to the N-terminus is reduced by the lack of Tat-type secretory apparatus.
- the nucleic acid sequence encoding the TorA signal peptide is not particularly limited as long as it encodes the TorA signal peptide as described above.
- heterologous protein secreted and produced by the method of the present invention examples include physiologically active proteins, receptor proteins, antigen proteins used as vaccines, enzymes, and other arbitrary proteins.
- Examples of the enzyme include transglutaminase, protein glutaminase, isomaltdextranase, protease, endopeptidase, exopeptidase, aminopeptidase, carboxypeptidase, collagenase, chitinase and the like.
- transglutaminase examples include Streptoverticillium mobaraense IFO 13819 (WO01 / 23591), Streptoverticillium cinnamoneum IFO 12852, Streptoverticillium Griseocarneum IFO 12776, Streptomyces lydicus (Actinomycetes), such as mycobacterial fungi (96), Omycetes, and the like, such as Omycetes, such as 96, Omycetes, and Oomycetes.
- Examples of transglutaminase examples include transglutaminase.
- protein glutaminase include protein glutaminase of Chryseobacterium proteolyticum (WO2005 / 103278).
- isomaltdextranase examples include, for example, Arthrobacter globiformis isomaltdextranase (WO2005 / 103278).
- bioactive proteins include growth factors (growth factors), hormones, cytokines, and antibody-related molecules.
- growth factor examples include epidermal growth factor (EGF), insulin-like growth factor-1 (IGF-1), and transforming growth factor.
- TGF Transforming growth factor
- Nerve growth factor NGF
- Brain-derived neurotrophic factor BDNF
- Vascular endothelial growth factor VEGF
- G-CSF Granulocyte Colony stimulating factor
- GM-CSF Granulocyte-macrophage-colony stimulating factor
- PDGF Platelet-derived growth factor
- Erythropoietin Erythropoietin
- EPO thrombopoietin
- TPO acidic fibroblast growth factor
- aFGF or FGF1 Basic fibroblast growth factor
- bFGF or FGF2 Basic fibroblast growth factor
- keratinocyte growth factor Keratinocyte growth factor
- Hepatocyte growth factor Hepatocyte growth factor
- HGF hepatocyte growth factor
- hormones for example, insulin, glucagon, somatostatin (somatostatin), human growth hormone (human growth hormone; hGH), parathyroid hormone (parathyroid hormone; PTH), calcitonin (calcitonin), exenatide (exenatide) Can be mentioned.
- cytokines include interleukins, interferons, and tumor necrosis factor (Tumor Necrosis Factor; TNF).
- TNF Tumor Necrosis Factor
- growth factors growth factors
- hormones and cytokines
- the physiologically active protein may belong to any one group selected from growth factors (growth factors), hormones, and cytokines, and may belong to a plurality of groups selected from them. Good.
- the bioactive protein may be the whole protein or a part thereof.
- the protein include a portion having a physiological activity.
- Specific examples of the physiologically active moiety include the physiologically active peptide Teriparatide consisting of the N-terminal 34 amino acid residues of the mature form of parathyroid hormone (PTH).
- the antibody-related molecule refers to a protein containing a molecular species consisting of a single domain selected from domains constituting a complete antibody or a combination of two or more domains. Domains that make up a complete antibody include the heavy chain domains VH, CH1, CH2, and CH3, and the light chain domains VL and CL.
- the antibody-related molecule may be a monomeric protein or a multimeric protein as long as it includes the above-mentioned molecular species. When the antibody-related molecule is a multimeric protein, it may be a homomultimer composed of a single type of subunit, or a heteromultimer composed of two or more types of subunits. Good.
- the antibody-related molecule include complete antibody, Fab, F (ab ′), F (ab ′) 2 , Fc, a dimer composed of a heavy chain (H chain) and a light chain (L chain). , Fc fusion protein, heavy chain (H chain), light chain (L chain), single chain Fv (scFv), sc (Fv) 2 , disulfide bond Fv (sdFv), Diabody, VHH fragment (Nanobody (registered trademark)) Is mentioned.
- Specific examples of the antibody-related molecule include trastuzumab (Trastuzumab), adalimumab (Adalimumab), and nivolumab (Nivolumab).
- the receptor protein is not particularly limited, and may be, for example, a receptor protein for a physiologically active protein or other physiologically active substance. Examples of other physiologically active substances include neurotransmitters such as dopamine.
- the receptor protein may also be an orphan receptor for which the corresponding ligand is unknown.
- the antigen protein used as a vaccine is not particularly limited as long as it can elicit an immune response, and may be appropriately selected depending on the intended target of the immune response.
- LFABP Liver-type fatty acid-binding protein
- fluorescent protein include Green Fluorescent Protein (GFP).
- immunoglobulin-binding proteins include Protein A, Protein G, Protein L.
- albumin include human serum albumin.
- Extracellular proteins include fibronectin, vitronectin, collagen, osteopontin, laminin, and their partial sequences.
- Laminin is a protein having a heterotrimeric structure consisting of an ⁇ chain, a ⁇ chain, and a ⁇ chain.
- laminin include mammalian laminin. Examples of mammals include humans, monkeys, primates such as chimpanzees, rodents such as mice, rats, hamsters and guinea pigs, rabbits, horses, cows, sheep, goats, pigs, dogs, cats, and other various mammals. To be Mammals include in particular humans.
- the laminin subunit chains include five types of ⁇ chains ( ⁇ 1 to ⁇ 5), three types of ⁇ chains ( ⁇ 1 to ⁇ 3), and three types of ⁇ chains ( ⁇ 1). To ⁇ 3) are included.
- Laminin constitutes various isoforms by the combination of these subunit chains.
- Specific examples of the laminin include, for example, laminin 111, laminin 121, laminin 211, laminin 213, laminin 221, laminin 311, laminin 321, laminin 332, laminin 411, laminin 421, laminin 423, laminin 511, laminin 521, laminin. 523 is mentioned.
- laminin E8 which is an E8 fragment of laminin can be mentioned.
- Laminin E8 specifically has a heterotrimeric structure consisting of an ⁇ chain E8 fragment ( ⁇ chain E8), a ⁇ chain E8 fragment ( ⁇ chain E8), and a ⁇ chain E8 fragment ( ⁇ chain E8). It is a protein that has.
- the subunit chains of laminin E8 ie, ⁇ chain E8, ⁇ chain E8, and ⁇ chain E8) are also collectively referred to as “E8 subunit chain”. Examples of the E8 subunit chain include the E8 fragment of the laminin subunit chain exemplified above.
- Laminin E8 constitutes various isoforms by the combination of these E8 subunit chains.
- laminin E8 examples include laminin 111E8, laminin 121E8, laminin 211E8, laminin 221E8, laminin 332E8, laminin 421E8, laminin 411E8, laminin 511E8, and laminin 521E8.
- heterologous proteins such as these proteins can be used as they are or after being appropriately modified.
- the gene encoding the heterologous protein can be modified, eg, depending on the host used and / or to obtain the desired activity.
- a gene encoding a heterologous protein may be modified so that the amino acid sequence of the encoded heterologous protein contains one or several amino acid substitutions, deletions, insertions, and / or additions.
- the above description regarding the variants of the LepB protein and lepB gene can be applied correspondingly to the heterologous protein secreted and produced by the method of the present invention and the gene encoding the same.
- the protein specified in the biological species of origin is not limited to the protein itself found in the biological species, but includes proteins having the amino acid sequence of the protein found in the biological species and variants thereof.
- the variants may or may not be found in the species of interest. That is, for example, "human-derived protein” is not limited to the protein itself found in humans, but includes proteins having the amino acid sequence of the protein found in humans and variants thereof.
- the gene encoding the heterologous protein may be one in which any codon is replaced with a codon equivalent thereto.
- a gene encoding a heterologous protein may be modified to have an optimal codon depending on the codon usage of the host used.
- the N-terminal region of the heterologous protein finally obtained by the method of the present invention may or may not be the same as the natural protein as long as the TorA signal peptide is completely removed. Good.
- the N-terminal region of the finally obtained heterologous protein may have an extra addition or deletion of one or several amino acids as compared with the naturally occurring protein.
- the above-mentioned "1 or several" varies depending on the total length and structure of the heterologous protein of interest, but specifically, it is preferably 1 to 20, more preferably 1 to 10, and further preferably 1 to 5. It means one, particularly preferably one to three.
- the heterologous protein secreted and produced may be a protein to which a pro-structure portion is added (proprotein). If the heterologous protein secreted and produced is a proprotein, the finally obtained heterologous protein may or may not be a proprotein. That is, the proprotein may be cleaved at the prostructure to become a mature protein. Cleavage can be performed with, for example, a protease. When using a protease, it is generally preferable that the proprotein be cleaved at almost the same position as the natural protein, from the viewpoint of the activity of the finally obtained protein, and the proprotein should be cleaved at exactly the same position as the natural protein. More preferably, a mature protein identical to the natural one is obtained.
- proteases that cleave the proprotein at positions that result in the same protein as the naturally occurring mature protein are most preferred.
- the N-terminal region of the finally obtained heterologous protein may not be identical to the naturally occurring protein.
- a protein having an N-terminal longer or shorter by one to several amino acids than a naturally occurring protein may have more appropriate activity.
- Proteases that can be used in the present invention include those that are commercially available such as Dispase (manufactured by Boehringer Mannheim), as well as those obtained from a culture solution of a microorganism, such as a culture solution of actinomycetes. Such a protease may be used in an unpurified state, or may be used after being purified to an appropriate purity if necessary.
- the method for introducing the gene construct used in the present invention into coryneform bacteria is not particularly limited.
- “Introduction of the gene construct used in the present invention” refers to allowing the host to retain the gene construct.
- the “introduction of the gene construct used in the present invention” is not limited to the case where the previously constructed gene construct is introduced into the host all at once, and at least a heterologous protein gene is introduced into the host, and the gene construct is introduced in the host. Is also included.
- the gene construct used in the present invention may be present on a vector that autonomously propagates extrachromosomally such as a plasmid, or may be integrated on the chromosome.
- the introduction of the gene construct used in the present invention can be performed, for example, in the same manner as the introduction of the gene in the above-described method for increasing the expression of the gene.
- introduction of the genetic construct used in the present invention, increase of activity of LepB protein, and other modifications can be performed in any order.
- the gene construct used in the present invention can be introduced into a host using, for example, a vector containing the gene construct.
- the gene construct used in the present invention can be ligated to a vector to construct an expression vector of the gene construct, and the host can be transformed with the expression vector to introduce the gene construct into the host.
- the expression vector of the gene construct used in the present invention can also be obtained by linking the nucleotide sequence encoding the fusion protein of the present invention downstream of the promoter. Can be built.
- the vector is not particularly limited as long as it is capable of autonomous replication in coryneform bacteria.
- the vectors that can be used in coryneform bacteria are as described above.
- the gene construct used in the present invention can be introduced into the host chromosome by using a transposon such as an artificial transposon.
- a transposon such as an artificial transposon.
- the gene construct used in the present invention is introduced into the chromosome by homologous recombination or its own transposition ability.
- the gene construct used in the present invention can be introduced into the host chromosome by an introduction method utilizing homologous recombination. Examples of the introduction method utilizing homologous recombination include a method using a linear DNA, a plasmid containing a temperature-sensitive origin of replication, a plasmid capable of conjugative transfer, or a suicide vector having no origin of replication that functions in the host. Can be mentioned.
- At least a heterologous protein gene may be introduced on the chromosome to construct the gene construct used in the present invention on the chromosome.
- some or all of the components of the gene construct used in the present invention other than the heterologous protein gene may be originally present on the chromosome of the host.
- the promoter sequence originally present on the host chromosome is used as it is, and only the gene connected downstream of the promoter sequence is replaced with the nucleic acid sequence encoding the TorA signal peptide and the target heterologous protein gene.
- the gene construct used in the present invention can be constructed on the chromosome, and the bacterium of the present invention can be constructed.
- the introduction of a heterologous protein gene or the like into a part of the chromosome of the gene construct used in the present invention can be performed in the same manner as the introduction of the gene construct used in the present invention into the chromosome.
- the gene construct and its constituents (promoter sequence, nucleic acid sequence encoding TorA signal peptide, nucleic acid sequence encoding heterologous protein, etc.) used in the present invention can be obtained by, for example, cloning.
- a heterologous protein gene is obtained by cloning from an organism having a heterologous protein of interest, and modifications such as introduction of a base sequence encoding a TorA signal peptide and introduction of a promoter sequence are carried out and used in the present invention. Can be obtained.
- the gene construct and its constituents used in the present invention can also be obtained by chemical synthesis (Gene, 60 (1), 115-127 (1987)). The obtained gene construct and its constituent elements can be used as they are or after being appropriately modified.
- the gene construct for secretory expression of each protein may be retained in the bacterium of the present invention so that the secretory expression of the target heterologous protein can be achieved.
- all of the gene constructs for secretory expression of each protein may be held on a single expression vector, or all may be held on the chromosome.
- the gene construct for secretory expression of each protein may be separately held on a plurality of expression vectors, or may be separately held on a single or a plurality of expression vectors and on a chromosome. “When expressing two or more kinds of proteins” means, for example, a case where two or more kinds of heterologous proteins are secreted and produced, or a case where a heteromultimeric protein is secreted and produced.
- the method for introducing the gene construct used in the present invention into a coryneform bacterium is not particularly limited, and a commonly used method such as the protoplast method (Gene, 39, 281-286 (1985)), the electroporation method (Bio / Technology, 7, 1067-1070 (1989)), the electric pulse method (Japanese Patent Laid-Open No. 2-207791), etc. can be used.
- the bacterium of the present invention can be cultivated according to the methods and conditions usually used.
- the bacterium of the present invention can be cultured in an ordinary medium containing a carbon source, a nitrogen source, and an inorganic ion. If necessary, organic micronutrients such as vitamins and amino acids can be added to obtain higher growth.
- the carbon source carbohydrates such as glucose and sucrose, organic acids such as acetic acid, alcohols, etc. can be used.
- the nitrogen source ammonia gas, aqueous ammonia, ammonium salt, etc. can be used.
- the inorganic ion calcium ion, magnesium ion, phosphate ion, potassium ion, iron ion and the like are appropriately used as necessary.
- the culture is carried out under an aerobic condition in an appropriate range of pH 5.0 to 8.5 and 15 ° C to 37 ° C, and the culture is performed for about 1 to 7 days.
- the culture conditions for L-amino acid production of coryneform bacteria and the conditions described in the method for secretory production of proteins using signal peptides can be used (see WO01 / 23591, WO2005 / 103278).
- a promoter inducer may be added to the medium for culturing.
- the produced heterologous protein is secreted outside the microbial cell, for example, a protein that is generally lethal when accumulated in a large amount in the microbial cell of a microorganism such as transglutaminase also has a lethal effect. Can be continuously produced without receiving.
- the protein secreted into the medium by the method of the present invention can be separated and purified from the medium after culture according to the method well known to those skilled in the art. For example, after removing cells by centrifugation, salting out, ethanol precipitation, ultrafiltration, gel filtration chromatography, ion exchange column chromatography, affinity chromatography, medium and high pressure liquid chromatography, reverse phase chromatography, hydrophobicity. It can be separated and purified by a known appropriate method such as chromatography or a combination thereof. In some cases, the culture or culture supernatant may be used as it is.
- the protein secreted in the cell surface layer by the method of the present invention is the same as that secreted into the medium after being solubilized by a method well known to those skilled in the art, for example, by increasing the salt concentration, using a surfactant, etc. Can be separated and purified.
- the protein secreted in the cell surface may be used as, for example, an immobilized enzyme without being solubilized.
- the secreted production of the target heterologous protein can be confirmed by performing SDS-PAGE using the culture supernatant and / or the fraction containing the cell surface layer as a sample and confirming the molecular weight of the separated protein band.
- the secretory production of the target heterologous protein can be confirmed by Western blotting using an antibody using the culture supernatant and / or the fraction containing the cell surface as a sample (Molecular cloning (Cold Spring Laboratory Laboratory Press, Cold Spring Harbor (USA), 2001)).
- the secretory production of the target heterologous protein can be confirmed by detecting the N-terminal amino acid sequence of the target protein using a protein sequencer.
- the secretory production of the target heterologous protein can be confirmed by determining the mass of the target protein using a mass spectrometer.
- the secretory production of the heterologous protein of interest means that the culture supernatant and / or the fraction containing the cell surface layer is It can be confirmed as a sample by measuring the enzymatic activity or physiological activity of the target heterologous protein.
- Example 1 Construction of vector for amplifying C. glutamicum ATCC13869-derived signal peptidase gene (lepB)
- the genomic sequence of C. glutamicum ATCC13869 strain and the nucleotide sequence of lepB gene encoding Type I signal peptidase (LepB) have already been determined.
- GenBank Accession No. AP017557, NCBI locus_tag CGBL_0119390 The nucleotide sequence of the lepB gene derived from the C. glutamicum ATCC13869 strain is shown in ⁇ SEQ ID NO: 01>, and the amino acid sequence of the LepB protein is shown in ⁇ SEQ ID NO: 02>.
- This PCR fragment was digested with restriction enzymes KpnI and XbaI and inserted into the KpnI-XbaI site of the pPK5 vector described in WO2016 / 171224 by a ligation reaction to construct a vector pPK5lepB for amplifying lepB gene.
- the vector pPK6lepB for tatABC secretory apparatus gene and lepB gene amplification was built.
- the pPK5 vector is a vector obtained by modifying the NaeI restriction enzyme site in the pPK4 vector described in JP-A-9-322774
- the pPK6 vector is a vector for TatABC secretion apparatus amplification in which the tatABC gene is mounted on the pPK5 vector (Fig. 1). Panels A and C).
- Nucleotide sequence was determined using BigDye (R) Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and 3130 Genetic Analyzer (Applied Biosystems).
- the loading order of the expression cassette of the lepB gene and the target protein can be regulated (Fig. 1 panels B and D).
- Example 2 Evaluation of lepB gene amplification effect on secretory expression of transglutaminase (PTG) with a pro structure using a TorA signal sequence
- Secretion expression YDK010 :: phoS (W302C) / pPK6_T_PTG strain described in WO2016 / 171224 was added to MMTG liquid medium containing 25 mg / l kanamycin (glucose 120 g, magnesium sulfate heptahydrate 3 g, ammonium sulfate 30 g, phosphorus Potassium dihydrogen acid 1.5 g, iron sulfate heptahydrate 0.03 g, manganese sulfate pentahydrate 0.03 g, thiamine hydrochloride 0.45 mg, biotin 0.45 mg, DL-methionine 0.15 g, soy hydrochloric acid hydroly
- pPK6_T_PTG is a vector for secretory expression of transglutaminase (PTG) with a pro-structure part constructed from the tatABC gene amplification vector pPK6, and a promoter derived from the cspB gene of C. glutamicum ATCC13869 strain, downstream of the promoter.
- the YDK010 :: phoS (W302C) strain is a PhoS (W302C) mutation in the phoS gene on the chromosome of YDK010 strain (WO2002 / 081694), which is a defective strain of the cell surface protein CspB of C. glutamicum AJ12036 (FERM BP-734). Is a strain introduced with (WO2016 / 171224). After completion of the culture, 1.0 ⁇ l of the culture supernatant obtained by centrifuging the culture solution was subjected to reducing SDS-PAGE using MULTIGEL (R) II mini 15/20 (Cosmo Bio), and then SYPRO (R) Orange.
- the plasmids pPK6lepB (K) _T_PTG and pPK6lepB (A) _T_PTG were constructed (FIG. 1, panel D).
- the plasmid names (K) and (A) represent the restriction enzyme sites (KpnI site and ApaI site) of the pPK6lepB vector into which the PTG expression cassette was inserted.
- the In-Fusion (R) HD Cloning Kit (Takara Bio) was used for the infusion reaction, and the reaction conditions followed the protocol recommended by the vendor. As a result of determining the nucleotide sequence of the inserted fragment, it was confirmed that the expected genes were inserted. Nucleotide sequence was determined using BigDye (R) Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and 3130 Genetic Analyzer (Applied Biosystems).
- Each of the obtained transformants was cultured in an MMTG liquid medium containing 25 mg / l kanamycin at 30 ° C. for 72 hours. After culturing, 1.0 ⁇ l of the culture supernatant obtained by centrifuging each culture was subjected to reducing SDS-PAGE using MULTIGEL (R) II mini 15/20 (Cosmo Bio), and then SYPRO (R). Staining was performed with Orange (Thermo Fisher Scientific).
- Example 3 Evaluation of lepB gene amplification effect in secretory expression of protein glutaminase (PPG) with a pro-structured portion using TorA signal sequence
- PPG protein glutaminase
- TorA signal sequence a pro-structured portion using TorA signal sequence
- pPK6_T_PPG is a vector for secretory expression of protein glutaminase (PPG) with a pro-structure part constructed from the tatABC gene amplification vector pPK6, and a promoter derived from the cspB gene of C. glutamicum ATCC13869 strain, downstream of the promoter.
- PPG protein glutaminase
- Plasmids pPK6lepB (K) _T_PPG and pPK6lepB (A) _T_PPG were constructed (Panel D in Figure 1).
- the plasmid names (K) and (A) represent the restriction enzyme sites (KpnI site and ApaI site) of the pPK6lepB vector into which the PPG expression cassette was inserted.
- the In-Fusion (R) HD Cloning Kit (Takara Bio) was used for the infusion reaction, and the reaction conditions followed the protocol recommended by the vendor. As a result of determining the nucleotide sequence of the inserted fragment, it was confirmed that the expected genes were inserted. Nucleotide sequence was determined using BigDye (R) Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and 3130 Genetic Analyzer (Applied Biosystems).
- Each of the obtained transformants was cultured in an MMTG liquid medium containing 25 mg / l kanamycin at 30 ° C. for 72 hours. After completion of the culture, 2.5 ⁇ l of the culture supernatant obtained by centrifuging each culture was subjected to reducing SDS-PAGE using MULTIGEL (R) II mini 15/20 (Cosmo Bio), and then SYPRO (R). Staining was performed with Orange (Thermo Fisher Scientific).
- Example 4 Evaluation of lepB gene amplification effect on ⁇ -lactamase (Bla) secretion expression using TorA signal sequence
- Bla a co-expression plasmid for TEM-
- the amino acid sequence of the TEM-type class A broad-spectrum ⁇ -lactamase TEM-116, which is a type of ⁇ -lactamase (hereinafter referred to as Bla) is already known.
- the amino acid sequence of 263 residues at positions 24-286 excluding the N-terminal signal sequence is shown in ⁇ SEQ ID NO: 11>.
- the nucleotide sequence encoding Bla of SEQ ID NO: 11 was designed.
- the designed nucleotide sequence is shown in ⁇ SEQ ID NO: 12>.
- pPK6_T_Bla which is a Bla secretory expression plasmid using the TorA signal sequence (FIG. 1, panel C).
- pPK6_T_Bla a Bla secretory expression plasmid using the TorA signal sequence (FIG. 1, panel C).
- Plasmids pPK6lepB (K) _T_Bla and pPK6lepB (A) _T_Bla were constructed (Panel D in Figure 1).
- the plasmid names (K) and (A) represent the restriction enzyme sites (KpnI site and ApaI site) of the pPK6lepB vector into which the Bla expression cassette was inserted.
- the In-Fusion (R) HD Cloning Kit (Takara Bio) was used for the infusion reaction, and the reaction conditions followed the protocol recommended by the vendor. As a result of determining the nucleotide sequence of the inserted fragment, it was confirmed that the expected genes were inserted. Nucleotide sequence was determined using BigDye (R) Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and 3130 Genetic Analyzer (Applied Biosystems).
- Each of the obtained transformants was cultured in an MMTG liquid medium containing 25 mg / l kanamycin at 30 ° C. for 72 hours. After culturing, 5.0 ⁇ l of the culture supernatant obtained by centrifuging each culture was subjected to reducing SDS-PAGE using NuPAGE (R) 4-12% Bis-Tirs Gel (Thermo Fisher Scientific). Staining was performed with SYPRO (R) Ruby (Thermo Fisher Scientific).
- Trx thioredoxin
- the DNA encoding the 39 amino acid residues of the signal peptide of the TorA protein (UniProtAccession number: P33225) derived from E.coli downstream of the promoter of the cspB gene derived from C.glutamicum ATCC13869 strain and ⁇ SEQ ID NO: 16> was ligated, the KpnI site was added to the 5'-side, and the ApaI site was added to the 3'-side, and the expression cassette of the fusion protein of the TorA signal peptide and Trx was totally synthesized.
- TrP secretory expression plasmid pPK6_T_Trx (FIG. 1, panel C).
- the Trx gene expression cassette as designed was constructed. Nucleotide sequence was determined using BigDye (R) Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and 3130 Genetic Analyzer (Applied Biosystems).
- Trx Secretion Expression Vector Using the Trx secretory expression vector pPK6_T_Trx constructed in Example 5 (1) as a template, ⁇ SEQ ID NO: 05> and ⁇ SEQ ID NO: 17> primers, or ⁇ Using the primers of SEQ ID NO: 07> and ⁇ SEQ ID NO: 18>, a DNA fragment of about 1.1 kbp containing the expression cassette of cspB promoter-TorA signal sequence-Trx was amplified by PCR.
- the plasmids pPK6lepB (K) _T_Trx and pPK6lepB (A) _T_Trx were constructed (panel D of FIG. 1).
- the plasmid names (K) and (A) represent the restriction enzyme sites (KpnI site and ApaI site) of the pPK6lepB vector into which the Trx expression cassette was inserted.
- the In-Fusion (R) HD Cloning Kit (Takara Bio) was used for the infusion reaction, and the reaction conditions followed the protocol recommended by the vendor. As a result of determining the nucleotide sequence of the inserted fragment, it was confirmed that the expected genes were inserted. Nucleotide sequence was determined using BigDye (R) Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and 3130 Genetic Analyzer (Applied Biosystems).
- Tr2016 secretion expression plasmids pPK6lepB (K) _T_Trx and pPK6lepB (A) _T_Trx constructed in Example 5 (3) were used to WO2016 / 171224.
- YDK010 was transformed to obtain the YDK010 :: phoS (W302C) / pPK6lepB (K) _T_Trx strain and the YDK010 :: phoS (W302C) / pPK6lepB (A) _T_Trx strain.
- Each of the obtained transformants was cultured in an MMTG liquid medium containing 25 mg / l kanamycin at 30 ° C. for 72 hours.
- Trx secretion production using the TorA signal sequence under the non-amplification condition of the lepB gene, a residual residue of the C-terminal 15 residues of the TorA signal peptide remains, but by amplification of the lepB gene, the TorA signal peptide It was found that processing can be promoted and the production efficiency of Trx having the correct N-terminal amino acid sequence can be significantly improved.
- Example 6 Evaluation of lepB gene amplification effect on secretory expression of Liver-type fatty acid-binding protein (LFABP) using TorA signal sequence
- LFABP Liver-type fatty acid-binding protein
- DNA encoding the 39 amino acid residues of the signal peptide of the E. coli-derived TorA protein (UniProtAccession number: P33225) downstream of the promoter of the cspB gene derived from C. glutamicum ATCC13869 strain and described in ⁇ SEQ ID NO: 20> was ligated, and a KpnI site was added to the 5'-side and an ApaI site was added to the 3'-side, and an expression cassette of a fusion protein of the TorA signal peptide and LFABP was totally synthesized.
- the totally synthesized DNA fragment was inserted into the KpnI-ApaI site of the pPK6 vector described in WO2016 / 171224 to construct a secretory expression plasmid of LFABP, pPK6_T_LFABP (FIG. 1, panel C).
- a secretory expression plasmid of LFABP LFABP
- pPK6_T_LFABP LFABP gene expression cassette as designed was constructed.
- Nucleotide sequence was determined using BigDye (R) Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and 3130 Genetic Analyzer (Applied Biosystems).
- the amino acid sequence (GMLGPSLLTP; SEQ ID NO: 47) showing that the C-terminal 15 residues of the TorA signal sequence remains at the N-terminal of LFABP in the high-molecular side band ), And the N-terminal sequence (APDSDWDRLA; SEQ ID NO: 52) of the mature protein of C. glutamicum-derived resuscitation-promoting factor Rpf1 (GenBank Accession No. AP017557, NCBI locus_tag CGBL_0109030) is detected, and the high molecular weight band is mainly It was confirmed to be a mixed band of these two proteins (FIG. 6, panel B).
- the primers of ⁇ SEQ ID NO: 05> and ⁇ SEQ ID NO: 21> are designed with the restriction enzyme KpnI recognition sequence
- the primers of ⁇ SEQ ID NO: 07> and ⁇ SEQ ID NO: 22> are designed with the restriction enzyme ApaI recognition sequence.
- PrimeSTAR (R) HS DNA Polymerase (Takara Bio) was used for PCR, and the reaction conditions followed the protocol recommended by the manufacturer.
- Plasmids pPK6lepB (K) _T_LFABP and pPK6lepB (A) _T_FABP were constructed (Panel D in Figure 1).
- the plasmid names (K) and (A) represent the restriction enzyme sites (KpnI site and ApaI site) of the pPK6lepB vector into which the LFABP expression cassette was inserted.
- the In-Fusion (R) HD Cloning Kit (Takara Bio) was used for the infusion reaction, and the reaction conditions followed the protocol recommended by the vendor. As a result of determining the nucleotide sequence of the inserted fragment, it was confirmed that the expected genes were inserted. Nucleotide sequence was determined using BigDye (R) Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and 3130 Genetic Analyzer (Applied Biosystems).
- YDK010 was transformed to obtain the YDK010 :: phoS (W302C) / pPK6lepB (K) _T_LFABP strain and the YDK010 :: phoS (W302C) / pPK6lepB (A) _T_LFABP strain.
- Each of the obtained transformants was cultured in an MMTG liquid medium containing 25 mg / l kanamycin at 30 ° C. for 72 hours. After culturing, 5.0 ⁇ l of the culture supernatant obtained by centrifuging each culture was subjected to reducing SDS-PAGE using NuPAGE (R) 4-12% Bis-Tirs Gel (Thermo Fisher Scientific).
- the N-terminal amino acid sequence of LFABP (MSFSGKYQLQ; SEQ ID NO: 53) was confirmed in the low molecular weight band. That is, in LFABP secretory production using a TorA signal sequence, under the non-amplification condition of lepB gene, a residual residue of the C-terminal 15 residues of the TorA signal peptide remains, but by amplification of the lepB gene of the TorA signal peptide It was found that processing can be promoted and the production efficiency of LFABP having the correct N-terminal amino acid sequence can be significantly improved.
- Example 7 Evaluation of lepB gene amplification effect on secretory expression of transglutaminase (PTG) with pro-structure part using SlpA signal sequence
- PTG transglutaminase
- the recognition sequences for the restriction enzyme KpnI are designed in the primers of ⁇ SEQ ID NO: 23> and ⁇ SEQ ID NO: 24>, respectively.
- PrimeSTAR (R) HS DNA Polymerase (Takara Bio) was used for PCR, and the reaction conditions followed the protocol recommended by the manufacturer.
- This DNA fragment was inserted into the KpnI site of the pPK5 vector described in WO2016 / 171224 by an infusion reaction to construct pPK5_S_PTG which is a PTG secretory expression vector using the SlpA signal sequence (FIG. 1, panel A).
- In-Fusion (R) HD Cloning Kit (Takara Bio) was used for the infusion reaction, and the reaction conditions followed the protocol recommended by the manufacturer.
- nucleotide sequence of the inserted fragment As a result of determining the nucleotide sequence of the inserted fragment, it was confirmed that the expected gene had been inserted.
- the nucleotide sequence was determined using BigDye (R) Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and 3130 Genetic Analyzer (Applied Biosystems).
- the ⁇ SEQ ID NO: 23> and ⁇ SEQ ID NO: 25> primers are designed with a restriction enzyme KpnI recognition sequence
- the ⁇ SEQ ID NO: 26> and ⁇ SEQ ID NO: 27> primers are designed with a restriction enzyme ApaI recognition sequence.
- PrimeSTAR (R) HS DNA Polymerase (Takara Bio) was used for PCR, and the reaction conditions followed the protocol recommended by the manufacturer. These DNA fragments were inserted into the KpnI site or the ApaI site of the pPK5lepB vector constructed in Example 1 by an infusion reaction to obtain the lepB gene and pPK5lepB which is a co-expression vector for PTG secretion using the SlpA signal sequence.
- (K) _S_PTG and pPK5lepB (A) _S_PTG were constructed (panel B in Figure 1).
- the plasmid names (K) and (A) represent the restriction enzyme sites (KpnI site and ApaI site) of the pPK5lepB vector into which the PTG expression cassette was inserted.
- In-Fusion (R) HD Cloning Kit (Takara Bio) was used for the infusion reaction, and the reaction conditions followed the protocol recommended by the manufacturer. As a result of determining the nucleotide sequence of the inserted fragment, it was confirmed that the expected genes were inserted.
- the nucleotide sequence was determined using BigDye (R) Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and 3130 Genetic Analyzer (Applied Biosystems).
- Each of the obtained transformants was cultured in an MMTG liquid medium containing 25 mg / l kanamycin at 30 ° C. for 72 hours. After completion of the culture, 5.0 ⁇ l of the culture supernatant obtained by centrifuging each culture was subjected to reducing SDS-PAGE using MULTIGEL (R) II mini 15/20 (Cosmo Bio), and then SYPRO (R). Staining was performed with Orange (Thermo Fisher Scientific).
- a heterologous protein can be efficiently secreted and produced.
- SEQ ID NO: 1 nucleotide sequence of lepB gene of C. glutamicum ATCC 13869
- SEQ ID NO: 2 amino acid sequence of LepB protein of C. glutamicum ATCC 13869
- SEQ ID NOS: 3 to 10 primer
- SEQ ID NO: 11 amino acid sequence of ⁇ -lactamase TEM-116
- SEQ ID NO: 12 nucleotide sequence encoding ⁇ -lactamase TEM-116
- SEQ ID NOs: 13 to 14 primer SEQ ID NO: 15: amino acid sequence of modified TrxA protein of E. coli
- SEQ ID NO: 16 modified TrxA protein of E.
- SEQ ID NO: 32 amino acid sequence of PhoS protein of C. callunae
- SEQ ID NO: 33 amino acid sequence of PhoS protein of crenatum
- SEQ ID NO: 34 C. efficiens PhoS protein amino acid sequence
- SEQ ID NO: 35 nucleotide sequence of phoR gene of C. glutamicum ATCC 13032
- SEQ ID NO: 36 amino acid sequence of PhoR protein of C. glutamicum ATCC 13032
- Nucleotide sequence SEQ ID NO: 38 Amino acid sequence of CspB protein of C.
- SEQ ID NO: 45 amino acid sequence of twin arginine motif
- SEQ ID NO: 46 amino acid sequence of TorA signal peptide
- SEQ ID NOs: 47 to 53 N-terminal amino acid sequence
- SEQ ID NOs: 54 to 59 N-terminal amino acid sequence of protein containing signal peptide
Abstract
Description
[1]
異種タンパク質の製造方法であって、
異種タンパク質の分泌発現用の遺伝子構築物を有するコリネ型細菌を培養すること、および
分泌生産された異種タンパク質を回収することを含み、
前記コリネ型細菌が、LepBタンパク質の活性が非改変株と比較して増大するように改変されており、
前記遺伝子構築物が、5’から3’方向に、コリネ型細菌で機能するプロモーター配列、TorAシグナルペプチドをコードする核酸配列、および異種タンパク質をコードする核酸配列を含み、
前記異種タンパク質が、前記TorAシグナルペプチドとの融合タンパク質として発現する、方法。
[2]
前記LepBタンパク質が、下記(a)、(b)、または(c)に記載のタンパク質である、前記方法:
(a)配列番号2に示すアミノ酸配列を含むタンパク質;
(b)配列番号2に示すアミノ酸配列において、1~10個のアミノ酸残基の置換、欠失、挿入、および/または付加を含むアミノ酸配列を含み、且つ、TorAシグナルペプチドに対するシグナルペプチダーゼ活性を有するタンパク質;
(c)配列番号2に示すアミノ酸配列に対して90%以上の同一性を有するアミノ酸配列を含み、且つ、TorAシグナルペプチドに対するシグナルペプチダーゼ活性を有するタンパク質。
[3]
lepB遺伝子の発現を上昇させることにより、前記LepBタンパク質の活性が増大した、前記方法。
[4]
前記lepB遺伝子の発現が、該遺伝子のコピー数を高めること、および/または該遺伝子の発現調節配列を改変することによって上昇した、前記方法。
[5]
前記TorAシグナルペプチドが、下記(a)、(b)、または(c)に記載のペプチドである、前記方法:
(a)配列番号46に示すアミノ酸配列を含むペプチド;
(b)配列番号46に示すアミノ酸配列において、1~3個のアミノ酸残基の置換、欠失、挿入、および/または付加を含むアミノ酸配列を含み、且つ、Tat系依存シグナルペプチドとしての機能を有するペプチド;
(c)配列番号46に示すアミノ酸配列に対して90%以上の同一性を有するアミノ酸配列を含み、且つ、Tat系依存シグナルペプチドとしての機能を有するペプチド。
[6]
前記TorAシグナルペプチドが、配列番号46に示すアミノ酸配列からなる、前記方法。
[7]
前記分泌生産された異種タンパク質が、前記TorAシグナルペプチドが完全に除去された異種タンパク質である、前記方法。
[8]
前記コリネ型細菌が、さらに、変異型PhoSタンパク質をコードするphoS遺伝子を保持するように改変されている、前記方法。
[9]
前記変異が、野生型PhoSタンパク質において、配列番号29の302位のトリプトファン残基に相当するアミノ酸残基が芳香族アミノ酸およびヒスチジン以外のアミノ酸残基に置換される変異である、前記方法。
[10]
前記芳香族アミノ酸およびヒスチジン以外のアミノ酸残基が、リジン残基、アラニン残基、バリン残基、セリン残基、システイン残基、メチオニン残基、アスパラギン酸残基、またはアスパラギン残基である、前記方法。
[11]
前記野生型PhoSタンパク質が、下記(a)、(b)、または(c)に記載のタンパク質である、前記方法:
(a)配列番号29~34のいずれかに示すアミノ酸配列を含むタンパク質;
(b)配列番号29~34のいずれかに示すアミノ酸配列において、1~10個のアミノ酸残基の置換、欠失、挿入、および/または付加を含むアミノ酸配列を含み、且つ、PhoRSシステムのセンサーキナーゼとしての機能を有するタンパク質;
(c)配列番号29~34のいずれかに示すアミノ酸配列に対し90%以上の同一性を有するアミノ酸配列を含み、且つ、PhoRSシステムのセンサーキナーゼとしての機能を有するタンパク質。
[12]
前記コリネ型細菌が、さらに、Tat系分泌装置をコードする遺伝子から選択される1種またはそれ以上の遺伝子の発現が非改変株と比較して上昇するように改変されている、前記方法。
[13]
前記Tat系分泌装置をコードする遺伝子が、tatA遺伝子、tatB遺伝子、tatC遺伝子、およびtatE遺伝子からなる、前記方法。
[14]
前記コリネ型細菌が、コリネバクテリウム属細菌である、前記方法。
[15]
前記コリネ型細菌が、コリネバクテリウム・グルタミカムである、前記方法。
[16]
前記コリネ型細菌が、コリネバクテリウム・グルタミカムAJ12036(FERM BP-734)に由来する改変株またはコリネバクテリウム・グルタミカムATCC 13869に由来する改変株である、前記方法。
[17]
前記コリネ型細菌が、細胞表層タンパク質の細胞当たりの分子数が非改変株と比較して低下しているコリネ型細菌である、前記方法。
本発明の方法に用いられるコリネ型細菌は、異種タンパク質の分泌発現用の遺伝子構築物を有するコリネ型細菌であって、且つ、LepBタンパク質の活性が増大するように改変されたコリネ型細菌である。なお、本発明の方法に用いられるコリネ型細菌を「本発明の細菌」または「本発明のコリネ型細菌」ともいう。また、本発明の細菌が有する異種タンパク質の分泌発現用の遺伝子構築物を「本発明に用いられる遺伝子構築物」ともいう。また、本発明の細菌またはそれを構築するために用いられる株を「宿主」ともいう。
本発明のコリネ型細菌は、異種タンパク質(具体的には、完全切断型の異種タンパク質)を分泌生産する能力を有する。本発明のコリネ型細菌は、少なくとも異種タンパク質の分泌発現用の遺伝子構築物(本発明に用いられる遺伝子構築物)を有することに依拠して、異種タンパク質を分泌生産する能力を有する。本発明のコリネ型細菌は、具体的には、異種タンパク質の分泌発現用の遺伝子構築物を有することにより、または異種タンパク質の分泌発現用の遺伝子構築物を有することと他の性質との組み合わせにより、異種タンパク質を分泌生産する能力を有していてよい。
コリネバクテリウム・アセトアシドフィラム(Corynebacterium acetoacidophilum)
コリネバクテリウム・アセトグルタミカム(Corynebacterium acetoglutamicum)
コリネバクテリウム・アルカノリティカム(Corynebacterium alkanolyticum)
コリネバクテリウム・カルナエ(Corynebacterium callunae)
コリネバクテリウム・クレナタム(Corynebacterium crenatum)
コリネバクテリウム・グルタミカム(Corynebacterium glutamicum)
コリネバクテリウム・リリウム(Corynebacterium lilium)
コリネバクテリウム・メラセコーラ(Corynebacterium melassecola)
コリネバクテリウム・サーモアミノゲネス(コリネバクテリウム・エフィシエンス)(Corynebacterium thermoaminogenes (Corynebacterium efficiens))
コリネバクテリウム・ハーキュリス(Corynebacterium herculis)
ブレビバクテリウム・ディバリカタム(コリネバクテリウム・グルタミカム)(Brevibacterium divaricatum (Corynebacterium glutamicum))
ブレビバクテリウム・フラバム(コリネバクテリウム・グルタミカム)(Brevibacterium flavum (Corynebacterium glutamicum))
ブレビバクテリウム・イマリオフィラム(Brevibacterium immariophilum)
ブレビバクテリウム・ラクトファーメンタム(コリネバクテリウム・グルタミカム)(Brevibacterium lactofermentum (Corynebacterium glutamicum))
ブレビバクテリウム・ロゼウム(Brevibacterium roseum)
ブレビバクテリウム・サッカロリティカム(Brevibacterium saccharolyticum)
ブレビバクテリウム・チオゲニタリス(Brevibacterium thiogenitalis)
コリネバクテリウム・アンモニアゲネス(コリネバクテリウム・スタティオニス)(Corynebacterium ammoniagenes (Corynebacterium stationis))
ブレビバクテリウム・アルバム(Brevibacterium album)
ブレビバクテリウム・セリナム(Brevibacterium cerinum)
ミクロバクテリウム・アンモニアフィラム(Microbacterium ammoniaphilum)
Corynebacterium acetoacidophilum ATCC 13870
Corynebacterium acetoglutamicum ATCC 15806
Corynebacterium alkanolyticum ATCC 21511
Corynebacterium callunae ATCC 15991
Corynebacterium crenatum AS1.542
Corynebacterium glutamicum ATCC 13020, ATCC 13032, ATCC 13060, ATCC 13869, FERM BP-734
Corynebacterium lilium ATCC 15990
Corynebacterium melassecola ATCC 17965
Corynebacterium efficiens (Corynebacterium thermoaminogenes) AJ12340 (FERM BP-1539)
Corynebacterium herculis ATCC 13868
Brevibacterium divaricatum (Corynebacterium glutamicum) ATCC 14020
Brevibacterium flavum (Corynebacterium glutamicum) ATCC 13826, ATCC 14067, AJ12418 (FERM BP-2205)
Brevibacterium immariophilum ATCC 14068
Brevibacterium lactofermentum (Corynebacterium glutamicum) ATCC 13869
Brevibacterium roseum ATCC 13825
Brevibacterium saccharolyticum ATCC 14066
Brevibacterium thiogenitalis ATCC 19240
Corynebacterium ammoniagenes (Corynebacterium stationis) ATCC 6871, ATCC 6872
Brevibacterium album ATCC 15111
Brevibacterium cerinum ATCC 15112
Microbacterium ammoniaphilum ATCC 15354
本発明の細菌は、LepBタンパク質の活性が増大するように改変されている。本発明の細菌は、具体的には、LepBタンパク質の活性が非改変株と比較して増大するように改変されている。本発明の細菌は、より具体的には、lepB遺伝子の発現が増大するように改変されていてよい。LepBタンパク質の活性が増大するようにコリネ型細菌を改変することにより、同細菌によるTorAシグナルペプチドを利用した異種タンパク質の分泌生産におけるTorAシグナルペプチドの切れ残りを低減することができる。TorAシグナルペプチドの切れ残りの低減としては、TorAシグナルペプチドの切れ残り率の低下が挙げられる。「TorAシグナルペプチドの切れ残り率」とは、異種タンパク質の総分泌生産量に対する切れ残り型(mis-cleaved form)の異種タンパク質の分泌生産量の重量比をいう。「異種タンパク質の総分泌生産量」とは、完全切断型の異種タンパク質の分泌生産量と切れ残り型の異種タンパク質の分泌生産量との合計をいう。「切れ残り型の異種タンパク質」とは、TorAシグナルペプチドが部分的に除去された、すなわち、TorAシグナルペプチドのC末端側部分配列を保持する、異種タンパク質をいう。TorAシグナルペプチドのC末端側部分配列としては、TorAシグナルペプチドのC末端側15残基のアミノ酸配列が挙げられる。TorAシグナルペプチドのC末端側部分配列として、具体的には、配列番号46の25~39位のアミノ酸配列が挙げられる。本発明の方法におけるTorAシグナルペプチドの切れ残り率は、例えば、3%以下、1%以下、0.5%以下、0.3%以下、0.1%以下、または0%であってよい。また、本発明の方法におけるTorAシグナルペプチドの切れ残り率は、例えば、非改変株(ここではLepBタンパク質の活性が増大するように改変されていない株)を用いた場合のTorAシグナルペプチドの切れ残り率の、50%以下、30%以下、10%以下、5%以下、3%以下、1%以下、または0%であってよい。また、LepBタンパク質の活性が増大するようにコリネ型細菌を改変することにより、TorAシグナルペプチドを利用する際の同細菌の異種タンパク質(具体的には、完全切断型の異種タンパク質)を分泌生産する能力を向上させることができる、すなわち、同細菌によるTorAシグナルペプチドを利用した異種タンパク質(具体的には、完全切断型の異種タンパク質)の分泌生産を増大させることができる、と期待される。
本発明の細菌は、異種タンパク質を分泌生産できる限り、所望の性質を有していてよい。例えば、本発明の細菌は、細胞表層タンパク質の活性が低下していてよい(WO2013/065869、WO2013/065772、WO2013/118544、WO2013/062029)。また、本発明の細菌は、ペニシリン結合タンパク質の活性が低下するように改変されていてよい(WO2013/065869)。また、本発明の細菌は、メタロペプチダーゼをコードする遺伝子の発現が上昇するように改変されていてよい(WO2013/065772)。また、本発明の細菌は、変異型リボソームタンパク質S1遺伝子(変異型rpsA遺伝子)を有するように改変されていてよい(WO2013/118544)。また、本発明の細菌は、変異型phoS遺伝子を有するように改変されていてよい(WO2016/171224)。また、本発明の細菌は、RegX3タンパク質の活性が低下するように改変されていてよい(WO2018/074578)。また、本発明の細菌は、HrrSAシステムの活性が低下するように改変されていてよい(WO2018/074579)。また、本発明の細菌は、Tat系分泌装置の活性が増大するように改変されていてよい。これらの性質または改変は、単独で、あるいは適宜組み合わせて、利用することができる。
本発明の細菌は、変異型phoS遺伝子を保持するように改変されていてよい。「変異型phoS遺伝子を保持する」ことを、「変異型phoS遺伝子を有する」または「phoS遺伝子に変異を有する」ともいう。また、「変異型phoS遺伝子を保持する」ことを、「変異型PhoSタンパク質を有する」または「PhoSタンパク質に変異を有する」ともいう。
本発明の細菌は、細胞表層タンパク質の活性が低下しているものであってよい。本発明の細菌は、具体的には、細胞表層タンパク質の活性が非改変株と比較して低下しているものであってよい。「細胞表層タンパク質の活性が低下する」とは、特に、細胞表層タンパク質の細胞当たりの分子数が低下することを意味してもよい。以下に、細胞表層タンパク質およびそれをコードする遺伝子について説明する。
C. glutamicum ATCC13058(AY524990)
C. glutamicum ATCC13744(AY524991)
C. glutamicum ATCC13745(AY524992)
C. glutamicum ATCC14017(AY524993)
C. glutamicum ATCC14020(AY525009)
C. glutamicum ATCC14067(AY524994)
C. glutamicum ATCC14068(AY525010)
C. glutamicum ATCC14747(AY525011)
C. glutamicum ATCC14751(AY524995)
C. glutamicum ATCC14752(AY524996)
C. glutamicum ATCC14915(AY524997)
C. glutamicum ATCC15243(AY524998)
C. glutamicum ATCC15354(AY524999)
C. glutamicum ATCC17965(AY525000)
C. glutamicum ATCC17966(AY525001)
C. glutamicum ATCC19223(AY525002)
C. glutamicum ATCC19240(AY525012)
C. glutamicum ATCC21341(AY525003)
C. glutamicum ATCC21645(AY525004)
C. glutamicum ATCC31808(AY525013)
C. glutamicum ATCC31830(AY525007)
C. glutamicum ATCC31832(AY525008)
C. glutamicum LP-6(AY525014)
C. glutamicum DSM20137(AY525015)
C. glutamicum DSM20598(AY525016)
C. glutamicum DSM46307(AY525017)
C. glutamicum 22220(AY525005)
C. glutamicum 22243(AY525006)
本発明の細菌は、タンパク質の分泌系であるTat系(Tat系分泌装置)を有する。本発明の細菌は、本来的にTat系分泌装置を有していてよい。本発明の細菌は、Tat系分泌装置の活性が増大するように改変されていてもよい。本発明の細菌は、具体的には、Tat系分泌装置の活性が非改変株と比較して増大するように改変されていてもよい。Tat系分泌装置の活性は、例えば、Tat系分泌装置をコードする遺伝子から選択される1またはそれ以上の遺伝子の発現が上昇させることにより、増大させることができる。すなわち、本発明の細菌は、より具体的には、Tat系分泌装置をコードする遺伝子から選択される1またはそれ以上の遺伝子の発現が上昇するように改変されていてもよい。Tat系分泌装置をコードする遺伝子の発現を上昇させる手法については特許第4730302号に記載されている。Tat系分泌装置の活性が増大するようにコリネ型細菌を改変することにより、TorAシグナルペプチドを利用する際の同細菌の異種タンパク質(具体的には、完全切断型の異種タンパク質)を分泌生産する能力を向上させることができる、すなわち、同細菌によるTorAシグナルペプチドを利用した異種タンパク質(具体的には、完全切断型の異種タンパク質)の分泌生産を増大させることができる、と期待される。
以下に、LepBタンパク質等のタンパク質の活性を増大させる手法(遺伝子の発現を増大させる手法も含む)について説明する。
以下に、タンパク質の活性を低下させる手法について説明する。なお、以下に記載するタンパク質の活性を低下させる手法は、野生型PhoSタンパク質の破壊にも利用できる。
分泌性タンパク質(secretory protein)は、一般に、プレタンパク質(プレペプチドともいう)またはプレプロタンパク質(プレプロペプチドともいう)として翻訳され、その後、プロセッシングにより成熟タンパク質(mature protein)になることが知られている。具体的には、分泌性タンパク質は、一般に、プレタンパク質またはプレプロタンパク質として翻訳された後、プレ部分であるシグナルペプチドがプロテアーゼ(一般にシグナルペプチダーゼと呼ばれる)によって切断されて成熟タンパク質またはプロタンパク質に変換され、プロタンパク質はプロテアーゼによってさらにプロ部分が切断されて成熟タンパク質になる。よって、本発明の方法においては、異種タンパク質の分泌生産にシグナルペプチドを利用する。なお、本発明において、分泌型タンパク質のプレタンパク質およびプレプロタンパク質を総称して「分泌型タンパク質前駆体」という場合がある。
上記のようにして得られる本発明の細菌を培養し、異種タンパク質を発現させることにより、菌体外に分泌された多量の異種タンパク質が得られる。
C. glutamicum ATCC13869株のゲノム配列およびType I signal peptidase(LepB)をコードするlepB遺伝子の塩基配列は既に決定されている(GenBank Accession No. AP017557、NCBI locus_tag CGBL_0119390)。C. glutamicum ATCC13869株由来のlepB遺伝子の塩基配列を<配列番号01>に、LepBタンパク質のアミノ酸配列を<配列番号02>に示す。
(1)既存(lepB遺伝子非増幅)の条件下におけるTorAシグナルペプチドを用いたPTGの分泌発現
WO2016/171224に記載のYDK010::phoS(W302C)/pPK6_T_PTG株を、25 mg/lのカナマイシンを含むMMTG液体培地(グルコース 120 g、硫酸マグネシウム七水和物 3 g、硫酸アンモニウム 30 g、リン酸二水素カリウム 1.5 g、硫酸鉄七水和物 0.03 g、硫酸マンガン五水和物 0.03 g、チアミン塩酸塩 0.45 mg、ビオチン 0.45 mg、DL-メチオニン 0.15 g、大豆塩酸加水分解液(全窒素量 0.2 g)、炭酸カルシウム 50 g、水で1 LにしてpH7.0に調整)で30℃、72時間培養した。なお、pPK6_T_PTGは、tatABC遺伝子増幅用ベクターpPK6から構築されたプロ構造部付きトランスグルタミナーゼ(PTG)の分泌発現用ベクターであって、C. glutamicum ATCC13869株のcspB遺伝子由来のプロモーター、同プロモーターの下流に発現可能に連結されたE. coli由来のTorAシグナルペプチドをコードするDNA、および同シグナルペプチドとの融合タンパク質として発現するよう連結されたStreptomyces mobaraense由来のPTG遺伝子を有するプラスミドである(WO2016/171224)。YDK010::phoS(W302C) 株は、C. glutamicum AJ12036(FERM BP-734)の細胞表層タンパク質CspBの欠損株であるYDK010株(WO2002/081694)の染色体上のphoS遺伝子中にPhoS(W302C) 変異を導入した株である(WO2016/171224)。培養終了後、培養液を遠心分離して得られた培養上清1.0 μlを、MULTIGEL(R) II mini 15/20(Cosmo Bio)を用いて還元SDS-PAGEに供してからSYPRO(R) Orange(Thermo Fisher Scientific)にて染色を行った結果、主に2本のバンドが検出された(図2のパネルA、lanes 3-5)。それぞれのバンドのN末端アミノ酸配列を解析した結果、高分子側のバンドではPTGのN末端にTorAシグナル配列のC末端側15残基が残存していることを示すアミノ酸配列(GMLGPSLLTP;配列番号47)が確認され、低分子側のバンドではPTGのN末端アミノ酸配列(DNGAGEETKS;配列番号48)が確認された(図2のパネルB)。即ち、TorAシグナル配列を用いたPTG分泌生産において、TorAシグナルペプチドのC末端側15残基の切れ残り型が顕著に残存していることが分かった。
WO2016/171224に記載のPTG分泌発現用ベクターpPK6_T_PTGを鋳型に、<配列番号05>と<配列番号06>のプライマー、または<配列番号07>と<配列番号08>のプライマーを用いて、cspBプロモーター-TorAシグナルペプチド-PTGの発現カセットを含む約1.9 kbpのDNA断片をPCR法によって増幅した。<配列番号05>と<配列番号06>のプライマーには制限酵素KpnIの認識配列が、<配列番号07>と<配列番号08>のプライマーには制限酵素ApaIの認識配列が、それぞれデザインしてある。PCRにはPrimeSTAR(R) HS DNA Polymerase(Takara Bio)を用い、反応条件は業者の推奨するプロトコルに従った。
実施例2(2)で構築したPTG分泌発現プラスミドpPK6lepB(K)_T_PTGおよびpPK6lepB(A)_T_PTGを用いて、WO2016/171224に記載のYDK010::phoS(W302C) 株を形質転換し、YDK010::phoS(W302C)/pPK6lepB(K)_T_PTG株およびYDK010::phoS(W302C)/pPK6lepB(A)_T_PTG株を得た。得られた各形質転換体を、25 mg/lのカナマイシンを含むMMTG液体培地でそれぞれ30℃、72時間培養した。培養終了後、各培養液を遠心分離して得られた培養上清1.0 μlを、MULTIGEL(R) II mini 15/20(Cosmo Bio)を用いて還元SDS-PAGEに供してからSYPRO(R) Orange(Thermo Fisher Scientific)にて染色を行った。その結果、lepB遺伝子を増幅していないpPK6_T_PTG導入株では主に2本のバンドが検出されていたのに対し、lepB遺伝子を増幅したpPK6lepB(K)_T_PTGおよびpPK6lepB(A)_T_PTG導入株では、いずれも、高分子側のバンドが減少してほとんど検出されなくなり、低分子側のバンドが増加した(図2のパネルA、lanes 6-11)。N末端アミノ酸配列を解析した結果、低分子側のバンドではPTGのN末端アミノ酸配列(DNGAGEETKS;配列番号48)が確認された。即ち、TorAシグナル配列を用いたPTG分泌生産において、lepB遺伝子非増幅条件下ではTorAシグナルペプチドのC末端側15残基の切れ残り型が顕著に残存しているが、lepB遺伝子の増幅によってTorAシグナルペプチドのプロセッシングを促進し、正しいN末端アミノ酸配列を有するPTGの生産効率を顕著に向上できることが分かった。
(1)既存(lepB遺伝子非増幅)の条件下におけるTorAシグナルペプチドを用いたPPGの分泌発現
WO2016/171224に記載のYDK010::phoS(W302C)/pPK6_T_PPG株を、25 mg/lのカナマイシンを含むMMTG液体培地で30℃、72時間培養した。なお、pPK6_T_PPGは、tatABC遺伝子増幅用ベクターpPK6から構築されたプロ構造部付きプロテイングルタミナーゼ(PPG)の分泌発現用ベクターであって、C. glutamicum ATCC13869株のcspB遺伝子由来のプロモーター、同プロモーターの下流に発現可能に連結されたE. coli由来のTorAシグナルペプチドをコードするDNA、および同シグナルペプチドとの融合タンパク質として発現するよう連結されたChryseobacterium proteolyticum由来のPPG遺伝子を有するプラスミドである(WO2016/171224)。培養終了後、各培養液を遠心分離して得られた培養上清2.5 μlを、MULTIGEL(R) II mini 15/20(Cosmo Bio)を用いて還元SDS-PAGEに供してからSYPRO(R) Orange(Thermo Fisher Scientific)にて染色を行った結果、主に2本のバンドが検出された(図3のパネルA、lanes 3-5)。それぞれのバンドのN末端アミノ酸配列を解析した結果、高分子側のバンドではPPGのN末端にTorAシグナル配列のC末端側15残基が残存していることを示すアミノ酸配列(GMLGPSLLTP;配列番号47)が確認され、低分子側のバンドではPPGのN末端アミノ酸配列(DSNGNQEING;配列番号49)が確認された(図3のパネルB)。即ち、TorAシグナル配列を用いたPPG分泌生産において、TorAシグナルペプチドのC末端側15残基の切れ残り型が顕著に残存していることが分かった。
WO2016/171224に記載のPPGの分泌発現用ベクターpPK6_T_PPGを鋳型に、<配列番号05>と<配列番号09>のプライマー、または<配列番号07>と<配列番号10>のプライマーを用いて、cspBプロモーター-TorAシグナル配列-PPGの発現カセットを含む約1.6 kbpのDNA断片をPCR法によって増幅した。<配列番号05>と<配列番号09>のプライマーには制限酵素KpnIの認識配列が、<配列番号07>と<配列番号10>のプライマーには制限酵素ApaIの認識配列が、それぞれデザインしてある。PCRにはPrimeSTAR(R) HS DNA Polymerase(Takara Bio)を用い、反応条件は業者の推奨するプロトコルに従った。
実施例3(2)で構築したPPG分泌発現プラスミドpPK6lepB(K)_T_PPGおよびpPK6lepB(A)_T_PPGを用いて、WO2016/171224に記載のYDK010::phoS(W302C) 株を形質転換し、YDK010::phoS(W302C)/pPK6lepB(K)_T_PPG株およびYDK010::phoS(W302C)/pPK6lepB(A)_T_PPG株を得た。得られた各形質転換体を、25 mg/lのカナマイシンを含むMMTG液体培地でそれぞれ30℃、72時間培養した。培養終了後、各培養液を遠心分離して得られた培養上清2.5 μlを、MULTIGEL(R) II mini 15/20(Cosmo Bio)を用いて還元SDS-PAGEに供してからSYPRO(R) Orange(Thermo Fisher Scientific)にて染色を行った。その結果、lepB遺伝子を増幅していないpPK6_T_PPG導入株では主に2本のバンドが検出されていたのに対し、lepB遺伝子を増幅したpPK6lepB(K)_T_PPGおよびpPK6lepB(A)_T_PPG導入株では、いずれも高分子側のバンドが減少してほとんど検出されなくなり、低分子側のバンドが増加した(図3のパネルA、lanes 6-11)。N末端アミノ酸配列を解析した結果、低分子側のバンドではPPGのN末端アミノ酸配列(DSNGNQEING;配列番号49)が確認された。即ち、TorAシグナル配列を用いたPPG分泌生産において、lepB遺伝子非増幅条件下ではTorAシグナルペプチドのC末端側15残基の切れ残り型が顕著に残存しているが、lepB遺伝子の増幅によってTorAシグナルペプチドのプロセッシングを促進し、正しいN末端アミノ酸配列を有するPPGの生産効率を顕著に向上できることが分かった。
(1)Tat系分泌装置をコードするtatABC遺伝子とTorAシグナル配列が付加されたBlaをコードする遺伝子の共発現プラスミドの構築
β-ラクタマーゼ(β-lactamase;以下、Blaと表記する)の一種である、TEM-型に属するクラスA広域性β-ラクタマーゼTEM-116のアミノ酸配列は既に知られている(GenBank Accesson No. WP_000027050)。このアミノ酸配列のうち、N末端のシグナル配列を除いた24-286位の263残基のアミノ酸配列を<配列番号11>に示す。C. glutamicumのコドン使用頻度を考慮し、配列番号11のBlaをコードする塩基配列をデザインした。デザインした塩基配列を<配列番号12>に示す。
実施例4(1)で構築したBlaの分泌発現プラスミドpPK6_T_Blaを用いて、WO2016/171224に記載のYDK010::phoS(W302C)株を形質転換し、YDK010::phoS(W302C)/pPK6_T_Bla株を得た。得られた形質転換体を、25 mg/lのカナマイシンを含むMMTG液体培地で30℃、72時間培養した。培養終了後、各培養液を遠心分離して得られた培養上清5.0 μlを、NuPAGE(R) 4-12% Bis-Tirs Gel(Thermo Fisher Scientific)を用いて還元SDS-PAGEに供してからSYPRO(R) Ruby(Thermo Fisher Scientific)にて染色を行った結果、主に2本のバンドが検出された(図4のパネルA、lanes 3-5)。それぞれのバンドのN末端アミノ酸配列を解析した結果、高分子側のバンドではBlaのN末端にTorAシグナル配列のC末端側15残基が残存していることを示すアミノ酸配列(GMLGPSLLTP;配列番号47)が確認され、低分子側のバンドはBlaのN末端アミノ酸配列(HPETLVKVKD;配列番号50)が確認された(図4のパネルB)。即ち、TorAシグナル配列を用いたBla分泌生産において、TorAシグナルペプチドのC末端側15残基の切れ残り型が残存していることが分かった。
実施例4(1)で構築したBlaの分泌発現用ベクターpPK6_T_Blaを鋳型に、<配列番号05>と<配列番号13>のプライマー、または<配列番号07>と<配列番号14>のプライマーを用いて、cspBプロモーター-TorAシグナル配列-Blaの発現カセットを含む約1.5 kbpのDNA断片をPCR法によって増幅した。<配列番号05>と<配列番号13>のプライマーには制限酵素KpnIの認識配列が、<配列番号07>と<配列番号14>のプライマーには制限酵素ApaIの認識配列が、それぞれデザインしてある。PCRにはPrimeSTAR(R) HS DNA Polymerase(Takara Bio)を用い、反応条件は業者の推奨するプロトコルに従った。
実施例4(3)で構築したBla分泌発現プラスミドpPK6lepB(K)_T_BlaおよびpPK6lepB(A)_T_Blaを用いて、WO2016/171224に記載のYDK010::phoS(W302C) 株を形質転換し、YDK010::phoS(W302C)/pPK6lepB(K)_T_Bla株およびYDK010::phoS(W302C)/pPK6lepB(A)_T_Bla株を得た。得られた各形質転換体を、25 mg/lのカナマイシンを含むMMTG液体培地でそれぞれ30℃、72時間培養した。培養終了後、各培養液を遠心分離して得られた培養上清5.0 μlを、NuPAGE(R) 4-12% Bis-Tirs Gel(Thermo Fisher Scientific)を用いて還元SDS-PAGEに供してからSYPRO(R) Ruby(Thermo Fisher Scientific)にて染色を行った。その結果、lepB遺伝子を増幅していないpPK6_T_Bla導入株では主に2本のバンドが検出されていたのに対し、lepB遺伝子を増幅したpPK6lepB(K)_T_BlaおよびpPK6lepB(A)_T_Bla導入株では、いずれも高分子側のバンドが減少してほとんど検出されなくなり、低分子側のバンドが増加した(図4のパネルA、lanes 6-11)。N末端アミノ酸配列を解析した結果、低分子側のバンドではBlaのN末端アミノ酸配列(HPETLVKVKD;配列番号50)が確認された。即ち、TorAシグナル配列を用いたBla分泌生産において、lepB遺伝子非増幅条件下ではTorAシグナルペプチドのC末端側15残基の切れ残り型が残存しているが、lepB遺伝子の増幅によってTorAシグナルペプチドのプロセッシングを促進し、正しいN末端アミノ酸配列を有するBlaの生産効率を顕著に向上できることが分かった。
(1)Tat系分泌装置をコードするtatABC遺伝子とTorAシグナル配列が付加されたTrxをコードする遺伝子の共発現プラスミドの構築
チオレドキシン(Thioredoxin;以下、Trxと表記する)の一種である、E. coli由来のTrxAタンパク質のアミノ酸配列は既に知られている(GenBank Accesson No. WP_001323277)。このアミノ酸配列からN末端19残基を除き、さらにN末端にAlaを1残基付加して得られた改変型Trxの109残基のアミノ酸配列を<配列番号15>に示す。C. glutamicumのコドン使用頻度を考慮し、配列番号15のTrxをコードする塩基配列をデザインした。デザインした塩基配列を<配列番号16>に示す。
実施例5(1)で構築したTrxの分泌発現プラスミドpPK6_T_Trxを用いて、WO2016/171224に記載のYDK010::phoS(W302C)株を形質転換し、YDK010::phoS(W302C)/pPK6_T_Trx株を得た。得られた形質転換体を、25 mg/lのカナマイシンを含むMMTG液体培地で30℃、72時間培養した。培養終了後、各培養液を遠心分離して得られた培養上清2.5 μlを、NuPAGE(R) 12% Bis-Tirs Gel(Thermo Fisher Scientific)を用いて還元SDS-PAGEに供してからSYPRO(R) Ruby(Thermo Fisher Scientific)にて染色を行った結果、主に2本のバンドが検出された(図5のパネルA、lanes 3-5)。それぞれのバンドのN末端アミノ酸配列を解析した結果、高分子側のバンドではTrxのN末端にTorAシグナル配列のC末端側15残基が残存していることを示すアミノ酸配列(GMLGPSLLTP;配列番号47)が確認され、低分子側のバンドではTrxのN末端アミノ酸配列(ASDKIIHLTD;配列番号51)が確認された(図5のパネルB)。即ち、TorAシグナル配列を用いたTrx分泌生産において、TorAシグナルペプチドのC末端側15残基の切れ残り型が残存していることが分かった。
実施例5(1)で構築したTrxの分泌発現用ベクターpPK6_T_Trxを鋳型に、<配列番号05>と<配列番号17>のプライマー、または<配列番号07>と<配列番号18>のプライマーを用いて、cspBプロモーター-TorAシグナル配列-Trxの発現カセットを含む約1.1 kbpのDNA断片をPCR法によって増幅した。<配列番号05>と<配列番号17>のプライマーには制限酵素KpnIの認識配列が、<配列番号07>と<配列番号18>のプライマーには制限酵素ApaIの認識配列が、それぞれデザインしてある。PCRにはPrimeSTAR(R) HS DNA Polymerase(Takara Bio)を用い、反応条件は業者の推奨するプロトコルに従った。
実施例5(3)で構築したTrx分泌発現プラスミドpPK6lepB(K)_T_TrxおよびpPK6lepB(A)_T_Trxを用いて、WO2016/171224に記載のYDK010::phoS(W302C) 株を形質転換し、YDK010::phoS(W302C)/pPK6lepB(K)_T_Trx株およびYDK010::phoS(W302C)/pPK6lepB(A)_T_Trx株を得た。得られた各形質転換体を、25 mg/lのカナマイシンを含むMMTG液体培地でそれぞれ30℃、72時間培養した。培養終了後、各培養液を遠心分離して得られた培養上清2.5 μlを、NuPAGE(R) 12% Bis-Tirs Gel(Thermo Fisher Scientific)を用いて還元SDS-PAGEに供してからSYPRO(R) Ruby(Thermo Fisher Scientific)にて染色を行った。その結果、lepB遺伝子を増幅していないpPK6_T_Trx導入株では主に2本のバンドが検出されていたのに対し、lepB遺伝子を増幅したpPK6lepB(K)_T_BlaおよびpPK6lepB(A)_T_Bla導入株では、いずれも高分子側のバンドが減少してほとんど検出されなくなり、低分子側のバンドが増加した(図5のパネルA、lanes 6-11)。N末端アミノ酸配列を解析した結果、低分子側のバンドではTrxのN末端アミノ酸配列(ASDKIIHLTD;配列番号51)が確認された。即ち、TorAシグナル配列を用いたTrx分泌生産において、lepB遺伝子非増幅条件下ではTorAシグナルペプチドのC末端側15残基の切れ残り型が残存しているが、lepB遺伝子の増幅によってTorAシグナルペプチドのプロセッシングを促進し、正しいN末端アミノ酸配列を有するTrxの生産効率を顕著に向上できることが分かった。
(1)Tat系分泌装置をコードするtatABC遺伝子とTorAシグナル配列が付加されたLFABPをコードする遺伝子の共発現プラスミドの構築
ヒトのLiver-type fatty acid-binding protein(以下、LFABPと表記する)のアミノ酸配列は既に知られている(GenBank Accession No. NP_001434)。この127残基のアミノ酸配列を<配列番号19>に示す。C. glutamicumのコドン使用頻度を考慮し、配列番号19のLFABPをコードする塩基配列をデザインした。デザインした塩基配列を<配列番号20>に示す。
実施例6(1)で構築したLFABPの分泌発現プラスミドpPK6_T_LFABPを用いて、WO2016/171224に記載のYDK010::phoS(W302C)株を形質転換し、YDK010::phoS(W302C)/pPK6_T_LFABP株を得た。得られた形質転換体を、25 mg/lのカナマイシンを含むMMTG液体培地で30℃、72時間培養した。培養終了後、各培養液を遠心分離して得られた培養上清5.0 μlを、NuPAGE(R) 4-12% Bis-Tirs Gel(Thermo Fisher Scientific)を用いて還元SDS-PAGEに供してからSYPRO(R) Ruby(Life Technologies)にて染色を行った結果、主に2本のバンドが検出された(図6のパネルA、lanes 3-5)。尚、高分子側のバンドは、ネガティブコントロールであるYDK010::phoS(W302C)/pPK6株の培養上清にも検出されたため(図6のパネルA、lane2)、宿主であるC. glutamicum由来のタンパク質が含まれていることが推定された。それぞれのバンドのN末端アミノ酸配列を解析した結果、高分子側のバンドではLFABPのN末端にTorAシグナル配列のC末端側15残基が残存していることを示すアミノ酸配列(GMLGPSLLTP;配列番号47)、およびC. glutamicum由来のresuscitation-promoting factor Rpf1(GenBank Accession No. AP017557、NCBI locus_tag CGBL_0109030)の成熟タンパク質のN末端配列(APDSDWDRLA;配列番号52)が検出され、高分子側のバンドは主にこれら2種類のタンパク質の混合バンドであることが確認された(図6のパネルB)。なお、Rpf1シグナル配列のC末端側の部分配列が残存していることを示すアミノ酸配列は検出されず、Rpf1については正常にシグナルペプチド全長が切断されていることが確認された。一方、低分子側のバンドではLFABPのN末端アミノ酸配列(MSFSGKYQLQ;配列番号53)が確認された(図6のパネルB)。即ち、TorAシグナル配列を用いたLFABP分泌生産において、TorAシグナルペプチドのC末端側15残基の切れ残り型が残存していることが分かった。
実施例6(1)で構築したLFABPの分泌発現用ベクターpPK6_T_LFABPを鋳型に、<配列番号05>と<配列番号21>のプライマー、または<配列番号07>と<配列番号22>のプライマーを用いて、cspBプロモーター-TorAシグナル配列-LFABPの発現カセットを含む約1.1 kbpのDNA断片をPCR法によって増幅した。<配列番号05>と<配列番号21>のプライマーには制限酵素KpnIの認識配列が、<配列番号07>と<配列番号22>のプライマーには制限酵素ApaIの認識配列がそれぞれデザインしてある。PCRにはPrimeSTAR(R) HS DNA Polymerase(Takara Bio)を用い、反応条件は業者の推奨するプロトコルに従った。
実施例6(3)で構築したLFABP分泌発現プラスミドpPK6lepB(K)_T_LFABPおよびpPK6lepB(A)_T_LFABPを用いて、WO2016/171224に記載のYDK010::phoS(W302C) 株を形質転換し、YDK010::phoS(W302C)/pPK6lepB(K)_T_LFABP株およびYDK010::phoS(W302C)/pPK6lepB(A)_T_LFABP株を得た。得られた各形質転換体を、25 mg/lのカナマイシンを含むMMTG液体培地でそれぞれ30℃、72時間培養した。培養終了後、各培養液を遠心分離して得られた培養上清5.0 μlを、NuPAGE(R) 4-12% Bis-Tirs Gel(Thermo Fisher Scientific)を用いて還元SDS-PAGEに供してからSYPRO(R) Ruby(Life Technologies)にて染色を行った。その結果、lepB遺伝子を増幅していないpPK6_T_LFABP導入株では主な2本のバンドがおよそ等量ずつ検出されていたのに対し、lepB遺伝子を増幅したpPK6lepB(K)_T_FABPおよびpPK6lepB(A)_T_FABP導入株では、いずれも低分子側の目的LFABPのバンドが顕著に増加した(図6のパネルA、lanes 6-11)。N末端アミノ酸配列を解析した結果、低分子側のバンドではLFABPのN末端アミノ酸配列(MSFSGKYQLQ;配列番号53)が確認された。即ち、TorAシグナル配列を用いたLFABP分泌生産において、lepB遺伝子非増幅条件下ではTorAシグナルペプチドのC末端側15残基の切れ残り型が残存しているが、lepB遺伝子の増幅によってTorAシグナルペプチドのプロセッシングを促進し、正しいN末端アミノ酸配列を有するLFABPの生産効率を顕著に向上できることが分かった。
(1)pPK5ベクターを用いたPTG分泌発現用ベクター構築
WO2002/081694に記載のPTGの分泌発現用ベクターpPKSPTG1を鋳型に、<配列番号23>と<配列番号24>のプライマーを用いて、cspBプロモーター-SlpAシグナル配列-PTGの発現カセットを含む約1.8 kbpのDNA断片をPCR法によって増幅した。<配列番号23>と<配列番号24>のプライマーには制限酵素KpnIの認識配列がそれぞれデザインしてある。PCRにはPrimeSTAR(R) HS DNA Polymerase(Takara Bio)を用い、反応条件は業者の推奨するプロトコルに従った。このDNA断片を、WO2016/171224に記載のpPK5ベクターのKpnI部位にインフュージョン反応により挿入することによって、SlpAシグナル配列を用いたPTG分泌発現ベクターであるpPK5_S_PTGを構築した(図1のパネルA)。インフュージョン反応にはIn-Fusion(R) HD Cloning Kit(Takara Bio)を用い、反応条件は業者の推奨するプロトコルに従った。挿入断片の塩基配列決定の結果、予想通りの遺伝子が挿入されていることを確認した。塩基配列の決定はBigDye(R) Terminator v3.1 Cycle Sequencing Kit(Applied Biosystems)と3130 Genetic Analyzer(Applied Biosystems)を用いて行った。
実施例7(1)と同様に、WO2002/081694に記載のPTGの分泌発現用ベクターpPKSPTG1を鋳型に、<配列番号23>と<配列番号25>のプライマー、または<配列番号26>と<配列番号27>のプライマーを用いて、cspBプロモーター-SlpAシグナル配列-PTGの発現カセットを含む約1.8 kbpのDNA断片をPCR法によってそれぞれ増幅した。<配列番号23>と<配列番号25>のプライマーには制限酵素KpnIの認識配列が、<配列番号26>と<配列番号27>のプライマーには制限酵素ApaIの認識配列がそれぞれデザインしてある。PCRにはPrimeSTAR(R) HS DNA Polymerase(Takara Bio)を用い、反応条件は業者の推奨するプロトコルに従った。これらのDNA断片を、実施例1で構築したpPK5lepBベクターのKpnI部位あるいはApaI部位にそれぞれインフュージョン反応により挿入することによって、lepB遺伝子と、SlpAシグナル配列を用いたPTG分泌の共発現ベクターであるpPK5lepB(K)_S_PTGおよびpPK5lepB(A)_S_PTGを構築した(図1のパネルB)。プラスミド名の (K) および (A) は、それぞれPTGの発現カセットを挿入したpPK5lepBベクターの制限酵素部位(KpnIサイトおよびApaIサイト)を表している。インフュージョン反応にはIn-Fusion(R) HD Cloning Kit(Takara Bio)を用い、反応条件は業者の推奨するプロトコルに従った。挿入断片の塩基配列決定の結果、予想通りの遺伝子がそれぞれ挿入されていることを確認した。塩基配列の決定はBigDye(R) Terminator v3.1 Cycle Sequencing Kit(Applied Biosystems)と3130 Genetic Analyzer(Applied Biosystems)を用いて行った。
実施例7(1)および(2)で構築した、SlpAシグナル配列を用いたPTG分泌発現プラスミドであるpPK5_S_PTG、pPK5lepB(K)_S_PTG、およびpPK5lepB(A)_S_PTGを用いてWO2016/171224に記載のYDK010::phoS(W302C) 株を形質転換し、YDK010::phoS(W302C)/pPK5_S_PTG株、YDK010::phoS(W302C)/pPK5lepB(K)_S_PTG株、およびYDK010::phoS(W302C)/pPK5lepB(A)_S_PTG株を得た。得られた各形質転換体を、25 mg/lのカナマイシンを含むMMTG液体培地でそれぞれ30℃、72時間培養した。培養終了後、各培養液を遠心分離して得られた培養上清5.0 μlを、MULTIGEL(R) II mini 15/20(Cosmo Bio)を用いて還元SDS-PAGEに供してからSYPRO(R) Orange(Thermo Fisher Scientific)にて染色を行った。その結果、TorAシグナル配列を用いた場合とは異なり、SlpAシグナル配列を用いた場合では、lepB遺伝子を増幅していないpPK5_S_PTG導入株においてPTGの単一バンドが検出され、SlpAシグナルペプチドC末端側の部分配列が残存した切れ残り型は全く検出されなかった(図7のパネルA、lane 7)。また、lepB遺伝子を増幅したpPK5lepB(K)_S_PTGおよびpPK5lepB(A)_S_PTG導入株においてもバンドパターンは変化せず、むしろPTGの分泌発現量が減少した(図7のパネルA、lanes 8-9)。
配列番号1:C. glutamicum ATCC 13869のlepB遺伝子の塩基配列
配列番号2:C. glutamicum ATCC 13869のLepBタンパク質のアミノ酸配列
配列番号3~10:プライマー
配列番号11:β-ラクタマーゼTEM-116のアミノ酸配列
配列番号12:β-ラクタマーゼTEM-116をコードする塩基配列
配列番号13~14:プライマー
配列番号15:E. coliの改変型TrxAタンパク質のアミノ酸配列
配列番号16:E. coliの改変型TrxAタンパク質をコードする塩基配列
配列番号17~18:プライマー
配列番号19:ヒトのLFABPのアミノ酸配列
配列番号20:ヒトのLFABPをコードする塩基配列
配列番号21~27:プライマー
配列番号28:C. glutamicum YDK010のphoS遺伝子の塩基配列
配列番号29:C. glutamicum YDK010のPhoSタンパク質のアミノ酸配列
配列番号30:C. glutamicum ATCC 13032のPhoSタンパク質のアミノ酸配列
配列番号31:C. glutamicum ATCC 14067のPhoSタンパク質のアミノ酸配列
配列番号32:C. callunaeのPhoSタンパク質のアミノ酸配列
配列番号33:C. crenatumのPhoSタンパク質のアミノ酸配列
配列番号34:C. efficiensのPhoSタンパク質のアミノ酸配列
配列番号35:C. glutamicum ATCC 13032のphoR遺伝子の塩基配列
配列番号36:C. glutamicum ATCC 13032のPhoRタンパク質のアミノ酸配列
配列番号37:C. glutamicum ATCC 13869のcspB遺伝子の塩基配列
配列番号38:C. glutamicum ATCC 13869のCspBタンパク質のアミノ酸配列
配列番号39:C. glutamicum ATCC 13032のtatA遺伝子の塩基配列
配列番号40:C. glutamicum ATCC 13032のTatAタンパク質のアミノ酸配列
配列番号41:C. glutamicum ATCC 13032のtatB遺伝子の塩基配列
配列番号42:C. glutamicum ATCC 13032のTatBタンパク質のアミノ酸配列
配列番号43:C. glutamicum ATCC 13032のtatC遺伝子の塩基配列
配列番号44:C. glutamicum ATCC 13032のTatCタンパク質のアミノ酸配列
配列番号45:ツイン・アルギニンモチーフのアミノ酸配列
配列番号46:TorAシグナルペプチドのアミノ酸配列
配列番号47~53:N末端アミノ酸配列
配列番号54~59:シグナルペプチドを含むタンパク質のN末端アミノ酸配列
Claims (17)
- 異種タンパク質の製造方法であって、
異種タンパク質の分泌発現用の遺伝子構築物を有するコリネ型細菌を培養すること、および
分泌生産された異種タンパク質を回収することを含み、
前記コリネ型細菌が、LepBタンパク質の活性が非改変株と比較して増大するように改変されており、
前記遺伝子構築物が、5’から3’方向に、コリネ型細菌で機能するプロモーター配列、TorAシグナルペプチドをコードする核酸配列、および異種タンパク質をコードする核酸配列を含み、
前記異種タンパク質が、前記TorAシグナルペプチドとの融合タンパク質として発現する、方法。 - 前記LepBタンパク質が、下記(a)、(b)、または(c)に記載のタンパク質である、請求項1に記載の方法:
(a)配列番号2に示すアミノ酸配列を含むタンパク質;
(b)配列番号2に示すアミノ酸配列において、1~10個のアミノ酸残基の置換、欠失、挿入、および/または付加を含むアミノ酸配列を含み、且つ、TorAシグナルペプチドに対するシグナルペプチダーゼ活性を有するタンパク質;
(c)配列番号2に示すアミノ酸配列に対して90%以上の同一性を有するアミノ酸配列を含み、且つ、TorAシグナルペプチドに対するシグナルペプチダーゼ活性を有するタンパク質。 - lepB遺伝子の発現を上昇させることにより、前記LepBタンパク質の活性が増大した、請求項1または2に記載の方法。
- 前記lepB遺伝子の発現が、該遺伝子のコピー数を高めること、および/または該遺伝子の発現調節配列を改変することによって上昇した、請求項3に記載の方法。
- 前記TorAシグナルペプチドが、下記(a)、(b)、または(c)に記載のペプチドである、請求項1~4のいずれか一項に記載の方法:
(a)配列番号46に示すアミノ酸配列を含むペプチド;
(b)配列番号46に示すアミノ酸配列において、1~3個のアミノ酸残基の置換、欠失、挿入、および/または付加を含むアミノ酸配列を含み、且つ、Tat系依存シグナルペプチドとしての機能を有するペプチド;
(c)配列番号46に示すアミノ酸配列に対して90%以上の同一性を有するアミノ酸配列を含み、且つ、Tat系依存シグナルペプチドとしての機能を有するペプチド。 - 前記TorAシグナルペプチドが、配列番号46に示すアミノ酸配列からなる、請求項1~5のいずれか一項に記載の方法。
- 前記分泌生産された異種タンパク質が、前記TorAシグナルペプチドが完全に除去された異種タンパク質である、請求項1~6のいずれか一項に記載の方法。
- 前記コリネ型細菌が、さらに、変異型PhoSタンパク質をコードするphoS遺伝子を保持するように改変されている、請求項1~7のいずれか一項に記載の方法。
- 前記変異が、野生型PhoSタンパク質において、配列番号29の302位のトリプトファン残基に相当するアミノ酸残基が芳香族アミノ酸およびヒスチジン以外のアミノ酸残基に置換される変異である、請求項8に記載の方法。
- 前記芳香族アミノ酸およびヒスチジン以外のアミノ酸残基が、リジン残基、アラニン残基、バリン残基、セリン残基、システイン残基、メチオニン残基、アスパラギン酸残基、またはアスパラギン残基である、請求項9に記載の方法。
- 前記野生型PhoSタンパク質が、下記(a)、(b)、または(c)に記載のタンパク質である、請求項9または10に記載の方法:
(a)配列番号29~34のいずれかに示すアミノ酸配列を含むタンパク質;
(b)配列番号29~34のいずれかに示すアミノ酸配列において、1~10個のアミノ酸残基の置換、欠失、挿入、および/または付加を含むアミノ酸配列を含み、且つ、PhoRSシステムのセンサーキナーゼとしての機能を有するタンパク質;
(c)配列番号29~34のいずれかに示すアミノ酸配列に対し90%以上の同一性を有するアミノ酸配列を含み、且つ、PhoRSシステムのセンサーキナーゼとしての機能を有するタンパク質。 - 前記コリネ型細菌が、さらに、Tat系分泌装置をコードする遺伝子から選択される1種またはそれ以上の遺伝子の発現が非改変株と比較して上昇するように改変されている、請求項1~11のいずれか一項に記載の方法。
- 前記Tat系分泌装置をコードする遺伝子が、tatA遺伝子、tatB遺伝子、tatC遺伝子、およびtatE遺伝子からなる、請求項12に記載の方法。
- 前記コリネ型細菌が、コリネバクテリウム属細菌である、請求項1~13のいずれか一項に記載の方法。
- 前記コリネ型細菌が、コリネバクテリウム・グルタミカムである、請求項14に記載の方法。
- 前記コリネ型細菌が、コリネバクテリウム・グルタミカムAJ12036(FERM BP-734)に由来する改変株またはコリネバクテリウム・グルタミカムATCC 13869に由来する改変株である、請求項15に記載の方法。
- 前記コリネ型細菌が、細胞表層タンパク質の細胞当たりの分子数が非改変株と比較して低下しているコリネ型細菌である、請求項1~16のいずれか一項に記載の方法。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020217015695A KR20210082212A (ko) | 2018-10-25 | 2019-10-25 | 단백질의 분비 생산법 |
AU2019364829A AU2019364829A1 (en) | 2018-10-25 | 2019-10-25 | Method for secretory production of protein |
CN201980069863.5A CN112930359A (zh) | 2018-10-25 | 2019-10-25 | 蛋白质的分泌生产方法 |
EP19877152.9A EP3872096A4 (en) | 2018-10-25 | 2019-10-25 | PROCESS FOR THE SECRETORY PRODUCTION OF A PROTEIN |
JP2020552639A JP7375767B2 (ja) | 2018-10-25 | 2019-10-25 | タンパク質の分泌生産法 |
US17/236,370 US20210246479A1 (en) | 2018-10-25 | 2021-04-21 | Method for Secretory Production of Protein |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018-200673 | 2018-10-25 | ||
JP2018200673 | 2018-10-25 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/236,370 Continuation US20210246479A1 (en) | 2018-10-25 | 2021-04-21 | Method for Secretory Production of Protein |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020085511A1 true WO2020085511A1 (ja) | 2020-04-30 |
Family
ID=70330620
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2019/042069 WO2020085511A1 (ja) | 2018-10-25 | 2019-10-25 | タンパク質の分泌生産法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20210246479A1 (ja) |
EP (1) | EP3872096A4 (ja) |
JP (1) | JP7375767B2 (ja) |
KR (1) | KR20210082212A (ja) |
CN (1) | CN112930359A (ja) |
AU (1) | AU2019364829A1 (ja) |
WO (1) | WO2020085511A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023063314A1 (ja) | 2021-10-11 | 2023-04-20 | 味の素株式会社 | 異種Tat系タンパク質を発現するよう改変された細菌 |
WO2023200008A1 (ja) * | 2022-04-15 | 2023-10-19 | 味の素株式会社 | 培養肉の製造方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114480409B (zh) * | 2022-02-25 | 2023-09-12 | 江南大学 | 一种信号肽及促进胶原蛋白在谷氨酸棒杆菌中分泌表达的方法 |
Citations (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57134500A (en) | 1981-02-12 | 1982-08-19 | Kyowa Hakko Kogyo Co Ltd | Plasmid pcg1 |
JPS57183799A (en) | 1981-04-17 | 1982-11-12 | Kyowa Hakko Kogyo Co Ltd | Novel plasmid |
JPS5835197A (ja) | 1981-08-26 | 1983-03-01 | Kyowa Hakko Kogyo Co Ltd | プラスミドpcg2 |
JPS58192900A (ja) | 1982-05-04 | 1983-11-10 | Ajinomoto Co Inc | 複合プラスミド |
JPH01191686A (ja) | 1988-01-26 | 1989-08-01 | Mitsubishi Petrochem Co Ltd | 複合プラスミド |
JPH0272876A (ja) | 1988-09-08 | 1990-03-13 | Mitsubishi Petrochem Co Ltd | トリプトフアンシンターゼの製造法 |
JPH02109985A (ja) | 1988-02-22 | 1990-04-23 | Eurolysine | 細菌染色体上ヘの目的遺伝子の組み込み方法及び該方法によって得られた細菌 |
JPH02207791A (ja) | 1989-02-07 | 1990-08-17 | Ajinomoto Co Inc | 微生物の形質転換法 |
EP0444759A1 (en) | 1990-02-28 | 1991-09-04 | Gist-Brocades N.V. | Improved processing of proteins |
JPH03210184A (ja) | 1990-01-11 | 1991-09-13 | Mitsubishi Petrochem Co Ltd | 新規プラスミドベクター |
JPH057491A (ja) | 1990-10-15 | 1993-01-19 | Ajinomoto Co Inc | 温度感受性プラスミド |
US5185262A (en) | 1988-07-27 | 1993-02-09 | Mitsubishi Petrochemical Co., Ltd. | DNA fragment containing gene which encodes the function of stabilizing plasmid in host microorganism |
JPH06502548A (ja) | 1991-07-30 | 1994-03-24 | オルサン | 特にコリネバクテリア中で用いることのできる蛋白質の発現および分泌系 |
WO1996006931A1 (en) | 1994-08-26 | 1996-03-07 | Novo Nordisk A/S | Microbial transglutaminases, their production and use |
WO1996022366A1 (en) | 1995-01-19 | 1996-07-25 | Novo Nordisk A/S | Transglutaminases from oomycetes |
JPH0970291A (ja) | 1995-06-30 | 1997-03-18 | Ajinomoto Co Inc | 人工トランスポゾンを用いた遺伝子増幅方法 |
JPH09322774A (ja) | 1996-06-05 | 1997-12-16 | Ajinomoto Co Inc | L−リジンの製造法 |
JPH10108675A (ja) | 1996-10-07 | 1998-04-28 | Ajinomoto Co Inc | コリネバクテリウム・アンモニアゲネス由来の新規な細胞表層蛋白質 |
JPH10215883A (ja) | 1996-12-05 | 1998-08-18 | Ajinomoto Co Inc | L−リジンの製造法 |
US5882888A (en) | 1995-01-23 | 1999-03-16 | Novo Nordisk A/S | DNA integration by transposition |
EP0974654A2 (en) | 1998-07-08 | 2000-01-26 | Mitsui Chemicals, Inc. | Method for secretory production of human growth hormone |
WO2000018935A1 (fr) | 1998-09-25 | 2000-04-06 | Ajinomoto Co.,Inc. | Procede de construction d'une bacterie produisant des acides amines, et procede de production d'acides amines par une technique de fermentation utilisant ladite bacterie |
US6303383B1 (en) | 1999-03-16 | 2001-10-16 | Ajinomoto Co., Inc. | Temperature sensitive plasmid for coryneform bacteria |
WO2002081694A1 (fr) | 2001-03-30 | 2002-10-17 | Ajinomoto Co.,Inc. | Procede de secretion et de production de proteine |
WO2004007740A1 (en) | 2002-07-12 | 2004-01-22 | Chung Kyung Kang | Biological method for producing t-20 peptide |
WO2005010175A1 (en) | 2003-07-29 | 2005-02-03 | Ajinomoto Co., Inc. | Method for producing l-lysine or l-threonine using escherichia bacteria having attnuated malic enzyme activity |
WO2005103278A1 (ja) | 2004-04-20 | 2005-11-03 | Ajinomoto Co., Inc. | タンパク質の製造法 |
DE102004035543A1 (de) | 2004-07-22 | 2006-02-09 | Henkel Kgaa | Neue sekretorische Genprodukte von Bacillus licheniformis und darauf aufbauende verbesserte biotechnologische Produktionsverfahren |
US20060141588A1 (en) | 2004-12-28 | 2006-06-29 | Jun Nakamura | L-glutamic acid-producing microorganism and a method for producing l-glutamic acid |
RU2006134574A (ru) | 2006-09-29 | 2008-04-10 | Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" (ЗАО АГРИ) (RU) | Способ конструирования рекомбинантных бактерий, принадлежащих к роду pantoea и способ продукции l-аминокислот с использованием бактерий, принадлежащих к роду pantoea |
KR101077783B1 (ko) | 2011-08-16 | 2011-10-28 | 바이오알앤디 주식회사 | 재조합 인간성장호르몬 단백질, 이의 발현 벡터, 및 이를 이용한 인간성장호르몬 단백질의 제조방법 |
WO2013062029A1 (ja) | 2011-10-25 | 2013-05-02 | 味の素株式会社 | タンパク質の分泌生産法 |
WO2013065869A1 (en) | 2011-11-02 | 2013-05-10 | Ajinomoto Co.,Inc. | Method for secretory production of protein |
WO2013065772A1 (ja) | 2011-11-02 | 2013-05-10 | 味の素株式会社 | タンパク質の分泌生産法 |
WO2013069634A1 (ja) | 2011-11-11 | 2013-05-16 | 味の素株式会社 | 発酵法による目的物質の製造法 |
WO2013118544A1 (ja) | 2012-02-08 | 2013-08-15 | 味の素株式会社 | タンパク質の分泌生産法 |
CN104611317A (zh) | 2015-03-09 | 2015-05-13 | 江南大学 | 一种提高l-天冬酰胺酶分泌表达的方法 |
WO2016171224A1 (ja) | 2015-04-24 | 2016-10-27 | 味の素株式会社 | タンパク質の分泌生産法 |
WO2018074578A1 (ja) | 2016-10-21 | 2018-04-26 | 味の素株式会社 | タンパク質の分泌生産法 |
WO2018074579A1 (ja) | 2016-10-21 | 2018-04-26 | 味の素株式会社 | タンパク質の分泌生産法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4730302Y1 (ja) | 1969-12-29 | 1972-09-11 | ||
CA2283193A1 (en) * | 1997-03-11 | 1998-09-17 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
TR200103711T2 (tr) * | 1999-06-25 | 2002-07-22 | Basf Aktiengesellschaft | Homeostas ve adaptasyondaki proteinleri kodlayan corynebacterıum glutamıcum genleri. |
JP2008508320A (ja) * | 2004-07-29 | 2008-03-21 | カイロン コーポレイション | Streptococcusagalactiaeのようなグラム陽性細菌に対する免疫原性組成物 |
-
2019
- 2019-10-25 JP JP2020552639A patent/JP7375767B2/ja active Active
- 2019-10-25 KR KR1020217015695A patent/KR20210082212A/ko active Search and Examination
- 2019-10-25 WO PCT/JP2019/042069 patent/WO2020085511A1/ja unknown
- 2019-10-25 AU AU2019364829A patent/AU2019364829A1/en active Pending
- 2019-10-25 CN CN201980069863.5A patent/CN112930359A/zh active Pending
- 2019-10-25 EP EP19877152.9A patent/EP3872096A4/en active Pending
-
2021
- 2021-04-21 US US17/236,370 patent/US20210246479A1/en active Pending
Patent Citations (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57134500A (en) | 1981-02-12 | 1982-08-19 | Kyowa Hakko Kogyo Co Ltd | Plasmid pcg1 |
JPS57183799A (en) | 1981-04-17 | 1982-11-12 | Kyowa Hakko Kogyo Co Ltd | Novel plasmid |
JPS5835197A (ja) | 1981-08-26 | 1983-03-01 | Kyowa Hakko Kogyo Co Ltd | プラスミドpcg2 |
JPS58192900A (ja) | 1982-05-04 | 1983-11-10 | Ajinomoto Co Inc | 複合プラスミド |
JPH01191686A (ja) | 1988-01-26 | 1989-08-01 | Mitsubishi Petrochem Co Ltd | 複合プラスミド |
JPH02109985A (ja) | 1988-02-22 | 1990-04-23 | Eurolysine | 細菌染色体上ヘの目的遺伝子の組み込み方法及び該方法によって得られた細菌 |
US5185262A (en) | 1988-07-27 | 1993-02-09 | Mitsubishi Petrochemical Co., Ltd. | DNA fragment containing gene which encodes the function of stabilizing plasmid in host microorganism |
JPH0272876A (ja) | 1988-09-08 | 1990-03-13 | Mitsubishi Petrochem Co Ltd | トリプトフアンシンターゼの製造法 |
JPH02207791A (ja) | 1989-02-07 | 1990-08-17 | Ajinomoto Co Inc | 微生物の形質転換法 |
JPH03210184A (ja) | 1990-01-11 | 1991-09-13 | Mitsubishi Petrochem Co Ltd | 新規プラスミドベクター |
EP0444759A1 (en) | 1990-02-28 | 1991-09-04 | Gist-Brocades N.V. | Improved processing of proteins |
JPH057491A (ja) | 1990-10-15 | 1993-01-19 | Ajinomoto Co Inc | 温度感受性プラスミド |
JPH06502548A (ja) | 1991-07-30 | 1994-03-24 | オルサン | 特にコリネバクテリア中で用いることのできる蛋白質の発現および分泌系 |
WO1996006931A1 (en) | 1994-08-26 | 1996-03-07 | Novo Nordisk A/S | Microbial transglutaminases, their production and use |
WO1996022366A1 (en) | 1995-01-19 | 1996-07-25 | Novo Nordisk A/S | Transglutaminases from oomycetes |
US5882888A (en) | 1995-01-23 | 1999-03-16 | Novo Nordisk A/S | DNA integration by transposition |
EP0805867B1 (en) | 1995-01-23 | 2003-12-17 | Novozymes A/S | Dna integration by transposition |
JPH0970291A (ja) | 1995-06-30 | 1997-03-18 | Ajinomoto Co Inc | 人工トランスポゾンを用いた遺伝子増幅方法 |
JPH09322774A (ja) | 1996-06-05 | 1997-12-16 | Ajinomoto Co Inc | L−リジンの製造法 |
JPH10108675A (ja) | 1996-10-07 | 1998-04-28 | Ajinomoto Co Inc | コリネバクテリウム・アンモニアゲネス由来の新規な細胞表層蛋白質 |
JPH10215883A (ja) | 1996-12-05 | 1998-08-18 | Ajinomoto Co Inc | L−リジンの製造法 |
EP0974654A2 (en) | 1998-07-08 | 2000-01-26 | Mitsui Chemicals, Inc. | Method for secretory production of human growth hormone |
WO2000018935A1 (fr) | 1998-09-25 | 2000-04-06 | Ajinomoto Co.,Inc. | Procede de construction d'une bacterie produisant des acides amines, et procede de production d'acides amines par une technique de fermentation utilisant ladite bacterie |
US6303383B1 (en) | 1999-03-16 | 2001-10-16 | Ajinomoto Co., Inc. | Temperature sensitive plasmid for coryneform bacteria |
WO2002081694A1 (fr) | 2001-03-30 | 2002-10-17 | Ajinomoto Co.,Inc. | Procede de secretion et de production de proteine |
WO2004007740A1 (en) | 2002-07-12 | 2004-01-22 | Chung Kyung Kang | Biological method for producing t-20 peptide |
WO2005010175A1 (en) | 2003-07-29 | 2005-02-03 | Ajinomoto Co., Inc. | Method for producing l-lysine or l-threonine using escherichia bacteria having attnuated malic enzyme activity |
WO2005103278A1 (ja) | 2004-04-20 | 2005-11-03 | Ajinomoto Co., Inc. | タンパク質の製造法 |
JP4730302B2 (ja) | 2004-04-20 | 2011-07-20 | 味の素株式会社 | タンパク質の製造法 |
DE102004035543A1 (de) | 2004-07-22 | 2006-02-09 | Henkel Kgaa | Neue sekretorische Genprodukte von Bacillus licheniformis und darauf aufbauende verbesserte biotechnologische Produktionsverfahren |
US20060141588A1 (en) | 2004-12-28 | 2006-06-29 | Jun Nakamura | L-glutamic acid-producing microorganism and a method for producing l-glutamic acid |
RU2006134574A (ru) | 2006-09-29 | 2008-04-10 | Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" (ЗАО АГРИ) (RU) | Способ конструирования рекомбинантных бактерий, принадлежащих к роду pantoea и способ продукции l-аминокислот с использованием бактерий, принадлежащих к роду pantoea |
KR101077783B1 (ko) | 2011-08-16 | 2011-10-28 | 바이오알앤디 주식회사 | 재조합 인간성장호르몬 단백질, 이의 발현 벡터, 및 이를 이용한 인간성장호르몬 단백질의 제조방법 |
WO2013062029A1 (ja) | 2011-10-25 | 2013-05-02 | 味の素株式会社 | タンパク質の分泌生産法 |
WO2013065869A1 (en) | 2011-11-02 | 2013-05-10 | Ajinomoto Co.,Inc. | Method for secretory production of protein |
WO2013065772A1 (ja) | 2011-11-02 | 2013-05-10 | 味の素株式会社 | タンパク質の分泌生産法 |
WO2013069634A1 (ja) | 2011-11-11 | 2013-05-16 | 味の素株式会社 | 発酵法による目的物質の製造法 |
WO2013118544A1 (ja) | 2012-02-08 | 2013-08-15 | 味の素株式会社 | タンパク質の分泌生産法 |
CN104611317A (zh) | 2015-03-09 | 2015-05-13 | 江南大学 | 一种提高l-天冬酰胺酶分泌表达的方法 |
WO2016171224A1 (ja) | 2015-04-24 | 2016-10-27 | 味の素株式会社 | タンパク質の分泌生産法 |
WO2018074578A1 (ja) | 2016-10-21 | 2018-04-26 | 味の素株式会社 | タンパク質の分泌生産法 |
WO2018074579A1 (ja) | 2016-10-21 | 2018-04-26 | 味の素株式会社 | タンパク質の分泌生産法 |
Non-Patent Citations (43)
Title |
---|
"GenBank", Database accession no. NC - 000913 |
"Genetic Engineering", vol. 8, 1987, KYORITSU SHUPPAN CO., LTD, article "Fundamental Microbiology" |
"NCBI", Database accession no. CGBL _| 0109030 |
"UniProt", Database accession no. P33225 |
AGRIC. BIOL. CHEM., vol. 48, 1984, pages 2901 - 2903 |
APPL. ENVIRON. MICROBIOL., vol. 71, no. 12, December 2005 (2005-12-01), pages 8587 - 96 |
APPL. MICROBIOL. BIOTECHNOL., vol. 53, 2000, pages 674 - 679 |
BARTON GJ ET AL., JOURNAL OF MOLECULAR BIOLOGY, vol. 198, no. 2, 1987, pages 327 - 37 |
BIBB, M.J.WARD, J.M.HOPWOOD, O.A., NATURE, vol. 274, 1978, pages 398 - 400 |
BIO/TECHNOLOGY, vol. 61, 1989, pages 1067 - 1070 |
BIOCHEM BIOPHYS RES COMMUN, vol. 255, no. 2, 1999, pages 444 - 50 |
BIOTECHNOL BIOENG, vol. 91, no. 5, 2005, pages 616 - 21 |
CARTER P., METH. IN ENZYMOL., vol. 154, 1987, pages 382 |
CHANG, S.CHOEN, S.N., MOL. GEN. GENET., vol. 168, 1979, pages 111 - 115 |
CHO, E.H.GUMPORT, R.I.GARDNER, J.F., J. BACTERIOL., vol. 184, 2002, pages 5200 - 5203 |
DATSENKO, K.A.WANNER, B.L., PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 6640 - 6645 |
DUNCAN, C.H.WILSON, G.A.YOUNG, F.E., GENE, vol. 1, 1977, pages 153 - 167 |
ELIZABETH C. TYLER ET AL., COMPUTERS AND BIOMEDICAL RESEARCH, vol. 24, no. 1, 1991, pages 72 - 96 |
EMBO J., vol. 14, 1995, pages 2715 - 2722 |
FREUDL, R.: "Beyond amino acids: Use of the Corynebacterium glutamicum cell factory for the secretion of heterologous proteins.", J. BIOTECHNOL., vol. 258, 2017, pages 101 - 109, XP085189384 * |
GENE, vol. 39, 1985, pages 281 - 286 |
GENE, vol. 60, no. 1, 1987, pages 115 - 127 |
GOLDSTEIN ET AL.: "Prokaryotic Promoters in Biotechnology", BIOTECHNOL. ANNU. REV., vol. 1, 1995, pages 105 - 128, XP008038474 |
HINNEN, A.HICKS, J.B.FINK, G.R., PROC. NATL. ACAD. SCI. USA, vol. 75, 1978, pages 1929 - 1933 |
INT. J. SYST. BACTERIOL., vol. 41, 1991, pages 255 |
INT. J. SYST. EVOL. MICROBIOL., vol. 60, 2010, pages 874 - 879 |
J APPL MICROBIOL, vol. 121, no. 3, September 2016 (2016-09-01), pages 704 - 12 |
J BIOL CHEM., vol. 286, no. 51, 23 December 2011 (2011-12-23), pages 43601 - 10 |
J MICROBIOL BIOTECHNOL, vol. 17, no. 8, August 2007 (2007-08-01), pages 1316 - 23 |
J. BACTERIOL., vol. 188, 2006, pages 724 - 732 |
J. BIOL. CHEM., vol. 273, no. 52, 1998, pages 34868 - 74 |
J. BIOTECHNOL., vol. 112, 2004, pages 177 - 193 |
JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 26, no. 116, 1991, pages 20833 - 20839 |
JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, 1997, pages 8611 - 8617 |
JOURNAL OF BIOTECHNOLOGY, vol. 104, 2003, pages 311 - 323 |
KRAMER, W.FRITS, H.J., METH. IN ENZYMOL., vol. 154, 1987, pages 382 |
LUKE, I. ET AL.: "Proteolytic processing of Escherichia coli twin-arginine signal peptides by LepB.", ARCH. MICROBIOL., vol. 191, no. 12, 2009, pages 919 - 925, XP019756290, DOI: 10.1007/s00203-009-0516-5 * |
MANDEL, M.HIGA, A., J. MOL. BIOL., vol. 53, 1970, pages 159 - 162 |
MILLER, J.H.: "Experiments in Molecular Genetics", 1972, COLD SPRING HARBOR LABORATORY |
NAKAMURA, Y. ET AL.: "Codon Usage Database", NUCL. ACIDS RES., vol. 28, 2000, pages 292, Retrieved from the Internet <URL:http://www.kazusa.or.jp/codon> |
OLINS P.O. ET AL., GENE, vol. 73, 1988, pages 227 - 235 |
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, USA, vol. 95, 1998, pages 5511 - 5515 |
SAMBROOK, J. ET AL.: "Molecular Cloning: A Laboratory Manual", 2001, COLD SPRING HARBOR LABORATORY PRESS |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023063314A1 (ja) | 2021-10-11 | 2023-04-20 | 味の素株式会社 | 異種Tat系タンパク質を発現するよう改変された細菌 |
WO2023200008A1 (ja) * | 2022-04-15 | 2023-10-19 | 味の素株式会社 | 培養肉の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
CN112930359A (zh) | 2021-06-08 |
EP3872096A4 (en) | 2022-11-30 |
JPWO2020085511A1 (ja) | 2021-09-16 |
US20210246479A1 (en) | 2021-08-12 |
JP7375767B2 (ja) | 2023-11-08 |
AU2019364829A1 (en) | 2021-06-03 |
EP3872096A1 (en) | 2021-09-01 |
KR20210082212A (ko) | 2021-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6741000B2 (ja) | タンパク質の分泌生産法 | |
JP7159867B2 (ja) | タンパク質の分泌生産法 | |
WO2013118544A1 (ja) | タンパク質の分泌生産法 | |
WO2013062029A1 (ja) | タンパク質の分泌生産法 | |
WO2013065772A1 (ja) | タンパク質の分泌生産法 | |
JP7021639B2 (ja) | タンパク質の分泌生産法 | |
US20210246479A1 (en) | Method for Secretory Production of Protein | |
JP2023184699A (ja) | タンパク質の分泌生産法 | |
WO2023282315A1 (ja) | 非天然アミノ酸含有タンパク質の分泌生産法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19877152 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2020552639 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20217015695 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019877152 Country of ref document: EP Effective date: 20210525 |
|
ENP | Entry into the national phase |
Ref document number: 2019364829 Country of ref document: AU Date of ref document: 20191025 Kind code of ref document: A |